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ABSTRACT 
Over the past decade there has been a rapid increase in the development and use of 
nanoparticles (NPs, <100nm). Silver (Ag) NPs, due to their antimicrobial activity, are the 
most commercialised NPs in the world and are incorporated into several consumer goods. 
However, little is known about the potential adverse effects of AgNPs in humans. 
Approximately 50% of inhaled NPs preferentially deposit in the alveoli, where alveolar 
epithelial type-I cells (AT1) form 95% of the alveolar surface, thus constituting a significant 
target for deposition. 
 
We hypothesised that (I) inhalation of AgNPs induces oxidative stress in AT1 cells, leading 
to a pro-inflammatory response, autophagy activation and DNA damage; (II) in the presence 
of a microbial infection, AgNP exposure potentiates the innate immune response, leading to 
increased inflammation and genotoxicity. 
 
An immortalised human transformed alveolar type1-like cell line (TT1) was used to 
investigate these hypotheses. TT1 cells were exposed to AgNPs in the presence/absence of 
Poly I:C (TLR-3 ligand) and LPS (TLR-4 ligand) prior to assaying cell viability, inflammatory 
mediator release, oxidative stress, autophagy and DNA damage. 
 
AgNPs induced oxidative stress in TT1 cells, as well as inflammation, autophagy activation 
and DNA damage. The AgNPs-Poly I:C combination further stimulated IL-6 release, DNA 
damage and delayed autophagic flux, whereas the AgNPs-LPS combination did not. We 
also discovered two different sources of AgNP-mediated oxidative stress, mitochondria and 
NADPH oxidase. Pre-treatment of TT1 cells with a TLR-4 inhibitor prevented AgNP-induced 
inflammation, autophagy activation and DNA damage. On the contrary, TLR-3 inhibition did 
not affect any of the pathways investigated. In conclusion, we showed that AgNPs induce 
oxidative stress and act via TLR-4, leading to a pro-inflammatory response, autophagy 
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activation and DNA damage. These cellular pathways are potentiated by co-exposure with 
Poly I:C. This suggests that inhalation of AgNPs may exert deleterious effects on the lung 
and, in presence of a viral infection, a worsening of the pulmonary condition.  
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TBS-T - Tris-Buffered Saline Tween-20 
TEM - Transmission Electron Microscopy 
TiO2NPs- Titanium diOxide NanoParticles 
TLR - Toll-Like Receptor 
TLR-3 - Toll-Like Receptor 3 
TLR-4 - Toll-Like Receptor 4  
TNF - Tumour Necrosis Factor 
TT1 - Transformed human alveolar epithelial Type-1-like cell line 
UFPs - UltraFine Particles 
VAS-2870 - NADPH oxidase inhibitor 
XRD - X-ray Diffraction 
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1. INTRODUCTION 
1.1 Nanotechnology and Nanoparticles 
1.1.1 The concept and its steady development 
Nanotechnology is a rapidly developing industrial sector, based on the engineering of 
functional systems at the nanoscale. A nanomaterial (NM) is defined as a material that is 
less than 100nm in at least one dimension, while a nanoparticle (NP) is termed a 
nanomaterial with all three external dimensions less than 100nm (Figure 1.1) [1]. The focus 
of this study is on NPs. 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1 Classification of NMs according to CEN/ISO TS 27687 [2]. 
 
Since its establishment in the 1990s, nanotechnology has been extensively introduced into a 
broad spectrum of products such as electronics, medicine, cosmetics, construction and food 
[3]. By the year 2000, nanotechnology was universally recognised as a landmark innovation 
and defined “the sixth truly revolutionary technology introduced in the modern world” [4]. 
Between 2001 and 2008, the numbers of inventions, discoveries and research and 
development funding programs increased by an average annual rate of 25%, taking the 
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value of the worldwide market for products incorporating nanotechnology to approximately 
$254 billion in 2009 [3]. The Project on Emerging Nanotechnologies, which is an Institution 
dedicated to ensuring that, as nanotechnologies advance, possible risks are minimised and 
the public debate is informed, generated an inventory containing all the commercialised 
consumer products containing NPs [5]. As of October 2013, this inventory counted 1628 
products (spanning from health and fitness to food and beverage, home and garden, goods 
for children and other applications), compared to 54 registered in 2005, thus showing an 
exponential growth in commercialised NP-enhanced products (Figure 1.2) [5]. However, it is 
likely that these numbers may be an underestimation of the amount of actual 
nanotechnology products on the market, as the inventory relies only on data offered by 
manufacturers. As such, there may be many more commercialised products containing NPs 
which are not marketed for their NP-containing properties and therefore are not indexed. At 
present, of all the globally commercialised NMs, the one that counts for approximately half is 
silver, followed by titanium, carbon, silica, zinc and gold (Figure 1.3) [5]. Due to its potent 
antimicrobial activity, the applications of nanoscale silver are varied and continue to broaden 
[6]. Silver NP properties and applications are described in Chapter 2. 
 
 
 
 
 
 
 
 
 
 
Figure 1.2 Number of total nano-products commercialised, listed by date of inventory 
update. Graph adapted from “Project on Emerging Nanotechnologies” [5]. 
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Figure 1.3 Most commercialised NMs associated to consumer products. The most 
common NM is silver (383 products). Titanium (179) has surpassed carbon (87) and 
fullerenes, followed by silica (52), zinc (36) and gold (19). Graph adapted from “Project on 
Emerging Nanotechnologies” [5]. 
1.1.2 Nanoparticle properties: the benefits 
The characteristics that make NPs so desirable are acquired as they enter the nanometre 
scale. At this level, physical, chemical and biological properties of NPs are different from 
their bulk (macro) size counterparts, and are controlled by the effects of quantum 
mechanics, rather than classical physics [7]. The key feature of NPs is their small size: per 
unit mass there are millions more NPs compared to their macro-counterparts (Figure 1.4). 
This translates into a significantly greater total surface area, which results in a higher 
number of the particle’s atoms displayed on the surface, enhancing the reactivity of the 
material due to surface atom instability. Hence, the smaller the NP, the larger the surface 
area (intended as surface area/volume) and the greater the modified reactivity potential of 
the material [7]. This can modify the electronic configuration of the NP, hence its physico-
chemical properties, causing the acquisition of characteristics otherwise not seen with the 
same material in a larger form. For example, opaque bulk-sized copper becomes 
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transparent as a NP, while stable bulk aluminium becomes combustible when in the 
nanosize [8]. 
 
 
 
 
 
 
 
 
Figure 1.4 Surface molecules as a function of particle size. Surface molecules increases 
exponentially when particle size decreases. The smaller the particle size, the larger the 
surface area and the greater the biological reactivity. Figure from Oberdörster et al. [9]. 
 
Besides their small size, the unusual physico-chemical properties of the NPs that have 
encouraged their increased usage in various technological applications are attributable to 
their chemical composition (purity, crystallinity, electronic properties etc.), surface structure 
(surface reactivity, surface groups, inorganic or organic coatings etc.), solubility, shape and 
aggregation [10]. These properties offer tremendous potential benefits. From new cancer 
therapies to pollution-reducing compounds, from more durable consumer products to 
detectors for biohazards like anthrax, from novel foods to more efficient solar cells, 
nanotechnologies are changing the way people think about the future [5]. To cite some of 
the most successful commercialisation of NMs, titanium offers high stability, brightness and 
a very high refractive index, characteristics that allowed its integration in paints, coatings, 
plastics, papers, medicines, cosmetics, sunscreens and toothpaste. Thanks to its 
anticorrosive and photo-catalytic properties, titanium is also widely used in catalytic 
reactions, such as semiconductor photo-catalysis and air quality improvement (e.g. nitric 
oxide reduction) [11,12]. Another widely commercialised NM is carbon. Carbon 
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nanotechnology broadly expanded during the last decade due to carbon’s unique structural 
characteristics offering tensile strength, conductivity and thermal stability. Carbon is being 
applied in industries such as electronics (computer components), aerospace (aircraft 
structural components) and sporting equipment (tennis rackets, bicycles, and baseball bats) 
[13]. 
1.1.3 Nanoparticle properties: the other face of nanotechnology 
The small size of a NP, although responsible for the novel and beneficial properties exploited 
in nanotechnology, might also have potential adverse effects, both on human health and the 
environment. In fact, as previously explained (see Section 1.1.2), by reducing the size of a 
material, its physico-chemical properties are likely to change and may differ from those of 
the original bulk material. From a physico-chemical perspective, this implies the generation 
of a new material, with possibly toxic attributes. 
The concern surrounding the possible toxicity of inhaled NPs originates from studies on the 
adverse health effects of air pollution, and in particular those of airborne ultrafine particles 
(UFPs). UFPs, variably called airborne nano-sized particles, are defined as particles 
<100nm in diameter, therefore similar in size to NPs. Possible sources of UFPs can be both 
natural and anthropogenic. Naturally derived NPs are generated, for example, from ash 
emitted from erupting volcanoes, forest fires, soil and rock weathering processes. On the 
contrary, anthropogenic NPs can be released unintentionally (as a by-product of internal 
combustion engines, jet engines, incinerators and other sources), or intentionally 
(nanotechnology products). Interestingly, several epidemiological studies have found 
positive associations between atmospheric levels of airborne UFPs and adverse respiratory 
and cardiovascular effects, resulting in increased morbidity and mortality in susceptible 
subjects, such as asthmatic children [14] or asthmatic adults [15–17]. Parallels between NPs 
and UFPs are drawn because NPs have the potential to become airborne. Although there 
are NP-containing products already in a gaseous state (nasal spray, deodorant, air 
disinfectants and cosmetics) that allow for NPs to become readily airborne, the possibility 
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also exists for solid products. During the entire life cycle of a product engineered with NPs, 
its usage as well as any wear and tear can cause release of NPs, which become airborne 
and could behave in a similar manner to UFPs, thus making the inhalation route and the 
subsequent lung exposure a cause of primary concern. 
1.1.4 Inhaled nanoparticles 
The potential toxicity of inhaled NPs depends on the same interlinked physico-chemical 
factors that make NPs so desirable, such as size, shape and surface area (see Section 
1.1.2) [18]. The reduced size, besides conferring a greater biological reactivity, is important 
in the systemic translocation of NPs from the lung, following inhalation exposure. An 
inhalation study in rats, using gold NPs, demonstrated that smaller NPs (1.4nm) were able to 
translocate across the cellular membrane more efficiently that the larger ones (18nm) [19]. 
Furthermore, particle size is likely to affect clearance by phagocytic cells, such as 
macrophages, which are responsible for clearing inhaled foreign material from the lung. 
Indeed, due to their small size, NPs that remain dispersed and do not agglomerate into 
larger structures are able to escape phagocytosis. Consequently, they may interact with the 
epithelial layer generating inflammation [20], and they can translocate into the pulmonary 
circulation, thus reaching other organs, where they can elicit systemic effects [21–23]. 
Another key factor determining NP toxicity is the particle shape. In a study by Misra et al. 
copper oxide NPs of three different shapes (sphere, rods and spindles) were used to 
examine the effect of shape on the various physico-chemical properties of the NPs 
themselves. It was shown that NPs with the same chemical composition but different shapes 
resulted in differences in their respective surface area, suspension stability and dissolution. 
The spherical NPs showed the highest surface area, stability in suspension and dissolution, 
followed by the rods and the spindles [24]. Therefore, the shape of a NP is responsible for 
the reactivity of the NP itself: changes in the shape alter the surface area and the surface 
energy of the NP, which could result in different absorption and affinity of protons on the 
surface [25]. 
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Bioreactivity of NPs also depends on the surface properties of the NPs. To modify their 
properties, NPs can be surface functionalised; by coating the NP surface with specific 
agents, it is possible to alter the cellular binding and the uptake of NPs. For instance, it has 
been shown that neutral-charged ligands, such as poly(ethylene glycol) (PEG) or poly(vinyl 
alcohol) (PVA), can provide a very useful route to minimise non-specific interactions of NPs 
with their biological environment (e.g. cell membranes or other biological macromolecules), 
thus stabilising the solution and preventing particle agglomeration [26]. On the contrary, 
most charged functional groups are responsible for active NP interaction with cells. For 
example, Cho et al. observed that positively charged NPs (amine-modified) are adsorbed 
more readily into the negatively charged cell membrane surface and consequently show 
higher levels of reactivity and internalisation as compared to the neutral (PVA-coated) NPs 
[27]. 
The examples described demonstrate that the same properties that make NPs so attractive 
for the development in nanomedicine and technology could also cause toxicity when NPs 
interact with cells. Thus, evaluating the safety of commercialised NPs should be of highest 
priority, given their expected worldwide distribution and the likelihood of human exposure [9]. 
However, categorising the toxicity of NPs is difficult because of the great variability in the 
materials used (e.g. titanium, silver, carbon, gold, cadmium and silica among others) and in 
their respective physico-chemical properties (size, shape, surface characteristics, chemical 
composition etc.) [10]. The current focus of International risk assessment bodies, such as 
the Organization for Economic Cooperation and Development (OECD), the World Health 
Organization (WHO) and others, is establishing the probability of human risks/harm upon 
exposure to NPs. However, this is complicated by the fact that even the smallest alteration in 
the physico-chemistry of a NP can have a significant impact on its bioreactivity. To control 
occupational exposure, specific measures put in place by the International Standards 
Organization (ISO), good manufacturing practices (GMP), and good laboratory practice 
(GLP) have been adopted in workplaces and laboratories where the handling of NPs is a 
routine process. At the moment, a substantial amount of data on NP properties and how 
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their effects relate to human health and the environment are being collected. At present, the 
available data on NP cytotoxicity and genotoxicity suggest that humans and laboratory 
animals may experience adverse health effects during chronic exposure to NPs [28]. 
Interestingly, these data identify airborne NPs as the greatest concern for humans, thus 
distinguishing inhalation as the primary route of exposure, and the lung as a significant site 
for deposition of inhaled NPs. 
1.2 The human respiratory system 
1.2.1 Anatomy of the human respiratory tract 
The human respiratory tract can be divided into two main regions (Figure 1.5): 
 Upper respiratory tract: consisting of the nose, nasal cavity, paranasal sinuses and 
the pharynx. These structures filter, warm and humidify the air as it enters the lungs; 
 Lower respiratory tract: including larynx, trachea, bronchi, bronchioles and alveoli  
 
 
 
 
 
 
 
 
 
 
 
Figure 1.5 Schematic representation of the human respiratory system. In green 
components of the upper respiratory system are indicated; in red those of the lower (distal 
or peripheral) lung. Picture adapted from Nair, 2013 [29]. 
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At the edge of the larynx begins the trachea, which allows air to pass from the larynx to the 
bronchi and then into the lungs. The trachea then divides into primary bronchi, which branch 
into secondary and tertiary bronchi. From this point onwards the tubes are called bronchioles 
(less than 1mm in diameter), which divide into terminal bronchioles and then into respiratory 
bronchioles that terminate at the alveolar sacs, each containing several alveoli. The alveoli 
are the gas-exchange units and functional areas of the lungs (Figure 1.6). Starting at the 
larynx, the respiratory tree up until the terminal bronchioles is termed the “conducting zone”. 
The respiratory bronchioles together with the alveoli form the “respiratory zone” (Figure 1.6). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.6 Schematic representation of the human lower respiratory tract from the 
bronchioles to the alveoli. Components of the “conducting zone” are indicated in red; 
those of the “respiratory zone” in blue. Picture adapted from Saladin, 2007 [30]. 
1.2.2 Cellular components of the human respiratory tract 
All along the respiratory tract there is an uninterrupted layer of epithelial cells. The structural 
properties of these cells differ considerably between the conducting zone and the gas-
exchange zone. The pseudo-stratified epithelium of the trachea and bronchi is composed of 
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a number of different cell types; among which are secretory goblet cells and ciliated cells. 
The former produce mucus, whereas the latter enable mucociliary clearance via the 
“mucociliary escalator” to the pharynx, where components are then swallowed or 
expectorated. In the bronchioles, the epithelium becomes a simple columnar epithelium with 
shorter cilia and secretory Clara cells. At the level of the alveoli, where the mucociliary 
escalator is absent, there is a transition to a thin, squamous epithelium, occupied by alveolar 
epithelial type 1 (AT1) and cuboidal alveolar epithelial type 2 (AT2) cells [31] (Figure 1.7). 
As mentioned above, the alveolus constitutes the gas exchange region of the lung. The air-
blood barrier is made of three tissue compartments: the alveolar epithelium, the interstitium 
(including cellular elements and connective tissue), and the capillary endothelium. This 
highly specialised structure provides a thin barrier to gas exchange between the airspace 
and the underlying vasculature. The total surface area available for gas exchange in the 
human lung is about 140m2, equivalent to almost the size of a single tennis court [31]. The 
alveolar epithelium is formed of two different cell types: AT1 and AT2 cells. Within the 
alveolar unit, the first line of cellular defence is formed by alveolar macrophages (AMs) 
(Figure 1.7). 
1.2.2.1 Alveolar type 1 cells (AT1) 
AT1 are large, thin, squamous cells (depth, 0.2-0.5μm; diameter, 80-100μm) that cover 
approximately 95% of the alveolar surface (Figure 1.7 and Table 1.1). These cells provide a 
physical barrier with minimal diffusion distance between the alveolar air space and the 
underlying capillary network, thus maximising gas exchange [32]. AT1 cells are also 
important in regulating the alveolar fluid balance by expressing membrane transport 
proteins, such as epithelial sodium channels and aquaporin water channels [33,34]. Rich in 
caveolae and vesicles, monocultures of AT1 cells have been demonstrated to internalise 
significantly more NPs than monocultures of AT2 cells (75% of the initial amount of NPs are 
internalised by the former, 10% by the latter) [35]. In addition, the process of uptake is rapid: 
one-third of the total NPs internalised over 24h was taken up during the first hour [35]. 
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Therefore, AT1 cells could be fundamental in the understanding of NP behaviour at their 
primary site of deposition. Also, by demonstrating an avid uptake of NPs, AT1 cells might be 
crucial in translocation of inhaled nano-sized particles across the lung and in facilitating their 
subsequent possible effects in target organs (see Section 1.2.3.2). On the contrary, AT2 
cells seem to have a relatively small role to play in this process, whereas macrophages are 
predominantly involved in particle clearance from the alveoli (see Section 1.2.2.3). However, 
the acquisition of a large amount of evidence relating to AT1 cells is hindered by their fragile 
nature, which makes AT1 cell isolation and subsequent culture extremely difficult [33,36]. In 
order to overcome this challenge, AT2 cells have been isolated and cultured on a plastic 
support for approximately 7 days, in order to drive the cells towards an AT1-like phenotype 
[37–39]. These terminally differentiated cells cannot be passaged though, and primary AT2 
cells would need to be isolated regularly, complicating and prolonging NP studies in AT1 
cells.  
In our laboratory, human AT1-like cells have been successfully immortalised from freshly 
isolated and cultured primary human AT2 cells. AT2 cells were transduced using hTERT (i.e. 
the catalytic subunit of human telomerase reverse transcriptase) and a temperature sensitive 
mutant of simian virus 40 large-tumor antigen [35]. These AT1-like, or transformed type-1-
like (TT1) cells, represent the first ever human AT1-like cell line to be produced. They are 
negative for the typical AT2 cell markers pro-surfactant protein C, alkaline phosphatase and 
thyroid transcription factor-1, they lack lamellar bodies (characteristic of AT2 cells) and 
display a flattened morphology, containing vesicles and caveolae (refer to Table 1.1). 
Furthermore, this unique cell line has been further validated by Swain and colleagues that 
showed, using the Raman microspectroscopy, that TT1 cells provide a suitable model for 
AT1 cells [39]. 
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 AT1 cells AT2 cells 
 
 
 
Structure 
and 
morphology 
- Diameter 80-100µm 
- Flattened morphology 
- Presence of caveolae, vesicles 
- Absence of microvilli, lamellar bodies 
- Diameter 9µm 
- Cuboidal morphology 
- Presence of microvilli, lamellar bodies 
- Absence of caveolae, vesicles 
Cell 
markers 
- Caveolin 1  
- RAGE 
- Aquaporin 5 
- Surfactant protein C 
- Thyroid transcription factor 1 
- Alkaline phosphatase  
Cytokines 
produced 
- IL-6, CXCL-8, MCP-1, INF-γ 
- IL-6, CXCL-8, MCP-1, TNF-α, IL-1β,   
  CCL-20 
 
Table 1.1 Characteristics of human AT1 and AT2 cells. Pictures were taken at a light 
microscope; structure and morphology of the cells have been obtained by using TEM [33]; 
typical cell markers were identified using Western Blotting [33].  
1.2.2.2 Alveolar type 2 cells (AT2) 
AT2 cells are cuboidal in shape, with a diameter of approximately 9μm, contain lamellar 
bodies and express apical microvilli (Figure 1.7 and Table 1.1). They represent, by number, 
60% of the total alveolar epithelial cells, but only account for 5% of the alveolar surface area, 
as only a small part of the cell is exposed to the epithelial surface [32]. AT2 are secretory 
cells that synthesise, release and recycle pulmonary surfactant, which is a mixture of lipids 
(85-90%), proteins (10%) and carbohydrates (2%). The alveolar unit is covered in a thin 
aqueous hypophase, the alveolar lining fluid (a milieu for extracellular biochemical reactions) 
on top of which lays the pulmonary surfactant (Figure 1.7). The main function of the 
pulmonary surfactant is the reduction of the surface tension at the air-liquid interface and the 
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maintenance of the alveolar fluid balance [70]. AT2 cells also produce anti-proteases, 
antioxidants, defensins and other molecules that are important in lung defence and in 
maintaining pulmonary homeostasis. Importantly, they are also progenitor cells for AT1, and 
thus are essential for maintaining the integrity of the alveolar epithelial barrier. When an 
alveolar epithelial cell undergoes cell death, neighbouring AT2 cells will divide and 
differentiate to replace it and keep the epithelial layer intact [38,40,41]. 
1.2.2.3 Alveolar macrophages (AMs) 
AMs represent the most prevalent mechanism for defence of the alveoli and for clearance of 
particles/debris. During this process, they release a broad spectrum of pro-inflammatory 
mediators such as cytokines and chemokines [42]. However, phagocytosis by AMs does not 
seem to be efficient for inhaled NPs. Indeed, Oberdorster et al. presented the results of 
several studies in which rats were exposed to different sized particles, from 10µm to 15nm. 
After 24h, the lungs of the animals were lavaged and about 80% of the micron-sized 
particles were retrieved with the macrophages, whereas only 20% of nano-sized particles 
were lavaged with the macrophages [9]. The remainder of the nano-sized material was 
located within the parenchymal tissue. It has also been reported that the attempted 
clearance of long thin fibres (e.g. asbestos) in exposed AMs can induce “frustrated 
phagocytosis” [43], a phenomenon occurring when the target is physically too large for the 
AMs to engulf. This can lead to the release of potentially toxic pro-inflammatory mediators, 
thus amplifying the inflammatory response, with deleterious consequences on the 
surrounding cells. The fundamental mechanisms of NP clearance by AMs are still unclear.  
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Figure 1.7 Schematic representation of the human alveolus. Three cell types are shown: 
AT1 cells (in yellow; large and thin), AT2 cells (in red; cuboidal, with microvilli and lamellar 
bodies) and AM (in green). Secretory AT2 release the surfactant that lies on top of the lung 
lining fluid (LLF; in light blue). 
1.2.3 Nanoparticles in the respiratory tract 
1.2.3.1 Nanoparticle deposition  
Particle entry in the human respiratory tract is a dynamic process that depends on different 
factors, such as particle physico-chemical properties (size, shape, surface reactivity etc.), 
flow dynamics during breathing (during exercise or at rest), anatomy of the respiratory tract 
(e.g. the lung structure of a diseased person may be different from that of a healthy one) and 
the microenvironment (LLF, surfactant and the type of cells the NP come in contact with). 
Mechanisms of particle deposition include [44]: 
 Impaction: when particles approximately >1.5µm are driven into the airway walls by 
rapid changes in airflow direction (e.g. at branches or constrictions); 
 Sedimentation: when particles approximately >0.5µm are deposited onto the airway 
walls by gravitational forces; 
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 Diffusion: when particles approximately <0.5µm are directed towards the respiratory 
wall by random Brownian motion of the air molecules; 
 Interception: similar to impaction, but typical of high aspect-ratio particles (e.g. fibre, 
tubes, wires) 
 Electrostatic deposition: of particles with high surface charges. 
During a breathing cycle, depending on the particles being inhaled, a combination of these 
processes may occur. The regional deposition of differently sized inhaled NPs in the 
nasopharyngeal, tracheobronchial and alveolar regions of the human respiratory tract, under 
conditions of nose breathing during rest, has been described by the International 
Commission on Radiological Protection (ICRP, 1994) using a mathematical model [45]. 
According to this model (Figure 1.8), air drawn through the nose is filtered, warmed and 
humidified in transit. Airflow is then slowed down to allow the deposition of large particles 
(>10μm diameter) through impaction in the nose and throat, where they adhere to mucous 
and are swallowed (and then eliminated through the gastro-intestinal tract), coughed or 
sneezed away from the respiratory tract. At approximately the 18th airway bifurcation, 
between the trachea and the alveoli, further air slowing and particle deposition occur. As a 
result, large particles are mainly deposited in the upper airways, and only particles of less 
than 10μm diameter are deposited in the alveoli [46] (Figure 1.8). NPs behave like diffusing 
gas molecules and stochastically disperse through Brownian motion, penetrating deeply into 
the lung, reaching the alveolar unit. Considering only the nano-scale particles, slight 
changes in size result in major differences in the deposition site. For example, 1nm NPs 
preferentially (90%) deposit in the nasopharyngeal area, whereas 5nm particles show nearly 
equal deposition in all three regions. The 20nm particles, have the highest deposition 
efficiency in the alveolar compartment (at around 50%) [45] (Figure 1.8). Therefore, 
depending on the size, inhaled particles can target all three regions of the respiratory tract; 
NPs, in particular, mainly deposit in the alveoli. 
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Figure 1.8 Predicted fractional deposition of inhaled particles in the human 
respiratory tree. NP deposition in nasopharyngeal (in blue), tracheobronchial (in green) and 
alveolar (in red) regions has been predicted by the ICRP, under conditions of nose breathing 
during rest [45]. Picture adapted from Oberdörster et al. [9]. 
1.2.3.2 Nanoparticle clearance from the alveolar region 
Once NPs have reached the alveolus, they can encounter AMs which, as previously 
explained (Section 1.2.2.3), are not as efficient in recognising and eliminating NPs as they 
are micron-sized particles [9]. In vivo studies in rats show that, at least within the first 24h 
after aerosol inhalation of NPs, these NPs bypass the macrophagic clearance [47,48]. 
Consequently, the probability of NP uptake by epithelial cells increases, meaning a longer 
retention in the lung interstitium [48]. In fact, it has been shown that NPs can translocate 
from the lung into the interstitium and lymph nodes, thus reaching the lymphatic circulation 
[21]. Recent studies in healthy subjects suggested that insoluble ultrafine carbon particles 
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are retained in the lungs for a period longer than 3 days [45,49]. The authors hypothesised 
that the particles may translocate into the pulmonary interstitium without reaching the 
circulation, thus remaining in the lung. However, this was a short-term study spanning over a 
few days. Long-term human studies remain outstanding. 
It has also been suggested that NP clearance from the alveoli exploits the ability of NPs to 
enter cells. Indeed, NP cellular uptake has been demonstrated in both in vitro [35,50–53] 
and in vivo [22,23,53], and possible uptake mechanisms can include: 
 Diffusion (passive); 
 Clathrin-mediated endocytosis (active); 
 Caveolae-mediated endocytosis (active); 
 Clathrin- and caveolae-independent endocytosis (active); 
 Macropinocytosis: ingestion of fluid or molecules through fusion with the plasma 
membrane (active); 
 Phagocytosis: through invagination in the plasma membrane, although it is more 
specific to ingestion of large molecules (normally >250nm) (active). 
In vivo studies demonstrated that, once taken up by the alveolar epithelium, a small fraction 
of NPs were able to access the bloodstream and reach target organs, such as liver, brain 
and heart [21–23]. However, in humans the situation is less clear and there are conflicting 
opinions. Work by Nemmar et al. is the only study to date that suggests translocation of 
inhaled NPs into the circulation in humans [54]. In this study, Nemmar and colleagues 
assessed the extent to which inhaled carbon NPs pass into the human systemic circulation. 
Five healthy volunteers were given “Technegas”, an aerosol consisting mainly of ultrafine 
99mTechnetium-labeled carbon particles (<100nm). 99mTechnetium is a widely used 
radioactive tracer isotope in Nuclear Medicine. The distribution of radioactivity after 
inhalation was rapidly detected in blood at 1min, reached a maximum between 10 and 
20min, and remained at this level for up to 1h. Levels of radioactivity were also recorded in 
the liver and the bladder [54]. On the contrary, other studies performed in humans detected 
either a very low or insignificant degree of NP translocation into the circulation [55,56] or to 
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target organs [55]. Therefore, there is no conclusive evidence showing fast translocation of 
NPs into systemic circulation. Furthermore, translocation of radiolabeled NPs (e.g. 
99mTechnetium-labeled carbon particles) from the lung to other organs is currently under 
debate. Since a significant fraction of the radioactive label detaches from NPs, it has been 
suggested that the radioactivity observed throughout the body may not indicate the actual 
translocation of NPs, but instead just that of radiolabels. Translocation of NPs to the blood 
circulation could provide an explanation for epidemiological findings that showed 
cardiovascular effects after UFPs exposure (refer to Section 1.1.3). However, detailed 
understanding of the processes involved is lacking and more studies are needed. 
1.3 The pulmonary immune system 
1.3.1 Innate and adaptive immunity 
In order to cope with continuous exposure to a large variety of inhaled pathogens and 
noxious particles, the lung has a highly developed immune system, characterised by two 
types of reactions: the innate and the adaptive (acquired) immune response. The former 
provides an immediate (0-4h) but non-specific and short-term protective response to a 
pathogen [57]. At later time points, the immune system adapts to recognise specific 
pathogens, so that the body is able to mount an adaptive immune response. By developing 
immunological memory from a primary response to a specific pathogen, the adaptive 
immunity provides an enhanced response to secondary encounters with that same, specific 
pathogen [58]. 
Cells of the immune system of the lungs can be broadly classified as structural (or 
parenchymal cells) and cells of hematopoietic origin. Among the former there are epithelial 
cells, endothelial cells and fibroblasts, while the latter include erythrocytes, mast cells and 
leukocytes (i.e. monocytes, granulocytes and lymphocytes) [59]. Immune cells have the 
ability to recognise evolutionary conserved Pathogen-Associated Molecular Patterns 
(PAMPs) of microorganisms (lipopolysaccharide –LPS–, lipoteichoic acids, peptidoglycans, 
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glucans, viral or bacterial DNA) using pattern recognition receptors (PRRs) located both on 
the cell surface and intracellularly. The activation of PRRs leads to the release of 
antimicrobial proteases and oxidants, in conjunction with the development of an 
inflammatory reaction which results in the release of several pro-inflammatory mediators, 
such as cytokines and chemokines [60]. The role of some of these inflammatory mediators is 
discussed in Section 1.4.1. 
1.3.2 Toll-like Receptors (TLRs) 
The best characterised signalling PRRs to date are the Toll-like receptors (TLRs), which are 
able to recognise PAMPS. Present in vertebrates, invertebrates and plants, TLRs constitute 
a primitive host defence mechanism against a potentially limitless spectrum of microbes 
(bacteria, viruses and fungi). Recognition of a specific microbe by a TLR triggers an 
inflammatory response that will consequently induce activation of the innate immunity [61]. 
TLRs are type-1 integral membrane glycoproteins and, on the basis of considerable 
homology in the cytoplasmic region, are members of a larger superfamily that includes the 
interleukin-1 receptors (IL-1Rs). By contrast, the extracellular region of TLRs and IL-1Rs 
differ markedly: the extracellular region of TLRs contains leucine-rich repeat (LRR) motifs, 
whereas the extracellular region of IL-1Rs contains three immunoglobulin-like domains [62]. 
TLRs and IL-1Rs both have a conserved region of 200 amino acids in their cytoplasmic tails, 
which is known as the Toll/IL-1R (TIR) domain [63]. Within the TIR domain, the regions of 
homology comprise three conserved boxes crucial for signalling. 
The discovery of the TLR family began with identification of Toll, a receptor expressed by 
Drosophila flies essential for the establishment of the dorso-ventral pattern in developing 
embryos [64] as well as the insect’s innate immune response against fungal infection [65]. 
Homologues of Toll were subsequently identified through bioinformatics database searches, 
and so far, 10 members of the TLR family have been identified in humans (Table1.1). TLRs 
that recognise nucleic acids are associated with endosomes (TLR-3, -7, -8, -9), whereas 
cell-surface TLRs sense lipids and proteins (TLR-1, -2, -4, -5, -6) (Table 1.1). 
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The interaction between TLRs and microbial components triggers the activation of specific 
signalling pathways that culminate in the increased expression of inflammatory genes. Two 
major signalling pathways have been identified: the MyD88-dependent and the MyD88-
independent pathway (Figure 1.9). MyD88 (Myeloid differentiation primary response gene 
88) is an adaptor protein characterised by a carboxyl-terminal TIR domain and an amino-
terminal death domain. The MyD88-dependent pathway is triggered by all TLRs, except for 
TLR-3, and leads to activation of the MAP-kinases (Mitogen-Activated Protein Kinases: 
p38MAPK, p44/42 MAPK (Erk1/2) and JNK) and the transcription factor NF-κB (nuclear 
factor-κB), thus inducing pro-inflammatory gene expression (Figure 1.9). The MyD88-
independent pathway, activated by TLR-3 and TLR-4 only, uses the adaptor protein TRIF 
(TIR domain-containing adapter-inducing interferon-β) instead of MyD88, and induces NF-κB 
and IRF3 (interferon regulatory factor 3) transcription factors. This allows for an additional 
set of genes to be induced, type I interferons genes, which includes antiviral genes, such as 
IFN-β (interferon-β) (Figure 1.9). In this way, TLRs are able to provide a highly specific 
response to a broad range of microbial ligands [66]. Studies showed that airway epithelial 
cells constitutively express TLRs and therefore the involvement of these receptors in NP 
signalling and consequent action on the cell is interesting to this investigation [67]. 
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 LIGANDS ORIGIN 
TLR-1/2 triacyl lipopeptides 
OspA 
Bacteria, mycobacteria 
Borrelia burgdorferi 
TLR-2 lipoproteins/lipopeptides 
peptidoglycan, lipoteichoic acid  
many more 
A  variety of pathogens 
Gram-positive bacteria 
 
TLR-3 Poly I:C dsRNA virus 
TLR-4 Lipopolysaccharide (LPS) 
Fusion F protein  
HSP70 
Gram-negative bacteria 
Respiratory syncytial virus 
Host 
TLR-5 Flagellin Bacteria 
TLR-2/6 diacyl lipopeptides Mycoplasma 
TLR-7 Imidazoquinoline (imiquimod) 
loxoribine (a guanosine analogue) 
bropirimine 
Synthetic compounds 
Synthetic compounds 
Synthetic compounds 
TLR-8 small synthetic compounds  
TLR-9 Unmethylated CpG DNA Bacteria, virus, yeast, insects 
TLR-10 Unknown  
 
Table 1.2 Toll-like receptors ligands. Adapted from Gay and Gangloff, 2007 [68]. 
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Figure 1.9 Schematic representation of the TLR signalling: MyD88-dependent and 
MyD88-independent pathways. MyD88-dependent: TLR stimulation triggers MyD88 
association and activation, culminating in the release of pro-inflammatory cytokines. MyD88-
independent: it is a TRIF-dependent pathway that leads to pro-inflammatory gene 
expression and Type 1 IFN production. Proteins in the blue box represent signalling 
molecules contributing to the pathways but not mentioned in the text.  
1.3.3 Respiratory infections and nanoparticles: a further concern? 
Similar parallels to those between levels of ambient UFPs and increased hospitalisations for 
cardio-respiratory conditions have been drawn regarding inhalation of ambient pollution and 
respiratory infections. Indeed, there have been a number of studies examining the link 
between particulate matter (PM) exposure and the onset of respiratory infections. PM, or 
simply particle pollution, is a mixture of particles and droplets, consisting of a variety of 
components such as organic compounds, metals, acids, soil, and dust. The size of the 
different particles forming PM spans approximately four orders of magnitude from less than 
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1nm to more than 10μm. Studies by Dockery et al. examined the association between air 
pollution and respiratory health in children [69] and found that rates of chronic cough, 
bronchitis, and chest illness were positively associated with levels of PM. Another study in 
the Utah Valley, performed over a 3-year period during which a local steel mill was on strike 
for a year, presented a unique opportunity to examine the effects of PM in a more controlled 
environment, since the levels of PM while the mill was open were nearly double the levels 
observed when the mill was closed. An association was found between the increased levels 
of PM and hospital admissions for pneumonia, among other respiratory illnesses, in both 
children and adults [70]. 
Furthermore, Jaspers and colleagues found that, in occupational settings, diesel exhausted 
particles (DEPs; 94% of these particles are less than 2.5μm in diameter [71]) emitted from 
diesel engines can enhance the susceptibility and response to respiratory viral infection 
through an alteration of the host’s innate immune defences. By decreasing the expression of 
pulmonary surfactant proteins, which are important in immune defence against microbial 
organisms, exposure to DEPs increases the likelihood of becoming infected with influenza 
[72]. Similarly, in vitro studies using the adenocarcinoma A549 cell line demonstrated that 
exposure to DEPs can alter the innate immune defence responses against viral infections. 
The cause of this alteration was indicated in the increased expression of TLR-3, which is 
responsible for the recognition of, and response to, viruses and double-stranded RNA. By 
increasing TLR-3 levels, DEPs enhance part of the innate immune response that, within 
epithelial cells, translates into increased recruitment and activation of inflammatory and 
immune cells. Additionally, the increased immune signalling by epithelial cells may also 
recruit and activate dendritic cells, leading to increased antigen presentation and adaptive 
immune activation, possibly resulting in an autoimmune or allergic reaction [72]. 
Other studies have suggested that air pollution may also modify symptoms in individuals 
who are already infected. For instance, it has been reported that exposure to air pollution 
might enhance the respiratory symptoms in children experiencing respiratory infections [73]. 
Thus, there is a strong body of evidence suggesting a link between air pollution and severity 
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of illness associated with respiratory infections. Furthermore, individuals with pre-existing 
lung disease may be at greater risk. These studies have led to the hypothesis that, similarly 
to air pollution, exposure to inhaled NPs may increase the vulnerability to respiratory 
infections or exacerbate pre-existing pulmonary conditions. 
1.4 Bioreactivity of nanoparticles 
One of the fields that could benefit the most from nanotechnology is nanomedicine. A main 
goal of nanomedicine is the creation of multitask NPs for the enhanced diagnosis and 
treatment of human diseases, as well as for the increased efficacy and lower side effects of 
existing drugs [74]. However, a major obstacle remains the poor mechanistic understanding 
of the interactions between NPs and biological systems. In vitro exposure to NPs has been 
reported to induce changes in several cell types, including alterations in inflammatory and 
apoptotic markers, increased levels of oxidative stress, autophagy activation and damage to 
the DNA [10,75,76]. Therefore, those specific pathways are now being investigated to 
develop a full, critical knowledge of NP mechanisms and effects, useful, for example, for 
establishing a safe dose of a specific NP that needs to be commercialised. The study of 
cellular responses to specific NPs, at certain doses and exposure times, allows a 
mechanistic, biochemical and ultrastructural analysis of specific types of cells during specific 
NP exposures. 
The main pathways we decided to investigate in the present study are inflammation, 
autophagy, oxidative stress and genotoxicity; these are all introduced in the following 
Sections. 
1.4.1 Inflammatory mediators: cytokines 
As previously mentioned (Sections 1.3.1 and 1.3.2), the activation of the immune system by 
a pathogen or other exogenous stimuli triggers an inflammatory response, resulting in 
inflammatory mediator release. Low levels of inflammation are positive for cells as they 
represent a normal cellular reaction to injury or noxious stimuli, a fight for survival. However, 
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when in excess, inflammation can lead to diseases [77]. In vitro and in vivo experiments 
demonstrate that exposure to NPs can be associated with inflammation [76,77]. 
One of the most significant classes of mediators released as part of the inflammatory 
response is the cytokine family. Cytokines are a family of low molecular weight (10-50kD), 
small, soluble proteins, critical to the initiation and function of both the innate and adaptive 
immune response. With the exception of red blood cells, every cell can produce, as well as 
respond to, cytokines. Cytokines elicit their effects by binding to specific membrane 
receptors on target cells, activating cascades of intracellular signalling that alter cell function. 
The cytokine family includes chemokines (cytokines with chemotactic activities, produced by 
leukocytes and several types of tissue cells, e.g. endothelial cells, epithelial cells and 
fibroblasts); interleukins (cytokines mainly secreted by structural endothelial and epithelial 
cells, or by leukocytes, including monocytes and macrophages,); lymphokines (cytokines 
mainly produced by lymphocytes); monokines (cytokines produced exclusively by 
monocytes); growth factors and the tumor necrosis factor family (TNF) [78]. The action of the 
cytokines can be autocrine (the cytokine acts on the cell that secretes it), paracrine (the 
target is restricted to nearby cells) or endocrine (the cytokines diffuse to distant regions of 
the body where they act) [58]. A peculiarity of cytokines is redundancy. The term refers to 
the ability of sharing biological actions by sharing receptor subunits or targeting the same 
molecular pathway(s) [79]. This level of redundancy means that a robust inflammatory 
response can still be initiated even if a cytokine is absent or has reduced expression. 
Cytokines can be pro-inflammatory or anti-inflammatory [164-166]. The former will be 
investigated in this study. 
1.4.1.1 Pro-inflammatory cytokines  
Pro-inflammatory cytokines promote systemic inflammation and are produced by a wide 
variety of cells, such as epithelial cells, monocytes/macrophages, fibroblasts, neutrophils 
and T-cells. The gene expression of pro-inflammatory mediators is triggered, for example, by 
exogenous factors (e.g. infection, a trauma, ischemia or other pathological conditions), or by 
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the cytokines themselves [80]. A pivotal event in the resolution of any inflammatory response 
is the “switch” from innate to adaptive immunity. This transition, which requires a specific 
regulation between recruitment and clearance of leukocytes, is controlled by a network of 
regulators among which the cytokine IL-6 plays a predominant role [81]. IL-6 and CXCL-8 
(discussed below), representing the most abundant cytokines produced by AT1 cells (refer 
to Section 1.2.2.1) are a focus of the present study. IL-6 is regarded as the “immunological 
switch” from innate to adaptive immunity. By activating neutrophils, initiating macrophage 
recruitment and favouring maturation of dendritic cells [82], IL-6 allows for an optimal 
immunological response, balancing pro- and anti-inflammatory events, thus promoting the 
resolution of the inflammatory response [81]. Although mostly regarded as a pro-
inflammatory cytokine, pleiotropic IL-6 also has anti-inflammatory properties [83]. Two 
different signalling pathways have been attributed to IL-6: the classic-signalling and the 
trans-signalling pathways. In the former, IL-6 stimulates target cells via a membrane bound 
IL-6 receptor, which upon ligand binding associates with the receptor protein gp130. Gp130 
dimerizes, leading to the activation of the MAP-kinase pathway and the transcription of 
target genes [83]. Interestingly, only few cells express membrane bound IL-6 receptor 
whereas all cells display gp130 on the cell surface. Those cells only expressing gp130 are 
not responsive to IL-6 alone, but only to a complex of IL-6 bound to a naturally occurring 
soluble form of the IL-6 receptor. This process, named trans-signalling, enlarges the 
spectrum of IL-6 target cells. It has been shown that pro-inflammatory responses of IL-6 are 
mediated by trans-signalling, whereas anti-inflammatory activities of IL-6 are mediated by 
classic signalling [83]. IL-6 trans-signalling is observed in chronic inflammatory disorders and 
leads to activation of the immune system by the recruitment of monocytes to the inflamed 
area [83]. Systemically, IL-6 can induce effects such as fever, increased secretion of 
glucocorticoids, the activation of the complement and clotting cascades [84]. 
 
Among pro-inflammatory cytokines, chemokines are particularly relevant to the immune 
response. Chemokines (chemotactic cytokines) are a family of approximately 50 small, 
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distinct, but structurally related molecules that coordinate the immune response through 
chemo-attraction of immune cells (mainly regulating trafficking of leukocytes) into target 
organs. Chemokines can be divided into four subgroups, based on the position of their 
cysteine residues: CXC, CC, CX3C and C. Chemokines act through binding to their cell-
surface G protein-coupled receptors located on target cells [85]. Examples of the best known 
chemokines include CXCL-8, CCL-2 (MCP-1), CXCL-1 (GRO-α), CXCL-10 (IP10), CCL-3 
(MIP-1α) and CCL-5 (RANTES). 
As previously mentioned, CXCL-8, together with IL-6, is a focus of the present study. CXCL-
8 is a neutrophil chemo-attractant that belongs to the α-CXC family in which two cysteine 
residues are separated by a non-conserved amino acid. CXCL-8 binds two distinct 
receptors, CXCR1 and CXCR2, with similarly high affinity [86,87]. CXCL-8, produced by a 
wide range of cells throughout the body, is released in response to a number of stimuli such 
as infection, ischemia, trauma, and other disturbances of tissue homeostasis. In addition to 
its role as a chemokine, studies have demonstrated that CXCL-8 exhibits multiple effects on 
neutrophils via CXCR2, including induction of shape change, release of lysosomal enzymes, 
superoxide, hydrogen peroxide, induction of a respiratory burst and increases in the 
expression of adhesion molecules [88]. 
1.4.2 The autophagy machinery 
1.4.2.1 The importance of autophagy  
Autophagy (self-eating) is a general term for processes by which damaged, unnecessary or 
dysfunctional intracellular components (e.g. cellular proteins and organelles generally 
termed “cargo”) are sequestered, delivered to lysosomes and digested (degraded) by 
lysosomal hydrolases [89]. In fact, in contrast to proteasomal degradation, that specifically 
targets ubiquitinated proteins, autophagy is mediated via the lysosomes [90]. The major 
function of autophagy is to act as a survival mechanism that, by removing unwanted cellular 
material, maintains cellular homeostasis and regenerates metabolic precursors [91]. In 
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addition to this, autophagy also plays a fundamental role in the innate immune response 
during infections, by targeting and degrading intracellular viruses and bacteria [92]. 
1.4.2.2 Mechanism of autophagy activation 
The understanding of molecular mechanisms underlying the process have only become 
apparent in the last 25 years following yeast genetic screens that identified mutants of 
autophagy-related genes (Atgs). The first identified mammalian Atgs, Atg5 and Atg12, were 
shown to be highly homologous to those in yeast [92]. 
Conditions such as nutrient starvation, pathogen infection and other environmental stressors 
can induce autophagy. Autophagy activation requires several key molecules such as 
Microtubule-associated protein 1A/1B-light chain (MAP1LC3B), henceforth referred to as 
LC3, which is the mammalian homologue of yeast Atg8 (Figure 1.10). LC3 is a cytoplasmic 
protein conventionally regarded as a marker of autophagosomes in mammalian cells [93]. 
The first step in autophagy activation consists in the formation and elongation of an isolation 
membrane inside an intact cell (Figure 1.10). Recent studies indicate that these structures 
might originate from a pre-existing membrane structure called “phagophore”, or could be 
formed de novo [93]. LC3 is proteolytically cleaved and coupled to phosphatidyl-
ethanolamine (PE) to form LC3-II, which is inserted, together with adaptor protein p62 
(attached to the cargo), into the autophagosomal membrane, both in the inner and in the 
outer part of the membrane (Figure 1.10). This structure, called the autophagosome, is a 
double-membraned vesicle in which the cargo that will be degraded is isolated. The fusion of 
an autophagosome with a lysosome generates an autolysosome, in which the LC3-II in the 
inner membrane gets degraded with the internal material by lysosomal hydrolases, whereas 
the external LC3-II is recycled (Figure 1.10) [93]. Therefore, typical characteristics of 
autophagy activation are increased intracellular levels of LC3-II and autophagosomes 
formation [93,94]. 
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Figure 1.10 The cellular process of autophagy. Stimuli such as nutrient starvation or 
pathogen infection can induce autophagy. (I) formation of the isolation membranes; (II) 
sequestration of the cargo attached to p62; recruitment of LC3-II protein; maturation of the 
double membrane; formation of the autophagosome; (III) autophagosome-lysosome fusion; 
degradation of p62 and the attached ubquitinated cargo; recycling of the outer LC3-II. 
1.4.2.3 Autophagy and immunity 
The existence of a direct link between viruses, TLRs and autophagy is well documented. 
Studies have shown evidence of the ability of autophagosomes to selectively target viral 
nucleic acids and deliver them to endosomal TLRs (TLR-3, 7/8, 9) to stimulate the innate 
immune response via TLRs [95]. Although the precise mechanism by which viral nucleic 
acids are delivered to the TLRs remains to be determined, it has been suggested that the 
process involves fusion of an autophagosome with an endosome containing TLRs [90]. The 
opposite mechanism can also occur: direct activation of TLRs by viral nucleic acids can 
induce autophagy. Upon stimulation of TLR-3, 4 and 7 with different purified PAMPs, the 
TLR adaptors TRIF and MyD88 interact with Beclin-1, the mammalian orthologue of yeast 
Atg6, resulting in the disruption of its interaction with protein Bcl-2 [96], which normally 
functions to suppress autophagy [97]. As Chiramel et al. suggested, the ability for autophagy 
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to deliver PAMPs to TLRs, and vice versa the induction of autophagy upon TLR activation, 
implicates the existence of a positive feedback loop. The role of this loop might be important 
for antigen presentation via MHC-I and MHC-II molecules, and therefore the initiation of 
adaptive immune response [90]. In fact, autophagy is part of the adaptive immunity and, in 
particular, antigen presentation and lymphocyte development [92]. The connection between 
bacteria and autophagy is also well described in the literature. It has been demonstrated that 
stimulation of TLR-2, 4, and 7 with their ligands activate autophagy, which function to 
eliminate intracellular bacteria [96,98,99]. Thus, as for viruses, TLR responses can directly 
activate autophagy resulting in the killing of invading bacteria. 
1.4.3 Genotoxicity of nanoparticles 
1.4.3.1 Direct and indirect mechanisms of NP-induced DNA damage 
If NPs are able to gain access to the cell, their enhanced surface reactivity could result in 
increased interactions with biomolecules, causing direct cellular damage and promoting 
oxidative stress [100]. In addition to this, once inside the cell, NPs might be able to interact 
with DNA, for example during mitosis, when the nuclear membrane breaks down leaving the 
DNA free in the cytoplasm [100]. Alternatively, if small enough, NPs might gain access to the 
nucleus through nuclear membrane pores [101]. Large NPs are able to enter the nucleus 
through protein-mediated mechanisms [102]. 
DNA damage can also be induced by NPs indirectly, for example by interactions between 
the NPs and proteins other than the DNA molecule, such as those participating in cell 
division [100]. Another fundamental mechanism thought to be one of the major indirect 
sources of genotoxicity is oxidative stress. NP-induced oxidative stress leads to DNA 
damage that can be detected as single or double-stranded DNA breaks, phosphorylation of 
histone H2A.X or base modification, all of which, if unrepaired, can potentially initiate 
carcinogenesis [103]. Additionally, particle-mediated oxidative stress may arise from altered 
function of mitochondria or from the enzyme NADPH oxidase (nicotinamide adenine 
dinucleotide phosphate-oxidase) [104]. Importantly, NPs also have the potential to generate 
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DNA damage through a chronic inflammatory response; indeed, chronic inflammation has 
been associated with tumorigenesis [105,106]. The link between NPs and these 
mechanisms involved in DNA damage formation are investigated and discussed throughout 
this study. 
1.4.3.2 Cellular consequences of DNA damage 
DNA damage can induce various cellular responses, such as cell cycle arrest in G2/M or S 
phase, DNA repair and apoptosis. G2/M arrest has been demonstrated in human lung 
fibroblasts and glioblastoma cells, following exposure to capped AgNPs (AgNPs with surface 
modifications, e.g. addition of functional groups) [50], whereas hepatoma cells were arrested 
at the S phase after stimulation with unmodified AgNPs [107]. Cells that successfully repair 
the damage will re-enter the cell cycle; those with extensive damage will fail to repair and 
undergo apoptosis or necrosis. The mechanisms of cell death are activated in order to 
eliminate the single mutated cell for the benefit of the overall organism. However, if the 
repair fails to occur before or during replication of the damaged DNA molecule, there is a risk 
of mutagenesis and therefore of carcinogenic consequences. Indeed, high levels of oxidative 
DNA lesions have been found in many tumors [108]. Damage to the DNA could not only 
cause cancer, but could also affect fertility, if the mutation happens in reproductive cells 
[100]. 
As such, there is a growing necessity for investigating the genotoxic potential and the 
mechanism of action of every NP that will be commercialised or used in medical application.  
1.4.4 Oxidative stress 
1.4.4.1 Reactive oxygen species (ROS) and oxidative stress 
ROS production and consequent oxidative stress formation have been suggested to be a 
hallmark of cellular responses to NP exposure [10,109]. ROS are reactive species of 
molecular oxygen (O2) including superoxide anion (O2
•−
), hydroxyl radical (OH•), hydroxyl 
ion (OH-), hydrogen peroxide (H2O2) and singlet oxygen (
1O2). Molecular oxygen generates 
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superoxide anion, a precursor of most ROS, via one-electron reduction catalysed by NADPH 
oxidase. Further reduction of oxygen may either lead to H2O2 or OH•, via dismutation and 
metal-catalysed Fenton reaction respectively (Figure 1.11) [110]. 
Oxidative stress occurs when there is an imbalance between the production of oxidants and 
the system’s ability to readily neutralise the oxidants using antioxidants such as glutathione 
or ascorbic acid (see Section 1.4.4.5). The cells of the body are continuously exposed to a 
range of oxidants from both exogenous and endogenous sources. Examples of the former 
include UV radiation, drugs, toxins and air pollutants (e.g. car exhaust, industrial 
contaminants). Mitochondrial respiration, NADPH oxidase, phagocytosis of immune cells 
and presence of free radicals represent endogenous forms of oxidants [111]. Although the 
levels of exogenous oxidants can be high, it is the endogenous sources that are thought to 
be the most important, since they are continuously produced during the whole biological life 
of the cell [112]. Once formed, due to its reactivity, oxidative stress can cause different types 
of damage to the cell, including DNA damage, lipid peroxidation and oxidation of proteins 
[113]. In humans, oxidative stress has been implicated in several pathologies, including 
cancer, atherosclerosis, chronic inflammatory processes, ischemia/reperfusion injury and 
neurodegenerative diseases [114]. However, it has to be specified that the consequences of 
ROS generation are not always deleterious to the cell. During conditions of mild oxidative 
stress, transcription of phase II enzymes is activated via nuclear factor (erythroid-derived 2)-
like 2 (Nrf2) induction, which in turn ensures cellular homeostasis maintenance, suppression 
of tumor promotion and progression [5]. When the levels of oxidative stress are intermediate, 
redox-sensitive MAP-kinases and nuclear factor kappa-light-chain enhancer of activated B 
cells (NF-kB) cascades trigger a pro-inflammatory response to activate cellular defence. On 
the contrary, mitochondrial membrane damage and electron chain dysfunction are typical of 
very high levels of oxidative stress, which might then lead to cell death [6].  
In the following sections, the three main NP-associated sources of ROS are introduced: 
mitochondria, NADPH oxidase and free radicals. 
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Figure 1.11 Schematic model for generation of common ROS. NADPH oxidase 
catalyses the formation of superoxide anion (O2
•−
) from molecular oxygen (O2). Superoxide 
can be either dismutated to hydrogen peroxide (H2O2) and molecular oxygen (O2) by 
superoxide dismutase (SOD) or it can be transformed to hydroxyl radicals (OH•) by a 
Fenton-type reaction in the presence of peroxidases.  
1.4.4.2 Mitochondrial ROS   
Mitochondria are one of the major sources of endogenous oxidative stress [113]. During 
mitochondrial respiration, molecular oxygen is converted into water (H2O) and energy is 
generated in the form of adenosine triphosphate (ATP). In this process, the mitochondrial 
electron transport chain, which consists of several redox centres, may leak electrons that 
can serve as a primary source of superoxide production. About 1-2% of the molecular 
oxygen consumed during physiological respiration is transformed into superoxide radicals 
[113]. 
Mitochondria are a common source of NP-induced oxidative stress [115]. Once NPs gain 
access to the intracellular compartment of the cell and interact with mitochondria, they can 
generate ROS via several mechanisms, such as impairment of the mitochondrial electron 
transport chain, physical damage to the mitochondria or depolarisation of the mitochondrial 
membrane [115]. At the same time, mitochondria are also a target for the effect of ROS 
generated elsewhere in the cell [113]. Since cellular metabolism depends on the supply of 
ATP, provided by the mitochondria, any damage to these organelles might have deleterious 
effects on the cells and impact on cell viability [113]. 
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1.4.4.3 NADPH oxidase-derived ROS 
NADPH oxidase is an important enzyme in the innate immune response to inhaled microbes 
in the lung [116]. In the presence of microbes, TLRs trigger signalling pathways that may 
result in NADPH oxidase activation [116] and subsequent oxidative stress. In fact, NADPH 
oxidase is an oxidoreductase that catalyses the production of superoxide (O2
•−
) from oxygen 
and NADPH [117], but unlike other oxidoreductases, NADPH oxidase is a “professional” 
ROS producer, whereas the other enzymes generate ROS only as by-products [118]. 
The NADPH oxidase complex, which exists in the cellular membrane and subcellular 
compartment membranes, was originally identified and characterised in phagocytes, where it 
plays an essential role in non-specific host defence against microbial organisms [119]. 
NADPH oxidase exists in 5 different isoforms (NADPH oxidase1, 2, 3, 4 and 5), found in 
numerous non-phagocytic cell types, including endothelial cells, lung epithelial cells, 
cardiomyocytes and fibroblasts [120]. The classical NADPH oxidase comprises a 
membrane-bound gp91phox/p22phox heterodimer (also known as flavocytochrome) and 
other cytosolic subunits (p67phox, p47phox, p40phox and the small GTPase Rac2) which 
associate with this complex in the activated enzyme [117] (Figure 1.12). The enzyme is 
normally quiescent, but upon activation, the cytosolic subunits translocate and become 
assembled with the membrane flavocytochrome. In the activated enzyme complex, the 
flavin-containing catalytic subunit functions as an electron transport system which uses 
NADPH as a donor of electrons, that are ultimately transferred to molecular oxygen, 
resulting in the generation of O2
•− 
(Figure 1.12) [119].  
A feature of this enzyme is the heterogeneity of its activating stimuli, such as heavy metals, 
ROS, UV/ionizing radiations, pH (intracellular acidosis), environmental cytotoxic substances 
and others [121]. However, the current understanding of the mechanisms by which cellular 
stresses activate NADPH oxidase remain incomplete, especially in non-phagocytic cells. 
These mechanisms of NADPH oxidase activation that have been partially described include 
up-regulation of its expression, presence of Ca2+ sensing domains, direct protein-protein 
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interactions and presence of ROS molecules [121]. Interestingly, in human embryonic kidney 
293 (HEK293) cells ectopically expressing TLR-4 and its accessory proteins, Park et al. 
showed that stimulation with LPS induced direct association of TLR-4 and NADPH oxidase4, 
which then triggered ROS production and NF-kB activation [122]. 
Although a number of studies have demonstrated the ability of NPs to induce ROS 
production through NADPH oxidase [123–125], the mechanism of action of the NPs or the 
possible interaction between the enzyme and the NPs are still unknown. 
 
 
 
 
 
 
 
 
 
Figure 1.12 Structure of activated NADPH oxidase complex. The activated NADPH 
oxidase classically consists of a membrane-bound gp91phox/p22phox heterodimer and 
other subunits (p67phox, p47phox, p40phox and Rac) that associate with the heterodimer 
upon activation. The NADPH binding domain is predicted to be on one side of the 
membrane, whereas O2
•−
generation occurs on the other side. 
1.4.4.4 ROS from free radicals  
Several studies have demonstrated the importance of NP surface reactivity in ROS 
generation [126,127]. For example, free radicals (e.g. superoxide anion or hydroxyl radical) 
are either directly bound to the NP surface [128] or can be released as free entities in the 
aqueous solution in which the NPs are resuspended [104,128]. By definition, free radicals 
are molecules/ions with unpaired electrons, therefore with one or more “dangling” covalent 
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bonds, which are responsible for the high chemical reactivity of free radicals. These 
molecules will likely play a key role in some of the interactions of NPs inside the alveolar 
space.  
1.4.4.5 Antioxidants 
In order to protect themselves from high levels of oxidative stress, eukaryotic cells possess 
powerful antioxidant defence mechanisms, which can be either enzymatic or non-enzymatic. 
The three major classes of antioxidant enzymes are the superoxide dismutases (SOD), 
catalases and glutathione peroxidases [129]. Among the non-enzymatic antioxidants, 
glutathione (GSH) is the most important antioxidant defence against ROS and other oxidants 
[130]. GSH is a tripeptide (L-γ-glutamic acid, L-cysteine and glycine) containing a thiol 
(sulfhydryl) group [131]. It exists in relatively large amounts (0.5-10mM) in almost all living 
cells [132], and its reaction with oxidants converts it from reduced glutathione (GSH) to its 
oxidised form, glutathione disulphide (GSSG). By oxidising itself, GSH allows other cellular 
constituents to return to their reduced form, thus restoring the normal physiological 
environment of the cell. Under normal physiological conditions, the intracellular environment 
is highly reducing, due to a high GSH/GSSG ratio ranging from 30:1 to 100:1 [133]. 
Therefore, most of the cellular GSH is present in its reduced form. The bulk of intracellular 
GSH is found in the cytosol, but the existence of a minor mitochondrial pool has also been 
demonstrated [134]. GSH is synthesised in cells, and is then transported into the 
extracellular space where it is cleaved and its amino acids will be used to synthesise more 
GSH. Relevant to this study is the critical role of GSH in the lungs’ antioxidant defences, 
particularly the pulmonary epithelium [135]. An imbalance in GSH levels in the epithelial 
lining fluid of patients is associated with a number of respiratory diseases such as idiopathic 
pulmonary fibrosis [136], acute respiratory distress syndrome [137], cystic fibrosis [138] and 
human immune-deficiency virus (HIV)-positive patients [139]. Besides its main role in 
detoxifying ROS, GSH also serves to maintain the pool of other important non-enzymatic 
antioxidants, such as α-tocopherol and ascorbic acid, in their reduced form [130]. 
  
58 
1.5 Rationale  
The steady growth of the nanotechnology industry holds high hopes for important changes 
and benefits in a wide range of areas (from medical healthcare to electronics and aerospace 
engineering). However, the properties that make NPs so desirable may also be responsible 
for adverse biological effects. Having the same size as UFPs, will NPs exert the same 
effects as seen with these particles? Furthermore, once exposed to NPs, will individuals with 
pre-existing lung diseases or respiratory infections be exposed to a higher risk factor? 
Considering that NPs are already being used in a large number of consumer products and 
medical devices, international government agencies responsible for regulation and funding 
are underlining the urgent need to arrive at an appropriate risk assessment to enable the 
drafting of regulatory guidelines [76]. Consequently, in recent years, the onset of different 
studies on NP properties and their effects on human health has been strongly encouraged. 
However, there are specific factors that lead to critical limitations in the understanding of NP 
effects: 
a) A substantial amount of published data on NPs relies on A549, a tumour-derived human 
cell line that has been proven to exhibit different characteristics from normal human alveolar 
cells [36,39]. 
b) Although it has been shown that up to 50% inhaled NPs deposit in the alveolar region of 
the lung [9], bronchial epithelial cells (BEAS-2B) are widely used in NP studies. Therefore, at 
present, there are no physiologically relevant in vitro models of the pulmonary alveolar 
epithelium in which to investigate the effects of NPs. Covering 95% of the alveolar unit, AT1 
cells are the primary cell type to come in to contact with inhaled NPs. Furthermore, evidence 
shows that, when compared to AT2 cells, TT1 cells internalise significantly more NPs than 
AT2 cells [35]. 
c) In vivo testing is still used as a standard screening method. However, in vivo studies of 
the pulmonary effects of NPs use 100-200 rodents in order to study just one NP formulation. 
As the number of products containing NPs is increasing, there will be an enormous 
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expansion in the use of animals. It is therefore crucial that alternative, physiologically 
relevant strategies are developed for first line screening. Due to its simplicity and 
reproducibility, the in vitro approach is regarded as the most appropriate first line method to 
investigate mechanisms and cellular signalling pathways involved in NP reactivity with 
human cells [140]. In vitro model systems can be used to establish concentration-effect 
relationships in cells, thus are suited for high-throughput screening of an ever increasing 
number of new engineered NPs [140]. Once this information is identified and understood in 
vitro, then it can be transferred for in vivo study validation. 
d) Although incorporated in more than half of the globally commercialised consumer 
products containing NPs, AgNP reactivity has not yet been investigated in a model relevant 
to potential “real life” exposure. 
 
In this study, we propose to use physiologically relevant immortalised human alveolar type 1 
epithelial cell line (TT1) to fully characterise AgNP bioreactivity. This cell line, expressing 
AT1-specific markers, is highly novel and relevant to the in vivo human setting. Studies such 
as the present one are important in building a critical understanding of NP properties, 
reactivity and effects in the human lung. This is a fundamental step towards the achievement 
of a proper knowledge on the beneficial and deleterious effects of NPs to inform 
governments, industries and healthcare professionals in order to develop regulatory 
legislations for NP use and commercialisation. 
 
 
 
 
  
60 
1.6 Hypothesis  
We hypothesised that inhaled AgNPs drive a pro-inflammatory response in the human 
alveolar epithelium, involving a number of important cellular pathways (e.g. oxidative stress, 
autophagy machinery and DNA damage). We further hypothesised that, co-exposure to 
AgNPs and microbial infection potentiates those signalling pathways, potentially favouring 
the onset of airway diseases. 
1.7 Specific Aims 
1) Assess AgNP reactivity by: measurement of cellular viability, cytotoxic effects and 
innate immune responses of AgNPs, both alone and in combination with viral (Poly 
I:C) and bacterial (LPS) ligands (Chapter 2). 
2) Investigate the effect of AgNPs on autophagy and DNA damage, both alone and in 
combination with viral (Poly I:C) and bacterial (LPS) ligands (Chapter 3). 
3) Determine whether oxidative stress is involved in TT1 cell responses to AgNPs 
(Chapter 4). 
4) Investigate the possible involvement of TLR-3 (Poly I:C) and TLR-4 (LPS) in AgNP-
induced effects (Chapter 5). 
5) Determine whether AgNPs are internalised by TT1 cells, possibly contributing to their 
bioreactivity (Chapter 5). 
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Figure 1.13 Molecular events by which NPs exert their toxic effects at the cellular level. The scheme summarises several pathways that have been 
reported to be activated by NPs and that will be the focus of this work. NP clearance from the lung by AMs is not as efficient as that for larger particles. This 
leads to longer retention of NPs in the lung, therefore to a higher probability of uptake by epithelial cells. Once inside the cell, NPs have been shown to be 
responsible for several interlinked deleterious effects, such as activation of a pro-inflammatory response, generation of ROS, damage to mitochondria and 
DNA, and a possible activation of apoptotic/necrotic pathways. 
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2. RESPONSE OF HUMAN ALVEOLAR EPITHELIUM TO 
SILVER NANOPARTICLES AND MICROBIAL LIGANDS 
2.1 Introduction 
2.1.1 Antimicrobial properties and commercialisation of AgNPs 
With the rapid development of nanotechnology, silver (Ag) has become the most 
commercialised NM of all manufacturer-identified products in the world. Ag, like other 
heavy metals, is a natural biocide, but compared with titanium, zinc and copper, shows 
the highest antimicrobial efficacy against bacteria, viruses, and also some eukaryotic 
microorganisms [6]. Historically, the clinical use of Ag compounds to prevent microbial 
growth is well documented. In the 1960s, creams containing Ag were prescribed to 
prevent bacterial growth on patients with burnt denuded skin [141]. Dietary 
supplements and a variety of Ag colloids have been sold for decades as a “cure-all” for 
such diseases as tuberculosis, syphilis, scarlet fever, herpes, pneumonia, and arthritis 
[142]. 
Although the mechanism of action by which AgNPs kill bacteria still remains unclear, it 
is known that AgNPs interact with sulphur-containing proteins as well as with the 
phosphorus-containing compounds [143]. In the former case, AgNPs may attach to the 
surface of the bacterial cell membrane, interfering with its permeability and metabolic 
pathways [144]. Alternatively, it has been shown that AgNPs can penetrate into the 
bacterial cell membrane and once inside, they can bind to the DNA, thus preventing its 
replication or interaction with the ribosome [145,146]. These mechanisms cause 
cellular distortion and a consequent loss of microbial cell viability. 
Recently, it has been demonstrated that AgNPs also bind to viruses such as hepatitis B 
virus (HBV) and extracellular virions. This interaction results in the inhibition of HBV 
and consequently inhibition of extracellular virion production [145,147]. 
Currently, products such as room deodorizing sprays, air/water disinfectants, face 
masks, acne creams, wound dressings, baby wipes, kitchen utensils and toys, all 
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exploit the natural antimicrobial activity of Ag [5]. To date, the most promising 
applications have been shown in the medical and pharmacological fields, such as 
wound treatment for infection (i.e. Acticoat) [148,149], antimicrobial gels (Pluronics 
[150]), gels for burn treatment [151], coatings for medical devices such as catheters 
[152] and orthopaedic implants [153]. However, despite the widespread application of 
AgNPs, there is a lack of information at the cellular and molecular level, concerning the 
possible toxicity of these NPs in humans. 
2.1.2 AgNP toxicity 
The potential toxicity of AgNPs has been known for many years. In the early 1980’s 
Rungby and Danscher showed that Ag salts intraperitoneally administered to rats could 
accumulate in neurons and in protoplasmic glial cells of the brain and spinal cord [154]. 
At present, inhalation studies in vivo only exist in rodents and show lung function 
changes along with chronic alveolar inflammation [155,156].  
AgNP toxicity seems to be more complicated than that of other NPs since it has been 
established that, upon contact with water, AgNPs release Ag ions from their surface 
[157]. The Ag ion is the most fundamental entity of Ag: it is an atom in which the 
number of electrons is one less than the number of protons (Ag+) [158]. Ag ions, highly 
reactive because of their positive charge, have a tendency to associate with negatively 
charged ions (e.g. fluoride, chloride, sulphate and hydroxide among others) in natural 
water, solutions, on dissolved organic matter or on particle surface [159]. Ag ions form 
particularly strong complexes with free sulphide (-SH) ligands, amino and phospho 
groups, protein, DNA and RNA. This indicates that Ag has the potential of causing 
damage to vital parts of an organism, such as the membranes. The binding of Ag ions 
with thiol groups of proteins may cause interruption of normal cell events, while 
interaction with thiol groups within the mitochondria can perturb mitochondrial functions 
causing oxidative damage [159]. However, it has been shown that, when Ag is 
complexed to a free sulphide, it becomes unavailable for uptake by organisms. This 
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process, called sulfidation of Ag, reduces Ag toxicity [159]. Although sulfide species 
exist in all human tissues, including the lung, it is not known whether a similar 
detoxification process occurs in the lung. The fact that most of the toxicity studies 
performed on AgNPs so far have overlooked their possible sulfidation, it might be one 
of the reasons leading to inconsistent results [159]. At present, AgNPs are engineered 
to release ions since they represent the source of Ag antimicrobial activity. For 
instance, Ag ions generators are commercially available to disperse ions into water 
machines to increase disinfection. However, the body of research on this subject 
presents ambiguous results. Some scientists suggest that a combination of AgNPs and 
Ag ions is responsible for Ag toxicity [160], while others attribute the toxic effect entirely 
to Ag ions [161]. In contrast, Kim et al. suggested that AgNP-induced toxicity is 
primarily the result of oxidative stress and is independent of the toxicity of free Ag+ 
[157]. In light of the well-established toxicity of Ag ions [159], Ag-based consumer 
products (see Section 1.1.2) do not contain ionic Ag but only nano-Ag.  
The amount of information on the toxicity of AgNPs in lung cells is limited and needs to 
be reinforced. In the first part of this work, the effects of AgNPs are investigated both 
alone and during co-exposure to a viral and a bacterial ligand. The viral and bacterial 
infections were simulated using polynosinic-polycytidylic acid (Poly I:C) and 
lipopolysaccharide (LPS) respectively. Poly I:C is a synthetic double-stranded RNA 
(dsRNA) ligand, used to activate TLR-3. LPS, that acts as a potent activator of TLR-4, 
is a major structural component of the outer wall of Gram-negative bacteria. We used 
the physiologically relevant TT1 cell line (see Section 1.2.2.1) to address the following 
hypothesis. 
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2.2 Hypothesis 
We hypothesised that TT1 cell exposure to AgNPs induces cytotoxicity and release of 
pro-inflammatory mediators, involving MAP-kinase activation. We also hypothesised 
that co-exposure to AgNPs and viral (Poly I:C) or bacterial (LPS) ligands generates a 
higher inflammatory response. 
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2.3 Materials and Methods 
2.3.1 Materials 
Trypsin, Bovine Serum Albumin (BSA), Phosphate Buffered Saline (PBS) tablets, 
dimethyl sulfoxide (DMSO), Bradford reagent, thiazolyl blue tetrazolium bromide, 
phosphatase inhibitor cocktail 2 and 3, Tween-20, CellLytic M cell lysis reagent, 
propidium iodide (PI) solution, antibody and JNK inhibitor (SP600125) were obtained 
from Sigma Aldrich (Poole, UK). Fluorescein isothiocyanate (FITC)-labelled Annexin V 
was purchased from BD Pharmingen (Oxford, UK). Penicillin-Streptomycin-Glutamine 
(PSG), Newborn Calf Serum (NCS), NuPage sample reducing agent, NuPage LDS 
sample buffer, NuPAGE Novex 4-12% Bis-Tris Gels and MOPS solutions, were 
purchased from Invitrogen (Paisley, UK). 96, 24, 12 and 6-well plates were obtained 
from Corning Incorporated (NY, USA); 96 V-bottom plates from Thermo Scientific 
(Denmark). DCCM-1 medium was obtained from React Scientific (Troon, UK). Duoset 
ELISA kits and substrate reagent were bought from R&D Systems (Abingdon, UK). Gel 
loading dye, p38MAPK, phospho-p38MAPK, p44/42 MAPK (Erk1/2), phospho-p44/42 
MAPK (phospho-ERK1/2), JNK, phospho-JNK antibodies, p38MAPK (SB203580) and 
ERK1/2 (U0126) inhibitors were purchased from New England Biolab (Massachusetts, 
USA); Western blot stripping solution re-blot plus mild from Merck-Millipore (Germany). 
LPS-EB ultrapure and Poly I:C ligand were obtained from Source Bioscience (San 
Diego, USA). Complete Mini protease inhibitor cocktail was ordered from Roche 
(Germany); anti-mouse, anti-rabbit secondary antibodies from DakoCytomation 
(Cambridgeshire, UK). Magic MarkXP and iBlot gel transfer stacks nitrocellulose Mini 
were ordered from Novex (Richmond BC). ECL Prime Western Blotting Detection 
Reagent was purchased from GE Healthcare (England). 
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2.3.2 Methods 
2.3.2.1 Physico-chemical characterisation of AgNPs  
The AgNPs used in this study were synthesised by QinetiQ (a British multinational 
defense technology company) and were fully characterised (Sections 2.3.2.1.1-4) by 
Prof. Eva Valsami-Jones’ team, in the Department of Mineralogy, Natural History 
Museum (NHM, UK). 
2.3.2.1.1 Surface area measurement 
Surface area of the samples was measured using 5 point nitrogen adsorption BET 
(Brunauer–Emmett–Teller) method in liquid nitrogen bath. Prior to the measurement, 
samples were degassed (using N2) at 100˚C overnight, using Flow-Prep 060. A 
reference NP (carbon black) was included in the analytical protocol for quality control 
purposes.  
2.3.2.1.2 Zeta Potential  
Surface charge was estimated using the zeta potential measurements, which were 
calculated through a flow cell with electric current (60mA). AgNPs were dispersed in 
deionised water and equilibrated at 25˚C. If the potential measured is above/below +/- 
30mV, then the suspension of particles is considered to be stable (i.e. particles do not 
sediment easily but remain suspended in solution). It is important to note that the 
stability of NPs, measured using zeta potential, is subject to the specific dispersing 
medium and may change when other dispersants are used. These measurements 
were taken using a Malvern Zetasizer Nano instrument. The samples were prepared by 
suspending 6mg of AgNPs in 10ml of water. This stock solution was then diluted 1:5 in 
water and measured by collecting data over 40min time period. 
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2.3.2.1.3 Scanning electron microscopy (SEM) and transmission electron 
microscopy (TEM) 
Particle size was determined using TEM (Hitachi 7100, Japan). Morphology and the 
aggregative/agglomerative state of AgNPs were determined by SEM, using a Phillips 
Field Emission SEM XL30. For SEM analysis, a drop of ethanolic suspension of the 
particles was placed on a polished aluminum stub and allowed to dry at room 
temperature (RT). The samples were then coated with a 5nm layer of gold-palladium 
coat for imaging. All images were collected with an accelerating voltage of 5kV, spot 
size of 300 and at a working distance of 5-10mm. All samples were additionally 
screened under TEM after dropping an ethanolic suspension of each sample on a 
Copper grid and prepared as described before. 
2.3.2.1.4 X-ray diffraction (XRD) 
The crystalline phase of AgNPs was determined by XRD (Enraf-Nonius powder X-ray 
diffractometer coupled to INEL CPS 120 position-sensitive detector-PSD). The 
properties of a material can often be linked back to the arrangement of atoms in its 
crystal structure. X-ray diffraction is a non-destructive analytical technique which can 
yield the unique fingerprint of a crystal structure. The samples were fixed onto a quartz 
substrate sample holder. All analyses were performed under the following conditions: 
sample holder tilt of 6.0mm, beam slits 0.24x5mm and scan time of 5min. The data 
were calibrated using silicon and silver behenate as standard reference materials. The 
collected diffraction patterns were analysed using STOE software which includes the 
ICDD (The International Centre for Diffraction Data) Powder Diffraction Files (PDF) and 
a search-match program 
2.3.2.2 Endotoxin measurement 
The measurement of endotoxin levels in AgNPs was necessary to rule out potential 
confounding responses due to contamination with endotoxins, which could alter both 
TT1 cell cytotoxicity and cytokine production induced by AgNPs. Endotoxin levels were 
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measured using the Limulus Amebocyte Lysate (LAL) chromogenic endotoxin 
quantitation assay. The assay was performed following the manufacturer’s directions 
[162]. Briefly, the experiment was run in an endotoxin-free 96-well microplate 
maintained at 37ºC. A four point standard curve prepared from a stock solution of 
1EU/ml (endotoxin units/ml) of E. Coli endotoxin was added to the plate, together with 
50μl of each sample in triplicate and a blank (50μL of endotoxin-free water). Positive 
controls were prepared spiking the samples with different concentrations of endotoxin. 
Following incubation of the plate at 37ºC for 5min, 50μL of LAL were added to each 
well. The plate was then shaken on a plate shaker for 10sec, and after 10min 
incubation at 37ºC, 100μL of substrate solution were added to each well and incubated 
for 6min at 37ºC. After adding 50μL of Stop Reagent (25% acetic acid) to each well, 
absorbance was measured at 405-410nm on a plate reader. The developed colour 
intensity is proportional to the amount of endotoxin present in the sample. The 
standard curve was prepared by plotting the average blank-corrected absorbance for 
each point versus its concentration in EU/ml. The coefficient of determination, r2, must 
be ≥ 0.98. The endotoxin concentration of each unknown sample was calculated by 
using the formulated standard curve. 
2.3.2.3 Culture of immortalised human transformed type I epithelial 
cells (TT1) 
As previously described (Section 1.2.2.1), we have created an immortalised human 
alveolar type 1 epithelial cell line, called transformed type 1 (TT1) that exhibits the 
same morphological and phenotypical characteristics as AT-1 cells in vivo [35]. Stocks 
of TT1 cells (passage number from 5 up to 40) were maintained in DCCM-1 medium 
containing 1% PSG (Penicillin, Streptomycin, Glutamine) and 10% NCS (complete 
medium), at 37oC and 5% CO2. Cells were passaged twice a week, by discarding the 
medium, washing with PBS and trypsinising to detach the monolayer. The trypsinised 
cells were collected and centrifuged at 290g for 10min. The supernatant was then 
removed and cells were resuspended in DCCM-1 complete medium. Cells were then 
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plated at a density of 8x103/well in a 96-well plate, 5x104/well in a 24-well plate and 
2.6x105/well in a 6-well plate. Cells reached confluence within 24h. Prior to 
experiments, cells were serum starved for 24h in DCCM-1 containing 1% PSG (serum 
free medium) in order to avoid serum-induced NP physico-chemical alterations [24]. 
2.3.2.4 Preparation of AgNPs in tissue culture medium and AgNP 
exposure 
AgNPs were suspended in DCCM-1 serum free culture medium for cell exposures. The 
solution was freshly prepared immediately prior to experiments to avoid agglomeration 
and aggregation of the NPs, and to minimise adsorption of components from the 
culture medium. Briefly, 2-5mg of AgNPs were suspended in 2ml of DCCM-1 serum-
free medium. This stock solution was then sonicated in a sonicating water bath for 
1min and vortexed for a further minute. Dilutions were prepared using DCCM-1 serum-
free medium as a diluent, to avoid serum-induced NP physico-chemical alterations 
[24]. Cells were exposed to increasing concentrations of AgNPs (1-100μg/ml), for a 
range of time points spacing from 30min to 24h. All treatments were carried out in 
triplicate. Following exposure, conditioned media were collected, transferred to a V-
bottom 96-well plate and centrifuged at 650g for 10min to remove NPs, as they may 
interfere with subsequent analytical assays. The supernatants were used for 
subsequent analyses.  
2.3.2.5 Poly I:C and LPS stimulation of TTI cells 
TT1 cells were cultured in 96-well plates, as described in Section 2.3.2.3. Cells were 
exposed to either Poly I:C (1-100μg/ml) or LPS (1-10000ng/ml), in DCCM-1 serum-free 
medium, for 24h. Each condition was carried out in triplicate. The medium was then 
harvested and used for subsequent analysis.  
2.3.2.6 AgNPs-Poly I:C and AgNPs-LPS co-stimulation of TTI cells 
TT1 cells were cultured in either 96 or 6-well plates, depending on the experiment. 
Following serum starvation, cells were treated with increasing concentrations of AgNPs 
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  after 1h 
and, after 1h, with either increasing concentrations of Poly I:C or LPS for another 23h 
(Table 2.1). Each condition was carried out in triplicate. The medium was collected, 
centrifuged at 650g for 10min and used for subsequent analysis. 
 
AgNPs 0 AgNPs 0 AgNPs 0 AgNPs 0 AgNPs 0 
AgNPs 1 AgNPs 1 AgNPs 1 AgNPs 1 AgNPs 1 
AgNPs 10 AgNPs 10 AgNPs 10 AgNPs 10 AgNPs 10 
AgNPs 30 AgNPs 30 AgNPs 30 AgNPs 30 AgNPs 30 
AgNPs 50 AgNPs 50 AgNPs 50 AgNPs 50 AgNPs 50 
 
 
AgNPs 0 +     
Poly I:C 0 
AgNPs 0 + 
Poly I:C 1 
AgNPs 0 + 
Poly I:C 20 
AgNPs 0 + 
Poly I:C 50 
AgNPs 0 + 
Poly I:C 100 
AgNPs 1 +  
Poly I:C 0 
AgNPs 1 +  
Poly I:C 1 
AgNPs 1 +  
Poly I:C 20 
AgNPs 1 +  
Poly I:C 50 
AgNPs 1 +  
Poly I:C 100 
AgNPs 10 +  
Poly I:C 0 
AgNPs 10 + 
Poly I:C 1 
AgNPs 10 + 
Poly I:C 20 
AgNPs 10 + 
Poly I:C 50 
AgNPs 10 + 
Poly I:C 100 
AgNPs 30 +  
Poly I:C 0 
AgNPs 30 + 
Poly I:C 1 
AgNPs 30 + 
Poly I:C 20 
AgNPs 30 + 
Poly I:C 50 
AgNPs 30 + 
Poly I:C 100 
AgNPs 50 +  
Poly I:C 0 
AgNPs 50 + 
Poly I:C 1 
AgNPs 50 + 
Poly I:C 20 
AgNPs 50 + 
Poly I:C 50 
AgNPs 50 + 
Poly I:C 100 
 
 
Table 2.1 Scheme of the protocol used in co-exposure experiments. Cells were 
first exposed to increasing concentrations of AgNPs (µg/ml), and, after 1h, to 
increasing concentrations of Poly I:C (µg/ml) for another 23h. The same scheme was 
applied to the experiments with AgNPs and LPS (ng/ml). 
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2.3.2.7 Cell viability assay  
To determine a range of non-cytotoxic AgNP, Poly I:C and LPS concentrations in which 
to perform subsequent studies, the 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium 
bromide (MTT) cell viability assay was performed. Following TT1 cell exposure, 150μl 
of MTT solution were added to each well, and the plate incubated at 37˚C for 1h. The 
MTT solution was then removed and replaced with 200μl DMSO to lyse the cells and 
release the formazan product. The media were transferred to a V-bottom 96-well plate 
and centrifuged at 650g for 10min. The optical density of the supernatants was read at 
555nm. Cytotoxicity was calculated as a percentage of the untreated control (100%).  
2.3.2.8 Measurement of apoptosis using Annexin V staining 
During early apoptosis, phosphatidylserine, normally found on the cytoplasmic side of 
the cell membrane, translocates from the inner part of the membrane to the outer part, 
allowing Annexin V protein to bind to the cell surface. Thus, conjugating Annexin V with 
a fluorescent probe, such as FITC, results in a selective probe for apoptotic cell 
identification. In addition, to discriminate between apoptosis and necrosis, dual staining 
with Annexin V and propidium iodide (PI) was performed. In fact, the red fluorescent PI 
nucleic acid binding dye, impermeable to live and apoptotic cells, is used as a counter-
stain indicator of necrotic cells [163]. Therefore, Annexin V positive/PI negative cells 
are regarded as early apoptotic cells, Annexin V/PI double positive cells as late 
apoptotic cells and PI positive cells as necrotic cells [163]. Briefly, TT1 cells were 
exposed to AgNPs (50µg/ml), Poly I:C (20µg/ml) and LPS (1000ng/ml), for 6 and 24h in 
triplicate. A positive control (250µM H2O2 prepared in serum free medium) was included 
in each experiment to validate the probe. Post-exposure, cells were washed twice with 
cold PBS and incubated with 100μl of 1X Binding Buffer, 5µl of FITC Annexin V 
solution and 10μl of PI solution, for 15min, at RT, in the dark. A further 200μl of 1X 
Binding Buffer was then added to each well and the preparations were visualized using 
an inverted fluorescent microscope. 
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2.3.2.9 Enzyme Linked ImmunoSorbent Assay (ELISA)  
IL-6 and CXCL-8 release was measured using a commercially available sandwich 
enzyme-linked immunosorbent assay (ELISA) as per the manufacturer’s instructions. 
Capture antibody (100µl) was added to each well of a 96-well plate (at supplier-
recommended concentration in PBS) and sealed for an overnight incubation at RT. 
Wells were then washed three times with PBS containing 0.05% Tween-20. Plates 
were blocked with PBS containing 1% BSA for 1h to minimise non-specific binding. 
Plates were then washed as before and 100µl of conditioned media added to each well 
(each treatment group was measured in triplicate). An eight point standard curve of the 
relevant recombinant cytokine or chemokine was also added to each plate. After a 2h 
incubation period, plates were washed as before and incubated with detection antibody 
(in PBS with 1% BSA) for another 2h. Plates were washed again before adding 
streptavidin-horseradish peroxidase (in PBS with 1% BSA) for 20min. After a final 
washing, peroxidase activity was determined using the chromogenic substrate 
tetramethylbenzidine. Blue colour development was stopped using 2N H2SO4, yielding 
a yellow colour which was measurable at 450nm using a SPECTRAFluor Plus 
microplate spectrophotometer (TECAN, Italy). Cytokine and chemokine concentrations 
were calculated using values derived from the standard curve plot. The threshold limits 
of detection of the assays were 4.7pg/ml for IL-6 and 31.3pg/ml for CXCL-8. 
2.3.2.10 ELISA antibody specificity and inter-assay variation 
In order to measure inter-assay variation, we compared all the standard curves of each 
experiment. 
2.3.2.11 Pharmacological inhibition of Mitogen-Activated Protein 
Kinases (MAP-kinases) 
To assess the role of individual MAP-kinases in AgNP-mediated cytokine and 
chemokine secretion, commercially available inhibitors of p38MAPK (SB203580), 
ERK1/2 (U0126) and JNK (SP600125) were used. SB203580 is a selective inhibitor of 
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p38MAPK and acts by blocking the activation of MAPKAPK2 (MK2) by p38MAPK. 
UO126 has been shown to be highly selective for ERK1 and ERK2 and acts by 
inhibiting ERK1/2 phosphorylation. SP600125 is an ATP-competitive inhibitor and has 
been shown to cause a concentration-dependent inhibition of the phosphorylation of c-
Jun [164]. The working concentrations of the ERK and JNK inhibitors have been 
previously optimised in our laboratory. All the inhibitors were dissolved in DMSO to 
make a 10mM stock, frozen in aliquots at −80°C and thawed immediately before use. 
TT1 cells were pre-treated with 10μM of either UO126 or SP600125 for 1h, then 
50μg/ml of AgNPs were added for another 24h. Cytokine release was measured by 
ELISA. 
2.3.2.12 Optimisation of p38MAPK inhibitor concentration 
In order to select the appropriate concentration of p38MAPK inhibitor to use, 
optimisation studies were conducted. As previously mentioned (Section 2.3.2.11), 
SB203580 blocks the activation of MK2, thus inhibiting phosphorylation of downstream 
HSP27 (heat shock protein 27), whereas phosphorylation of p38MAPK by upstream 
kinases is not affected (Figure 2.1). TT1 cells were pre-treated with increasing 
concentrations of SB203580 (0.5, 2.5 and 10μM) for 1h, then 50μg/ml of AgNPs were 
added for another 24h. Cells were collected, lysed and the whole cell extracts were run 
in sodium dodecylsulphate-polyacrylamide gel electrophoresis (SDS-PAGE) and 
imunoblotted against HSP27 (refer to Section 2.3.2.13). 
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Figure 2.1 p38MAPK signalling. External stimuli activate p38MAPK that, once 
phosphorylated, induces MK2, which in turn phosphorylates HSP27, transducing the 
signal to the nucleus. Inhibitor SB203580 inhibits MK2, therefore blocks the 
downstream pathway. 
2.3.2.13 Western blotting 
2.3.2.13.1 Sample preparation 
TT1 cells were seeded in 6-well plates, as described in Section 2.3.2.3. After 24h, cells 
were serum-starved and exposed to 50μg/ml of AgNPs for 30min, 1, 2, 4, 6 and 24h. 
2.3.2.13.2 Whole cell extraction  
TT1 cells were lysed using a buffer containing 50μl of a phosphatase inhibitor cocktail 
and one complete protease inhibitor cocktail tablet per 10ml of Cell Lytic M. Cell 
lysates were incubated with this mixture on ice for 30min, then centrifuged at 2900g for 
20min at 4°C, before the supernatant was transferred into ice-cold Eppendorf tubes for 
subsequent protein concentration analysis. 
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2.3.2.13.3 Bradford assay 
Protein concentration from whole cell extracts was determined using the Bradford 
Reagent. Serial dilutions of bovine serum albumin (BSA; 0, 0.5, 1.0, 2.0, 3.0, 4.0, 5.0, 
7.5, 10, 15μg/ml) were used as standards and applied in triplicates in 96-well plates. 
The unknown samples were added into the 96-well plates and 200μl of Bradford 
Reagent was added to each well. The plate was read at 595nm wavelength using a 
spectrophotometer plate reader. The concentration of protein in the test samples was 
calculated from the standard curve. 
2.3.2.13.4 Sodium DodecylSulphate-Polyacrylamide Gel Electrophoresis 
(SDS-PAGE) 
Equal volume of samples was loaded into NuPage 4-12% gels and electrophoretically 
separated using SDS-PAGE. Gels were rinsed with deionised water and transferred to 
an Xcell SuperLock Mini-Cell tank. Reservoirs in the tank were filled with 500ml of 
MOPS solution (MOPS 104.6g, Tris-Base 60.6g, SDS 10g, and EDTA 3.0g made up to 
500ml with deionised water). Protein samples were mixed with 4x NuPAGE LDS 
sample loading buffer and 10X NuPAGE sample reducing agent, made up to 18μl/well 
with Cell lytic M. Samples were then boiled at 100ºC for 5min. Protein samples were 
then loaded onto the gels and run at 200Volts for 43-45min. 
2.3.2.13.5 Western Blot protein transfer 
Following gel electrophoresis, gels were rinsed in distilled water then placed in an i-
Blot™ Dry Blotting System. An i-Blot™ Anode Stack was prepared by combining a 
bottom stack gel layer, a Transfer membrane of nitrocellulose and an electrode. The 
precast gel was placed on top of the nitrocellulose membrane with a water soaked filter 
paper and the subsequent i-Blot™ Cathode Stack and i-Blot™ disposable sponge. The 
proteins were transferred to the nitrocellulose membrane at 25Volts for 7min. The 
nitrocellulose membrane was then removed and briefly rinsed in Tris-buffered saline-
Tween (TBS-T). 
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2.3.2.13.6 Protein detection 
The nitrocellulose membrane was blocked with 5% dry skimmed milk in TBS-T, for at 
least 1h at RT on an orbital shaker. The membrane was then incubated with primary 
antibody overnight, at 4oC, in 5%BSA in TBS-T (for phospho protein analysis) or 5% 
milk in TBS-T (for non-phospho protein analysis). The membrane was then rinsed 3 
times for 10min and incubated for 45min in TBS-T buffer + 5% milk, at RT, with the 
relevant secondary antibody. After washing again in TBS-T, the membrane was 
developed using ECL Prime Western blot detection reagent. Proteins were detected 
using the primary antibodies shown in Table 2.2. Gels were imaged using Ultraviolet 
Transilluminator GelDoc-It and densitometric quantification was performed using 
Visionworks.  
2.3.2.13.7 Measurement of MAP-kinase activation 
Activation of MAP-kinases was determined by measuring the phosphorylation of the 
proteins. Phosphorylation was measured by probing with anti-phospho-p38MAPK, anti-
phospho-ERK1/2 and anti-phospho-JNK antibody (Table 2.2). For every kinase, the 
membrane was then stripped with Re-Blot Plus Mild Solution for 10-15min (depending 
on the signal of the primary antibody) and reprobed with the corresponding total 
antibody (p38MAPK, ERK1/2, or JNK antibody). Three independent experiments were 
performed using three separate TT1 cell passage generations. Densitometric results 
for every kinase were expressed as a ratio of phosphorylation versus total expression 
of the protein. Gels were imaged using Ultraviolet Transilluminator GelDoc-It and 
densitometric quantification was performed using Visionworks. 
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Primary Antibody 
(dilution) 
Company 
Secondary 
Antibody (dilution) 
Molecular Weight 
of target protein 
(kDa) 
p38MAPK             
(1:3,000) 
Cell Signalling 
Rabbit           
(1:2,500) 
43 
phospho-p38MAPK     
(1:10,000) 
Cell Signalling 
Rabbit            
(1:2,500) 
43 
ERK1/2               
(1:15,000) 
Cell Signalling 
Rabbit            
(1:2,500) 
42,44 
phospho-ERK1/2 
(1:30,000) 
Cell Signalling 
Mouse          
(1:2,500) 
42,44 
JNK                         
(1:400) 
Cell Signalling 
Rabbit 
(1:2,500) 
46 
phospho-JNK        
(1:1,500) 
Cell Signalling 
Rabbit 
(1:2,500) 
46 
phospho-HSP27        
(1:1,3000) 
Cell Signalling 
Rabbit 
(1:2,500) 
27 
 
Table 2.2 Antibodies used for protein detection. kDa: kilo Dalton 
2.3.2.14 Statistical analyses 
All statistical tests were performed using GraphPad Prism 4 software. Results are 
presented as fold-change ± standard error of the mean (SEM); n ≥ 3, where 3 (or more) 
independent experiments were performed using 3 (or more) separate TT1 cell passage 
generations. Data was considered to follow a normal distribution. We elected a priori to 
compare treated groups to the untreated control. Thus, significant effects of AgNPs, 
Poly I:C and LPS on cell viability, cytokine/chemokine release and protein 
expression/activation were determined using one-way ANOVA with Dunnett’s as a 
post-test to compare the different treatments to the unexposed control. All statistical 
tests have been performed on the raw data. A p value <0.05 was considered to be 
statistically significant. 
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2.4 Results  
2.4.1 AgNP characterisation  
Characterisation of AgNPs used in the present study was kindly provided by the 
Department of Mineralogy, Natural History Museum (NHM, UK). Table 2.3 lists the 
surface area measurement (BET method), the estimated particle size (TEM) and the 
surface charge (zeta potential) of the AgNPs used. 
 
Surface area (m2/g) 2.34 
Particle size (nm) 80-100 
Zeta Potential (mV) -24.29 
 
Table 2.3 Surface area, estimated particle size and surface charge of AgNPs. 
 
Given a zeta potential of -24mV, the NPs should not be stable in distilled water, 
therefore NPs will tend to agglomerate into bigger aggregates. In fact, SEM analysis 
(Figure 2.2) showed the presence of agglomerates of smaller primary particles present 
throughout the scanned area. The same result was obtained using TEM (Figure 2.3). 
The expected size measured using microscopic analysis suggests the particles to be in 
the range of 80-100nm in diameter. NP diameter is defined as “aerodynamic diameter” 
that accounts for the particle mobility diameter, i.e. the NP behavior in the air and its 
tendency of forming larger aggregates. The XRD pattern for AgNPs (Figure 2.4; green 
peaks), corresponded well with the elemental Ag from the ICDD database (Figure 2.4; 
red peaks) with no additional peaks. 
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Figure 2.2 SEM images of AgNPs at lower (a) and higher magnification (b). AgNPs 
aggregate together and generate agglomerates. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3 TEM image of AgNPs. Magnification x50K. 
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Figure 2.4 XRD pattern of AgNPs. The green peaks show the XRD pattern for our 
AgNPs. The red pattern indicates the matching ICDD reference patterns that enable 
phase identification. 
2.4.2 Endotoxin quantification in AgNPs  
Endotoxin levels in the samples were measured using the LAL Chromogenic Endotoxin 
Quantitation Kit. Two different concentrations of AgNPs were tested (25 and 50µg/ml) 
and results showed that the endotoxin level for both concentrations was lower than the 
standard limit accepted of 0.25EU/ml established by United States Pharmacopeia 
(USP) [165]. For three different measurements we obtained an average value of 
0.0124EU/ml for AgNPs 25µg/ml and 0.0112EU/ml for AgNPs 50µg/ml (Figure 2.5). 
Therefore, we can conclude that AgNPs samples were not affected by any endotoxin 
contamination. 
However, NPs might interfere with the LAL reaction, inhibiting the assay. This would 
result in a lower final absorbance, thus indicating lower levels of endotoxin than what 
may be present in the test sample. To verify this possibility, it is necessary to spike an 
aliquot of the test sample with a known amount of endotoxin (e.g. one point of the 
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standard). After assaying both the spiked and the corresponding unspiked sample, the 
difference between the two calculated endotoxin values should equal the known 
concentration of the spike ± 25%. We chose 0.5EU/ml as the known amount of 
endotoxin, to which we added our samples. The difference between the spiked and the 
unspiked samples were within the range of 0.5 ± 25% (0.625-0.375). This means that 
AgNPs were not interfering with the assay. 
 
 
 
 
 
 
 
 
 
Figure 2.5 Endotoxin assessment of AgNP samples. Two sample concentrations 
were tested, 25 and 50µg/ml. Data are presented as the mean ± SEM (n=3). 
 
 
Sample Conc 
(µg/ml) 
Spiked Conc 
(EU/ml) 
Unspiked Conc 
(EU/ml) 
Difference 
(EU/ml) 
25 0.6195 0.0124 0.6071 
50 0.6042 0.0112 0.5930 
 
Table 2.4 Assessment of AgNP interference with LAL assay. Two sample 
concentrations were tested (25 and 50µg/ml) and spiked with 0.5EU/ml of endotoxin. 
Difference=spiked-unspiked. 
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2.4.3 Reactivity of AgNPs, Poly I:C and LPS with TT1 cells 
2.4.3.1 Effect of AgNPs on TT1 cell viability 
In order to study the effect of AgNPs on cell viability, an MTT assay was carried out on 
cells exposed to increasing concentrations of AgNPs. At 24h, AgNPs induced a 
concentration-dependent decrease in cell viability with a significant reduction at 
50μg/ml (23%; p<0.01) and 100μg/ml (32%; p<0.001) (Figure 2.6). At 48h, the same 
concentrations resulted in 24% (p<0.001) and 26% (p<0.001) drop in cell viability 
respectively. After 72h exposure, cell viability was further decreased at 50μg/ml (34%; 
p<0.001) and 100μg/ml (50%; p<0.001). AgNPs at 30μg/ml affected cell viability only at 
48h (19% decrease; p<0.01) and 72h (17% decrease; p<0.05). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.6 Effect of AgNP exposure on TT1 cell viability. Cells were exposed to 
increasing concentrations of AgNPs (μg/ml) at different time points: 24, 48 and 72h. 
NT=non treated. Data are presented as a % of the control ± SEM; (n=4); *p<0.05; 
**p<0.01; ***p<0.001. 
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2.4.3.2 Effect of Poly I:C on TT1 cell viability 
In order to mimic a viral infection (see Section 2.1.2), TT1 cells were exposed to 
increasing concentrations of TLR-3 ligand Poly I:C (1, 10, 20, 50, 100μg/ml) for 24, 48 
and 72h (Figure 2.7) and cell viability was assessed by MTT assay. At 24h, a 
significant decrease was observed at 50μg/ml (23%; p<0.05) and 100μg/ml (31%; 
p<0.01). At 48h, the same concentrations induced a greater reduction in cell viability 
(26% for 50μg/ml and 100μg/ml; p<0.001). After 72h of exposure, TT1 cells showed a 
decrease in cell viability up to 28% (50μg/ml; p<0.01) and 35% (100μg/ml; p<0.001). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.7 Effect of Poly I:C exposure on TT1 cell viability. Cells were exposed to 
increasing concentrations of Poly I:C (μg/ml) at different time points: 24, 48 and 72h. 
NT=non treated. Data are presented as a % of the control ± SEM; (n=4); *p<0.05; 
**p<0.01; ***p<0.001. 
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2.4.3.3 Effect of LPS on TT1 cell viability 
Bacterial infection was simulated using LPS (see Section 2.1.2). MTT assay was 
performed using increasing concentrations of LPS (1, 10, 100, 1000 and 10000ng/ml), 
at 24, 48 and 72h. We showed that LPS did not affect TT1 cell viability at any time 
point (Figure 2.8). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.8 Effect of LPS exposure on TT1 cell viability. Cells were exposed to 
increasing concentrations of LPS (ng/ml) at different time points: 24, 48 and 72h. 
NT=non treated. Data are presented as a % of the control ± SEM; (n=4). 
2.4.3.4 Effect of co-exposure to AgNPs and Poly I:C on TT1 cell viability 
In order to investigate the effect of co-exposure to AgNPs and a respiratory viral 
infection on cell viability, a chequerboard analysis of AgNPs in combination with Poly 
I:C was performed (Table 2.5). TT1 cells were initially exposed to increasing 
concentrations of AgNPs (0, 1, 10, 30 and 50μg/ml) and, after 1h, to increasing 
concentrations of Poly I:C (0, 1, 20, 50 and 100μg/ml) for a further 23h (see Table 2.1, 
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Section 2.3.2.6). For an easier understanding of the data, cell viability results are 
shown in a “heat-map” (Table 2.5). By combining together increasing concentrations of 
AgNPs and Poly I:C, cell viability dropped progressively, to a maximum of 50% 
decrease at 100μg/ml of Poly I:C and 50μg/ml of AgNPs.  
 
 
Poly I:C     
0 
Poly I:C     
1 
Poly I:C   
20 
Poly I:C    
50 
Poly I:C 
100 
AgNPs 0 100 100 95 86 78 
AgNPs 1 98 98 91 88 69 
AgNPs 10 86 79 85 87 62 
AgNPs 30 82 75 84 82 54 
AgNPs 50 77 73 76 84 50 
 
Table 2.5 Effect of co-exposure to AgNPs and Poly I:C on TT1 cell viability. Cells 
were exposed first to increasing concentrations of AgNPs (μg/ml) and, after 1h, to 
increasing concentrations of Poly I:C (μg/ml) for another 23h. Data are presented as a 
% of the control; (n=3). 
 cell viability ≥ 90%;  89% ≤ cell viability ≤ 70%;  cell viability ≤ 69% 
2.4.3.5 Effect of co-exposure to AgNPs and LPS on TT1 cell viability 
Similarly, the effect of co-exposure to AgNPs and LPS on cell viability was assessed 
using MTT assay. The “heat-map” in Table 2.6 represents the percentage cell viability 
of different combinations of AgNPs and LPS. The co-exposure did not decrease cell 
viability by more than each treatment alone (yellow and orange cells), at least up to 30 
and 50μg/ml of AgNPs, when the decrease in cell viability was constantly higher than 
32% (green cells). 
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LPS        
0 
LPS        
1 
LPS      
10 
LPS    
100 
LPS   
1000 
LPS 
10000 
AgNPs   
0 
100 94 95 95 92 94 
AgNPs   
1 
96 94 94 93 92 92 
AgNPs 
10 
79 74 66 71 70 78 
AgNPs 
30 
68 54 49 52 57 59 
AgNPs 
50 
62 50 49 48 51 50 
 
Table 2.6 Effect of co-exposure to AgNPs and LPS on TT1 cell viability. Cells were 
exposed first to increasing concentrations of AgNPs (μg/ml) and, after 1h, to increasing 
concentrations of LPS (ng/ml) for another 23h. Data are presented as a % of the 
control; (n=3). 
 cell viability ≥ 90%;  89% ≤ cell viability ≤ 70%;  cell viability ≤ 69% 
2.4.3.6 Cytotoxic effects of AgNPs, Poly I:C and LPS in TT1 cells 
To elucidate the extent and the mode of AgNP-induced decrease in cell viability, 
induction of apoptosis and/or necrosis, in presence and absence of Poly I:C/LPS, was 
assessed using the Annexin-V (AV) / PI double staining. The chosen concentration of 
Poly I:C to use in the co-exposure study was 20µg/ml. In fact, at this concentration Poly 
I:C does not induce any decrease in cell viability, which could otherwise mask the 
mechanism induced by AgNPs. LPS was also included in the study to confirm the 
absence of cellular death (Section 2.4.3.3). H2O2 250µM was used as a positive control 
for both apoptotic and necrotic processes [166]. In our cell model, exposure to 250µM 
H2O2 for 4h was sufficient to induce both apoptosis and necrosis: both early apoptotic 
(AV+ve / PI-ve) and necrotic (PI+ve) cells could be observed (Figure 2.9). After 6h 
exposure to AgNPs (50µg/ml), Poly I:C (20µg/ml) and LPS (1000ng/ml), we did not 
observe any cells undergoing apoptosis or necrosis (Figure 2.9). Nevertheless, we 
noted that AgNPs alone, or in combination with Poly I:C or LPS, did cause areas of cell 
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detachment (bare patches) in the TT1 monolayer following 6h exposure (Figures 2.9). 
PI stained necrotic cells (PI+ve) were only observed at 24h AgNP-exposure, when 
areas of cell detachment were also visible (Figure 2.10). 
 H2O2
NT Poly I:C LPS
AgNPs+LPSAgNPs+Poly I:CAgNPs
10X
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.9 Cytotoxic effect of 6h exposure to AgNPs alone and in combination with Poly I:C or LPS. TT1 cells were exposed to AgNPs (50µg/ml), Poly 
I:C (20µg/ml) and LPS (1000ng/ml), then stained with AV and PI. H2O2 (250µM) was used as a positive control and incubated for 4h. Light micrograph of H2O2 
displays early apoptotic (AV+ve / PI-ve, in green) and necrotic (PI+ve, in red) cells, distinguishable from viable cells (unstained). Bare patches (red arrows) 
indicative of cell detachment are visible in TT1 monolayers when compared to the intact monolayer of unexposed cells (NT). Poly I:C and LPS micrographs 
are comparable to the one of the NT. AgNPs can be observed as dark aggregates covering the cells (yellow arrows). The presence of apoptotic/necrotic cells 
was not apparent; however the monolayers developed bare patches (red arrows). NT=non treated. Graphs representative of 3 independent experiments. 
 NT Poly I:C LPS
AgNPs+Poly I:C AgNPs+LPSAgNPs
10X
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.10 Cytotoxic effect of 24h exposure to AgNPs alone and in combination with Poly I:C or LPS. TT1 cells were exposed to AgNPs (50µg/ml), 
Poly I:C (20µg/ml) and LPS (1000ng/ml), then stained with AV and PI. AgNPs can be observed as dark aggregates covering the cells (yellow arrows). The 
presence of apoptotic cells was not apparent; however necrotic cells (PI+ve, in red) were present in any of the exposure to AgNPs. Bare patches in the cell 
monolayer (red arrows), similar to those seen with H2O2, were also observed. NT=non treated. Graphs representative of 3 independent experiments. 
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2.4.3.7 Effect of AgNPs, Poly I:C and LPS on IL-6 and CXCL-8 release  
2.4.3.7.1 Inter-assay variation  
Cell supernatants were assayed for cytokine and chemokine release by ELISA. For 
both IL-6 and CXCL-8 we carried out a comparison of the standard curves obtained in 
the different experiments (Figure 2.11). In all the assays the coefficient of variance (r2) 
was always ≥0.96, indicating a low inter-assay variation, therefore a high level of 
reproducibility in our assays. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.11 Inter-assay reproducibility of standard curves for IL-6 and CXCL-8. 
Seven point standard curves were constructed over suppliers recommended range of 
concentrations. Data are expressed as mean ± S.E.M; (n=18 assays). 
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2.4.3.7.2 Interleukin 6 (IL-6)  
Based on the previous cell viability results, we selected 24h as the time point for 
subsequent experiments. A full concentration rage of 1-100μg/ml for AgNPs and Poly 
I:C, and 1-10000ng/ml for LPS were tested for cytokine and chemokine release 
studies. TT1 cells were exposed to increasing concentrations of either AgNPs, Poly I:C 
or LPS, for 24h.  
AgNP exposure elicited a concentration-dependent stimulation of IL-6 (Figure 2.12), 
significant at concentrations greater than 30μg/ml. At 50 and 100μg/ml IL-6 release 
was 26- and 30-fold increase respectively (p<0.001). 
Exposure to Poly I:C or LPS for 24h also induced a concentration-dependent increase 
in IL-6 release (Figure 2.12). The lowest concentration of Poly I:C that significantly 
stimulated IL-6 release was 5μg/ml (42-fold increase; p<0.05). The maximum 
concentration of Poly I:C, 100μg/ml, resulted in 124-fold increase of IL-6 production 
(p<0.001). 
LPS caused a mild increase in IL-6, significant at 1000ng/ml (3-fold increase; p<0.05) 
and 10000ng/ml (4-fold increase; p<0.001) (Figure 2.12). 
2.4.3.7.3 Chemokine CXCL-8 (CXCL-8) 
The magnitude of the increase in CXCL-8 production by AgNP-, Poly I:C- and LPS-
exposed TT1 cells was lower than that observed for IL-6 (Figure 2.13). After 24h, 
although AgNP-induced CXCL-8 release was significant already at 30μg/ml (p<0.001), 
at 50 (6.4-fold; p<0.01) and 100μg/ml (7.4-fold; p<0.01) CXCL-8 production was lower 
than that of IL-6. Poly I:C exposure resulted in a significant increase in CXCL-8 release 
at 5μg/ml (2.2-fold increase; p<0.01) and at every concentration up to 100μg/ml (4.5-
fold increase; p<0.001). LPS did not induce any change in CXCL-8 production, even at 
the highest concentration of 10000ng/ml (Figure 2.13). 
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Figure 2.12 Effect of AgNPs, Poly I:C and LPS exposure on IL-6 release. TT1 cells 
were exposed to increasing concentrations of either AgNPs (μg/ml), Poly I:C (μg/ml) or 
LPS (ng/ml), for 24h. IL-6 expression was evaluated by ELISA. NT=non treated. Data 
are expressed as fold-change ± SEM; (n=4); *p<0.05; ***p<0.001. 
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Figure 2.13 Effect of AgNPs, Poly I:C and LPS exposure on CXCL-8 release. TT1 
cells were exposed to increasing concentrations of either AgNPs (μg/ml), Poly I:C 
(μg/ml) or LPS (ng/ml), for 24h. CXCL-8 expression was evaluated by ELISA. NT=non 
treated. Data are expressed as fold-change ± SEM; (n=4); **p<0.01; ***p<0.001. 
2.4.3.7.4 Effect of co-exposure to AgNPs and Poly I:C on IL-6 and CXCL-
8 release 
We assessed the effect of co-exposure to AgNPs and a viral infection on IL-6 and 
CXCL-8 production performing a chequerboard analysis of AgNPs in combination with 
Poly I:C (Tables 2.7, IL-6 and CXCL-8). In order to calculate the effects of this 
combination in terms of synergism/antagonism, we analyzed the data using the Chou-
Talalay method [167], the most accredited mathematical model developed to calculate 
drug combination effects. Along with the theory, Chou and Talalay have also 
elaborated software that calculates the type of effects (synergistic, additive or 
antagonistic) resulting from a particular drug combination [167]. However, due to the 
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nature of our data (refer to Section 2.5.3), little statistical reliance could be placed on 
the results obtained. Therefore, since no documented mathematical model has been 
applied to the analysis of our data, the terms “synergistic” (potentiation) or 
“antagonistic” that we used to describe the effects we measured in the combinations 
are limited to our experiments and observations. In order to simplify the understanding 
of our data and of a possible mechanism of action, we generated “heat maps” as 
previously described for cytotoxicity studies (Sections 2.4.3.4, 2.4.3.5).  
TT1 cells were initially exposed to increasing concentrations of AgNPs and, after 1h, to 
increasing concentrations of Poly I:C or LPS for a further 23h. The combination of 
AgNPs and Poly I:C resulted in a potentiation (more than the sum of the two) of IL-6 
production (Table 2.7, IL-6; red cells), with a few exceptions (yellow cells). 
Interestingly, in CXCL-8 release, the type of effect measured seemed to be 
antagonistic (less than the sum of the two) for every combinations of AgNPs-Poly I:C 
(Table 2.7, CXCL-8; yellow cells). 
 
IL-6 Poly I:C 0 Poly I:C 1 Poly I:C 20 Poly I:C 50 Poly I:C 100 
AgNPs 0 126.47 247.27 1702.61 1993.87 2346.25 
AgNPs 1 118.87 255.48 2111.39 2199.48 2200.70 
AgNPs 10 203.94 444.91 2176.06 2398.60 2472.72 
AgNPs 30 507.89 957.83 2889.68 3415.10 3677.98 
AgNPs 50 1122.4 1574.10 3489.37 3397.33 3583.28 
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Tables 2.7 Effect of co-exposure to AgNPs and Poly I:C on IL-6 and CXCL-8 
release. TT1 cells were exposed first to increasing concentrations of AgNPs (μg/ml) 
and, after 1h, to increasing concentrations of Poly I:C (µg/ml) for another 23h. IL-6 and 
CXCL-8 expression over 24h was evaluated by ELISA. Data are presented as the 
mean of three independent experiments; (n=3).  
 antagonistic effect;  additive/synergistic effect 
 
In order to better visualise the differences between IL-6 and CXCL-8 release from co-
exposed TT1 cells, values from the heat map were plotted into a graph, choosing only 
one concentration of Poly I:C against all the concentrations of AgNPs (Figure 2.14). 
Showing insignificant decrease in cell viability and sub-optimal release of IL-6 and 
CXCL-8, 20µg/ml was established as the concentration of Poly I:C for subsequent 
experiments. Thus, we plotted the values for Poly I:C 20µg/ml (pink bars) combined 
with all the increasing concentrations of AgNPs (light blue bars) into a graph. At every 
concentration of AgNPs, the combination with 20μg/ml of Poly I:C resulted in a 
potentiation of IL-6 production. In fact, the combined effect (dark blue bars) was higher 
CXCL-8 Poly I:C 0 Poly I:C 1 Poly I:C 20 Poly I:C 50 Poly I:C 100 
AgNPs 0 436.32 599.93 699.68 1188.38 1334.42 
AgNPs 1 341.09 451.32 652.46 812.56 797.37 
AgNPs 10 600.15 773.66 1147.17 1039.98 953.10 
AgNPs 30 1093.8 1038.47 1337.10 1256.33 1461.64 
AgNPs 50 1515.6 1218.98 1755.60 1523.84 1814.89 
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than the mathematical sum (horizontal orange lines) of the same effect. For every 
combination of AgNP and Poly I:C, we calculated two different values: the 
mathematical sum of the two single effects (horizontal orange lines) and the actual 
combined effect (dark blue lines). For example, for the combination AgNPs 50μg/ml 
and Poly I:C 20μg/ml (Table 2.7, heat map for IL-6), the mathematical sum (expressed 
in pg/ml) was 2825.01pg/ml (1122.40+1702.61), but the actual combined effect was 
3489.37. Therefore in this case, being the combined effect (3489.37) higher than the 
mathematical sum (2825.01pg/ml), the co-exposure seemed to result in a potentiation 
of the two single effects. The same applied to the other combinations. 
On the contrary, every combination of AgNPs and Poly I:C seemed to suggest an 
antagonistic effect on CXCL-8 production (the combined effect was lower than the 
mathematical sum; Figure 2.14).  
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Figure 2.14 Effect of co-exposure to AgNPs and Poly I:C on IL-6 and CXCL-8 
release. TT1 cells were exposed first to increasing concentrations of AgNPs (µg/ml; 
light blue bars) and, after 1h, to Poly I:C (20µg/ml; pink bars) for another 23h. IL-6 and 
CXCL-8 expression over 24h was evaluated by ELISA. The amount of IL-6 and CXCL-
8 measured at every combination is represented by dark blue bars while the 
mathematical sum of the 2 single effects (AgNPs + Poly I:C) is indicated by the orange 
lines. NT=non treated. Data are presented as the mean ± SEM; (n=3). 
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2.4.3.7.5 Effect of co-exposure to AgNPs and LPS on IL-6 and CXCL-8 
release  
In order to investigate the effect of AgNP exposure followed by a bacterial infection, the 
same analysis described for Poly I:C was repeated using LPS. In contrast to Poly I:C, 
AgNPs-LPS combination did not result in a synergism of IL-6, except for two 
combinations with AgNPs 50µg/ml (Table 2.8 IL-6, red cells). Conversely, the heat map 
generated for CXCL-8 release suggested that some of the combinations of AgNPs (30 
and 50µg/ml) with LPS have a synergistic effect (Table 2.8 CXCL-8, red cells). 
 
IL-6 LPS         
0 
LPS         
1 
LPS       
10 
LPS     
100 
LPS    
1000 
LPS 
10000 
AgNPs  0 7.38 10.09 15.67 21.77 34.73 154.81 
AgNPs  1 13.04 
14.59 
(0.63) 
7.33 
(0.26) 
10.57 
(0.30) 
20.56 
(0.43) 
132.73 
(0.79) 
AgNPs 10 20.72 
30.91 
(1.00) 
26.76 
(0.74) 
19.36 
(0.46) 
16.68 
(0.30) 
118.55 
(0.68) 
AgNPs 30 594.67 
558.71 
(0.92) 
339.25 
(0.56) 
262.90 
(0.43) 
533.43 
(0.85) 
341.76 
(0.46) 
AgNPs 50 1577.52 
2095.69 
(1.32) 
1255.92 
(0.79) 
1370.21 
(0.86) 
2061.40 
(1.28) 
1133.52 
(0.65) 
 
 
 
 
 
 
 
 
 
 
 
 
100 
CXCL-
8 
LPS         
0 
LPS         
1 
LPS       
10 
LPS     
100 
LPS    
1000 
LPS 
10000 
AgNPs 0 142.39 201.32 184.04 227.78 235.62 159.20 
AgNPs 1 162.17 
207.56 
(0.57) 
210.62 
(0.61) 
163.49 
(0.42) 
176.09 
(0.44) 
143.00 
(0.44) 
AgNPs 10 438.27 
456.80 
(0.71) 
371.13 
(0.60) 
370.77 
(0.56) 
300.51 
(0.45) 
340.07 
(0.57) 
AgNPs 30 1340.3 
1687.00 
(1.09) 
2024.54 
(1.33) 
1607.61 
(1.03) 
1531.21 
(0.97) 
1511.54 
(1.01) 
AgNPs 50 2755.3 
2974.79 
(1.01) 
3942.80 
(1.34) 
2591.05 
(0.87) 
2833.37 
(0.95) 
2881.88 
(0.99) 
 
Tables 2.8 Effect of co-exposure to AgNPs and LPS on IL-6 and CXCL-8 release. 
TT1 cells were exposed first to increasing concentrations of AgNPs (μg/ml) and, after 
1h, to increasing concentrations of LPS (ng/ml) for another 23h. IL-6 and CXCL-8 
expression over 24h was evaluated by ELISA. The values in brackets are the result of 
every measured value against its sum total. Data are presented as the mean of three 
independent experiments; (n=3). 
 antagonistic effect;   additive/synergistic effect. 
 
Showing an insignificant decrease in cell viability and sub-optimal release of IL-6, 
1000ng/ml was established as the concentration of LPS for subsequent experiments. 
As for Poly I:C, we plotted the values (from the heat map) corresponding to 1000ng/ml 
LPS against all the concentrations of AgNPs in a bar graph (Figure 2.15). The addition 
of LPS (green bars) to every concentration of AgNPs (light blue bars) resulted in a 
combined effect (dark blue bars) lower than the corresponding mathematical sum 
(orange lines), for both IL-6 and CXCL-8 release. This suggested an antagonistic 
effect.  
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Figure 2.15 Effect of co-exposure to AgNPs and LPS on IL-6 and CXCL-8 release. 
TT1 cells were exposed first to increasing concentrations of AgNPs (µg/ml; light blue 
bars) and, after 1h, to LPS (1000ng/ml; green bars) for another 23h. IL-6 and CXCL-8 
expression over 24h was evaluated by ELISA. The amount of IL-6 and CXCL-8 
measured at every combination is represented by dark blue bars while the 
mathematical sum of the 2 single effects (AgNPs + LPS) is indicated by the orange 
lines. NT=non treated. Data are presented as the mean ± SEM; (n=3). 
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2.4.4 Effect of AgNPs on MAP-kinase pathway  
2.4.4.1 Time course analysis of MAP-kinases activation 
The possible involvement of MAP-kinase cascades on AgNP-mediated cytokine 
production was investigated by measuring the activation (by phosphorylation) of 
p38MAPK, ERK1/2 and JNK, assessed by Western blotting (Figure 2.16).   
p38MAPK showed a time-dependent activation which was significant at 6h and 24h 
(2.6- and 3.1-fold increase respectively; p<0.001). ERK1/2 showed a transient 
activation at 2h (3.8-fold increase; p<0.05), followed by a second activation from 6h (5-
fold increase; p<0.01), which further increased at 24h (12-fold increase; p<0.001). 
AgNPs activation of JNK1 was bi-phasic; there was an initial phosphorylation at 4h (8-
fold increase; p<0.05) which was followed by a decrease to baseline at 6h and a 
second activation at 24h (87-fold; p<0.001). 
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Figure 2.16 Effect of AgNPs on MAP-kinase activation in TT1 cells. Cells were 
stimulated with AgNPs (50μg/ml) and whole cell extracts at 0.5, 1, 2, 4, 6 and 24h were 
run in SDS-PAGE/Western blotting. MAP-kinase activation was calculated as the ratio 
phospho/total of p38MAPK, ERK1/2 and JNK. Representative blots of three 
independent experiments (A) and graphs (B) showing activation of p38MAPK, ERK1/2 
and JNK following AgNP exposure. NT=non treated. Data are expressed as fold-
change ± SEM; (n=3); *p<0.05; **p<0.01; ***p<0.001. 
2.4.4.2 Optimisation of p38MAPK inhibitor concentration 
In order to choose the most appropriate concentration of p38MAPK inhibitor SB203580 
to use, we tested the effect of three different concentrations of the inhibitor (2.5, 5 and 
10μM) on the phosphorylation of downstream protein HSP27. As previously explained 
(Section 2.3.2.12), SB203580 acts downstream of p38MAPK by blocking protein MK2, 
thus inhibiting HSP27 phosphorylation. We intentionally decided not to use 
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β-actin
concentrations of the inhibitor higher than 10μM since it would induce non-specific 
effects, such as activation of the ERK1/2 and JNK signalling pathways, with 
concomitant activation of NF-kB-regulated gene transcription [168]. Western blotting 
analysis revealed that a concentration of 10μM of SB203580 completely prevented 
AgNP-induced HSP27 phosphorylation (Figure 2.17). These findings also confirm that 
the use of SB203580 does not affect p38MAPK phosphorylation (refer to Figure 2.1). 
 
 
 
 
 
 
 
Figure 2.17 Effect of SB203580 on HSP27 activation. TT1 cells were pre-treated 
(1h) with increasing concentrations of SB203580 (2.5, 5 and 10μM) and then exposed 
to AgNPs (50µg/ml) for 24h. Phosphorylation of HSP27 protein was determined by 
SDS-PAGE/Western blotting and normalised using the expression of β-actin. 
2.4.4.3 Effect of MAP-kinase inhibition on AgNP-induced IL-6 and 
CXCL-8 release  
Inhibition of MAP-kinases significantly reduced IL-6 and CXCL-8 production from 
AgNP-exposed TT1 cells. The p38MAPK inhibitor SB203580 induced the greatest 
inhibition of IL-6 and CXCL-8 release (Figure 2.18); inhibition of p38MAPK decreased 
IL-6 production by 73% (p<0.01) and CXCL-8 by 90% (p<0.001). Inhibition of ERK1/2 
also decreased both IL-6 and CXCL-8 release, but the inhibitory effect was not 
significant. Inhibition of JNK had no significant effect neither on IL-6 nor CXCL-8 
release. To assess any possible antagonistic/synergistic combined effect of the three 
inhibitors, TT1 cells were pre-treated with the three inhibitors together (Figure 2.18; 
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3+). This combination displayed the strongest inhibition in both IL-6 and CXCL-8 
release (80% and 97% respectively; p<0.001).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.18 Effect of MAP-kinase inhibitors on AgNP-induced IL-6 and CXCL-8 
release. TT1 cells were pre-treated (1h) with p38MAPK, ERK1/2 and JNK 1/2 
inhibitors, then exposed to AgNPs (50μg/ml). IL-6 and CXCL-8 expression over 24h 
was evaluated by ELISA. NT=non treated; 3+ indicates the addition of the 3 inhibitors 
together. Data are expressed as fold-change ± SEM; (n=4); **p<0.01; ***p<0.001. 
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2.5 Discussion 
2.5.1 Cytotoxicity assessment of AgNPs, Poly I:C and LPS 
AgNPs are the most commercialised nanoscale chemicals added to consumer 
products due to their exceptional antimicrobial activity [5] (Section 2.1). However, little 
is known about AgNP reactivity and toxicity on human health, mainly because of a lack 
of a relevant model of study. Most in vitro studies of inhaled NP toxicity have used 
carcinoma-derived cell lines or primary rodent cells. In this study, we used TT1 cells, 
that have been proven as a suitable model for AT1 cells [39], thus representing a 
physiologically relevant model for studying NP reactivity in the lung. 
We first examined the cytotoxic effects of AgNPs on TT1 cells using the MTT assay. 
Our results demonstrated that AgNPs induced a decrease in cell viability at 
concentrations greater than 30μg/ml. This is in accordance with other studies that have 
shown AgNP-induced epithelial cell cytotoxicity [169,170]. For instance, studies using 
A549 cells demonstrated that 50 and 100μg/ml of AgNPs caused a significant 
decrease in cell viability at both 24 and 48h [170]. Similar results were found by Lee et 
al. who measured a significant decrease in cell viability after 24h with 10 and 50μg/ml 
of AgNPs [169].  
In order to elucidate the extent of the AgNP-induced decrease in cell viability on TT1 
cells, we carried out Annexin V/propidium iodide double staining (AV/PI). The analysis 
of 6 and 24h exposure to AgNPs (50µg/ml) did not reveal any sign of early apoptosis. 
However, we detected necrotic cells at 24h, which suggest that the cytotoxic effect of 
AgNPs does not occur through an apoptotic pathway. In agreement with our findings, 
Gonzales et al. demonstrated that commercial AgNPs (30-50nm) caused necrosis but 
not apoptosis in a mouse tumor cell line [171]. However, studies in other cell types 
indicated apoptosis as the preferential pathway occurring after AgNP exposure. For 
example, in primary mouse fibroblast and liver cells 24h exposure to AgNPs 7-20nm 
induced caspase 3 activity [172]. Using Annexin V staining, Eom and Choi measured 
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an increase in cell death (human Jurkat cells) after 24h exposure to AgNPs 5-10nm 
[173]. Apoptosis was also detected in a human monocytic cell line (THP-1) exposed to 
7.5μg/ml of AgNPs (around 69nm) for a period of 24h [174]. One of the reasons for the 
differences observed between our results and those previously described is that the 
stain used may be detecting late apoptotic cells as necrotic, due to membrane 
damage. In addition, analysis at the microscope showed bare patches in the cell 
monolayer, both at 6h and 24h. It is therefore possible that, at earlier time points, cells 
undergo apoptosis and rapidly detach themselves from the monolayer, thus hampering 
their assessment for apoptosis. 
In vivo studies of AgNP toxicity are limited [155,156]. Sung and colleagues investigated 
the inflammatory responses and pulmonary function changes in Sprague-Dawley rats 
following a 90-day-inhalation exposure to AgNPs (50-515µg/m3) [155]. Although no 
statistically significant differences were found in the cellular differential counts 
(macrophages, polymorphonuclear cells and lymphocytes), the inflammation 
measurements (i.e. macrophages, lymphocytes and others) were increased in the high-
dose female rats. Among the parameters of the pulmonary function test (tidal volume, 
minute volume, respiratory frequency, inspiration and expiration time), a significant 
decrease in the tidal volume and minute volume was reported. Moreover, 
histopathological examination of lung samples indicated a dose-dependent increase in 
lesions related to AgNP exposure, mixed inflammatory cell infiltrate and chronic 
alveolar inflammation, with thickened alveolar walls and small granulomatous lesions 
[155]. Sung and colleagues reported similar findings in another 90-day-inhalation study 
in rats, using the same concentrations of AgNPs (50-515µg/m3) [156]. This data 
confirm the previous ones, suggesting that prolonged exposure to inhaled AgNPs could 
induce lung function changes, along with inflammation. The only reported study on 
AgNPs in human subjects is a 14-day oral exposure by Munger et al. [175]. Sixty 
healthy volunteers were enrolled and exposed to orally dosed commercial AgNPs (100-
480μg/day) for 14 days. Although the study showed no toxicity, it has to be considered 
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that, in order to better assess any possible NP accumulation in human lipid 
compartments (a hypothetical cause of chronic toxicity), the study timeframe of 14 days 
should be extended. Furthermore, volunteers were orally exposed to AgNPs, whereas 
the current study, as well as the previous ones in animals, focuses on inhalation as the 
main route of AgNP exposure and toxicity. 
When referring to NP toxicity, any surface modification of the NP under investigation 
has to be taken into account as it can alter its physico-chemical properties and thus its 
interactions with cells/biological material, cellular uptake and toxicity. Interestingly, 
while unmodified AgNPs have been shown to be toxic [157,176], a number of studies 
have reported that capped Ag-platinum alloy NPs [177], tiopronin (stabilising agent for 
metal NPs) AgNPs [178] and starch-capped AgNPs [50] exhibited either low or no 
toxicity at all. In these modified NPs, the capping agent hinders release of Ag ions, 
which have been suggested to be the cause of AgNP toxicity [161]. However, as 
explained in Section 2.1.2, the scientific opinion is ambiguous on this subject and 
difficulties in drawing a firm conclusion are also due to inconsistencies in the 
methodology used to obtain ionic solutions of NPs. In addition, ion generation from 
NPs is strictly dependent on NP physico-chemical properties, which largely vary among 
different NPs. Therefore, it is fundamental to characterise NPs intended for 
commercialisation in order to properly define their physico-chemical properties, thus 
limiting their toxicity. The AgNPs used in this study are unmodified, which might explain 
the toxicity measured. The investigation of particle dissolution and their consequent 
release of ions were not part of the present study; however it would be interesting to 
include them in future work.  
 
Cell viability evaluation of the TLR-3 ligand Poly I:C on TT1 cells revealed a 
concentration-dependent decrease in cell viability at 24, 48 and 72h, when 50µg/ml or 
100µg/ml of Poly I:C were used. Similar results were found by Park et al. in human oral 
squamous cell carcinoma cell lines [179]. Using flow cytometry and Western blotting 
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analysis, they demonstrated that Poly I:C induced apoptosis via a mitochondria-
dependent pathway [179]. To verify the activation of an apoptotic pathway in our study, 
as for AgNPs, we performed the Annexin V staining. Data showed that, up to 24h post-
exposure, at the chosen concentration (20µg/ml), Poly I:C did not induce any cell death 
via either apoptosis or necrosis, as expected following cell viability data, thus showing 
absence of cytotoxicity. A significant decrease in cell viability at 24h was measured at 
concentrations of Poly I:C higher than 20µg/ml, which, however, we did not assess by 
Annexin V staining. Therefore, we can only hypothesise that the reduction in cell 
viability could be due either to apoptosis/necrosis or to an inhibition of cell proliferation. 
To date, there are no studies on Poly I:C cytotoxicity in non-cancer cells. Poly I:C has 
been shown to cause apoptosis in a number of human cancer cell lines, even at low 
concentrations (1-10µg/ml) [180,181]. However, the exact mechanisms behind the 
induction of apoptosis by Poly I:C are still not well understood, and it is thought to be a 
complex process, involving multiple factors and signalling pathways [182].  
2.5.2 Effect of AgNPs, Poly I: C and LPS on TT1 IL-6 and CXCL-8 
release 
Given their fundamental function in pulmonary inflammation (Section 1.4.1.1), the role 
of IL-6 and CXCL-8 in AgNPs, Poly I:C and LPS reactivity was investigated. 
We reported a significant concentration-dependent increase in both IL-6 and CXCL-8 
production following exposure to AgNPs (24h). This is in agreement with previous 
studies demonstrating AgNP-induced release of pro-inflammatory mediators in other 
cell lines. In HEK cells it has been shown that naked AgNPs of different sizes (20, 50 
and 80nm) induce IL-6 and CXCL-8 release [183]. Similarly, increased IL-6 release has 
been observed in THP-1–derived macrophages exposed to naked 24nm AgNPs [184]. 
Regarding Poly I:C, we measured a concentration-dependent increase in both IL-6 and 
CXCL-8 release, following exposure to a range of concentrations from 1 up to 
100µg/ml. Cellular response to Poly I:C resulted in a particularly high IL-6 release, up 
to 124-fold greater (100µg/ml) than that seen in non-treated cells. This responsiveness 
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of alveolar epithelial cells to Poly I:C might explain the important role these cells play in 
the lung defense against viral infection, partly via TLRs. In fact, TLRs have been shown 
to be constitutively expressed on alveolar epithelial cells, including TLR-3 [67]. Poly I:C 
reactivity with cells of the lung was also confirmed in BEAS-2B by Matsukura and 
colleagues, who measured a time-dependent up-regulation of IL-6 and CXCL-8 
production following Poly I:C exposure [185]. Similarly, in primary non-transformed 
bronchial epithelial cells, Gern et al. showed that incubation with Poly I:C was a potent 
stimulus for CXCL-8 secretion (maximal 19.2pg/ml vs 0.4pg/ml in unstimulated cells) 
[186].  
 
LPS (1-10000ng/ml) did not have any effect on cell viability and did not induce any 
apoptotic and/or necrotic pathway. These data, in contrast with other works on LPS 
[187,188], may be explained by the hypo-responsiveness that LPS appears to have 
with TT1 cells. Indeed, exposure of TT1 cells to increasing concentrations of LPS 
resulted in a mild increase in IL-6 production, significant only at the two highest 
concentrations (1000ng/ml and 10000ng/ml), with no effect on CXCL-8 expression. 
Consistent with our results are those obtained by Monick et al. using an A549 cell line 
[189]. After incubation with 50µg/ml of LPS, they show a slight increase in IL-6 
production but no changes in CXCL-8 secretion. The authors hypothesised that the 
reason for this effect might be due to the low level of TLR-4 expression on the cell 
membrane. Indeed, following respiratory syncytial virus (RSV) infection, they showed 
ERK1/2 activation and increased membrane expression of TLR-4, with a consequent 
significant increase in CXCL-8 protein [189]. These results suggest a possible state of 
LPS hypo-responsiveness in normal airway epithelial cells, which might be linked to 
low level of TLR-4 expression on the cell membrane. Consequently, we studied further 
this possibility and discussed it in Chapter 5. In contrast with our data, a number of 
studies in human and murine monocytes, both in vivo and in vitro, have identified LPS 
as a major inducer of IL-6 cytokine [190]. Therefore, it seems that specific LPS 
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signalling pathways are likely to be dependent on cell type/function [190]. For instance, 
in airway epithelial cells, the secretion of inflammatory cytokines upon LPS exposure 
requires elevated amounts of LPS (1000–10000ng/ml) in comparison to phagocytic 
cells (1–10ng/ml). Thus, initiation and progression to downstream signalling events 
appears to be less efficient in the pulmonary epithelium than in myeloid cells [191]. In 
this context, it is important to consider that, due to regular exposure to ambient air 
containing bacteria and LPS, the lung is constantly exposed to potentially inflammatory 
material. Along with professional alveolar macrophages, pulmonary epithelial cells are 
the first cells to be challenged by LPS, therefore their response must be greatly 
regulated to prevent alteration of the epithelial barrier and consequent chronic 
pulmonary inflammation. Although at present the effect of LPS on airway epithelial cells 
remains unclear [189,192], we speculate that TLR-4 signalling may be triggered only 
upon exposure to a high amount of LPS, as occurs in occupational or infectious 
diseases. Subsequently, the pulmonary epithelium may participate in the local innate 
response through the secretion of cytokines and antimicrobial peptides. Lastly, the 
actual number of macrophages per alveolus is lower than the number of TT1 cells, 
therefore macrophages need to be more sensitive to LPS exposure, reflecting their 
main function as immune cells.  
2.5.3 Effect of co-exposure to AgNPs and Poly I:C (or LPS) on TT1 
IL-6 and CXCL-8 release 
In this study we carried out dual exposures of TT1 cells to AgNPs and either Poly I:C or 
LPS, in an attempt to model the effect that AgNP inhalation might have on the 
response of the alveolar epithelium to microbial infection. According to the most widely 
used method for studying drug combinations, the Chou-Talalay method, if drug A and 
drug B alone each has an effect, then in combination they may produce a synergistic, 
additive or antagonistic effect [167]. While synergism is defined as an effect that is 
more than additive and antagonism is less than additive [167], it took more than ten 
years to understand what an additive effect is, as it is not a simple arithmetic sum of 2 
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(or more) drugs [193]. Synergism and antagonism are determined using “combination 
index” (CI) values [194], proper statistical parameters [167] and by constructing an 
isobologram. The CI is a scientific term that quantitatively depicts synergism (CI < 1), 
additive effect (CI = 1), and antagonism (CI > 1) [194]. The isobologram is a dose-
oriented graph that can give information on the interaction of two drugs at any effect 
level. It is possible to transform experimental data in an isobologram automatically and 
mathematically by using commercially available softwares based on the Chou-Talaly 
method [167], such as CalcuSyn software (Biosoft) [195], which we used for the 
analysis of our data. However, we could not obtain accurate results for a number of 
reasons. To perform a CalcuSyn analysis, data entered needs to satisfy several 
criteria. The most important one is the construction of a dose-response curve for the 
drugs (compounds) used, in our case AgNPs and Poly I:C or LPS. In order to 
determine synergism/antagonism it is essential to know both the potency (Dm value) 
and the shape (m value) of each drug curve [167]. By entering our data points in the 
program, the software calculates both Dm and m values, elaborating statistical 
parameters as well. Through those values, the CI index for every single data point 
inserted is calculated, thus determining the type of effect (Table 2.9).  
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Range of CI Symbol Type of effect 
<0.1 +++++ Very strong synergism 
0.1-0.3 ++++ Strong synergism 
0.3-0.7 +++ Synergism 
0.7-0.85 ++ Moderate synergism 
0.85-0.90 + Slight synergism 
0.90-1.10 ± Additive 
1.10-1.20 – Slight antagonism 
1.20-1.45 – – Moderate antagonism 
1.45-3.3 – – – Antagonism 
3.3-10 – – – – Strong antagonism 
>10 – – – – – Very strong antagonism 
 
Table 2.9 CI index table. The CI method used in the CalcuSyn software is based on 
that described by Chou and Talalay [194]. CI<1, =1 and >1 indicate synergism, additive 
effect and antagonism respectively. 
 
The classic sigmoid dose-response curve normally shows the slope (required for the 
program to originate fit statistics) in the 0.2-0.8 effect range (Figure 2.19), therefore a 
minimum of 3 data points that give an effect in this range are required, otherwise no 
reliable results are guaranteed. In our experiments, even by increasing the number of 
data points to 8, we could not obtain more than 2 or 3 data points in the 0.2-0.8 range 
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and most of the values fell at the extreme ends of the curve. As a result, the statistical 
parameters (95% limits, standard deviation and r value of the graph) were quite poor, 
and the analysis not accurate. The statistical analysis for Poly I:C was better, but still 
insufficiently to obtain reliable results. We suggest that the way in which experimental 
data were transformed to fit the software, together with the nature of our data, might 
have been responsible for the poor fit of the results. Regarding the former, to perform a 
CalcuSyn analysis it is necessary to assign the value 1 to the maximum achievable 
effect obtainable in the experiments (in our case an OD value), after which all other 
effects are worked out as decimal fractions of this. The consequences of this data 
normalisation created problems in our analysis. Indeed, according to the software, it is 
fundamental that this OD reading (considered the maximum achievable under the 
experimental condition applied) is maintained consistent across the range of 
experiments. This was not applicable to our data, which presented a normal 
experimental variation that made it impossible to obtain a constant maximum value. 
Therefore, with different maximum values, the relative decimal fractions were changing 
each time the analysis was run, generating variable results. Even in the attempt of 
generating first an average of the data and inserting this in the program, we 
experienced the problem of too little data points falling in the desirable 0.2-0.8 range 
(explained above).  
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Figure 2.19 Example of a dose-effect sigmoidal curve of a drug simulated using 
CompuSyn software. Shape (m) and potency (Dm) parameters are indicated with “m” 
and “Dm” respectively. Graph taken from CalcuSyn software [195]. 
 
Having discovered that our data did not fit the requirements for the CalcuSyn software, 
mainly due to incompatibilities between mathematical statistics and biological data, we 
decided to present the results of the combination studies in heat maps and graphs, to 
better visualise a possible mechanism of action.    
Our results showed a difference between co-exposure to AgNPs and Poly I:C and co-
exposure to AgNPs to LPS. When cells were exposed to AgNPs in combination with 
Poly I:C, there was a tendency for IL-6 release to be potentiated, with an antagonistic 
effect on CXCL-8 release. When the study was repeated using AgNPs in combination 
with LPS, there was a tendency for an antagonistic effect on IL-6 release, as well as on 
CXCL-8 production for most of the combinations. The reason why the co-exposure to 
AgNPs and Poly I:C produced a potentiation in IL-6 production and inhibition of CXCL-
8 is not clear. Similar considerations apply to the results of the co-exposure to AgNPs 
and LPS. Drug combination analysis is a complicated topic, that has been studied for 
over a century and the understanding of the mechanism behind synergism is still 
largely unknown [167]. Although it is possible to know the dose or effect contributions 
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in a drug combination, it is difficult to determine the specific proportions of the 
mechanistic contribution of each drug that leads to the observed synergism or 
antagonism. We speculate that the potentiation measured for IL-6 following co-
exposure to AgNPs and Poly I:C might be a result of the two stimuli acting via two 
independent pathways or of synergistic effects on a common pathway. Potentiation in 
IL-6 production results in a prolonged inflammatory response, therefore in a delay of its 
successful resolution (Section 1.4.1.1). Indeed, increased levels of IL-6 have been 
associated with chronic inflammatory diseases [196]. Furthermore, studies on IL-6 
have revealed its biological role in the pathogenesis and progression of neoplasia [82]. 
On the other hand, antagonism in CXCL-8 production, resulting in lower neutrophil 
recruitment, may impair viral clearance. These data suggest that exposure to AgNPs 
during a viral respiratory infection could lead to prolonged pulmonary inflammation and 
impaired viral clearance. 
When considering the inhibitory effect of LPS and AgNPs co-exposure, we speculate 
that LPS is competing with AgNPs for a common pathway (discussed in Chapter 5) 
and thus prevents the significantly greater AgNP inflammatory response. The 
antagonistic effect on both IL-6 and CXCL-8 production by TT1 cells suggests that, in 
this scenario, besides the impairment in neutrophil recruitment (CXCL-8 decrease), the 
acute phase of inflammation also seems to be affected (IL-6 decrease). Taken 
together, our results suggest that inhalation of AgNPs during a viral or bacterial 
respiratory infection might prolong the inflammatory response, impair the pulmonary 
clearance in favour of the initiation, progression and chronicity of airway disease.  
There are no other similar studies assessing the effect of AgNPs on TLR stimulation in 
human non-carcinoma derived cells. Castillo et al. analysed the effect of co-treatment 
of Ag-tiopronin NPs with different TLR ligands, in a murine monocyte-macrophage cell 
line (RAW264.7 macrophages) [178]. The NPs had no pro-inflammatory effect on the 
cells, but inhibited the IL-6 secretion mediated by Poly I:C. A possible explanation for a 
discrepancy between our data and that from Castillo might be due to the type of NPs or 
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the cell type used. In fact, capped NPs generally express lower toxicity in comparison 
with the bare ones (see Section 2.5.1). Particularly interesting was a study by Herzog 
and colleagues in which CXCL-8 release was measured following co-exposure to LPS 
and colloid AgNPs in a triple cell-culture system composed of A549, monocyte derived 
macrophages and dendritic cells [197]. While LPS treatment alone induced an increase 
in CXCL-8 release and AgNP exposure did not, when the cells were challenged with 
both stimuli, no additive effects were observed. We suggest that the absence of any 
CXCL-8 increase after AgNP exposure can be due to the type of Ag used: colloidal Ag 
is different from normal Ag. A colloid is simply a solution where particles from 0.008 to 
10µm are naturally suspended and evenly distributed throughout, whereas normal Ag 
tends to aggregate in bigger agglomerates. Regarding the difference in results after 
LPS stimulation between our study and Herzog’s study, we suggest that the cell type 
might be the main factor responsible [190,198] (refer to Section 2.5.2).  
2.5.4 MAP-kinase pathway: activation and inhibition 
The involvement of AgNPs in different signal-transduction pathways was assessed by 
measuring the phosphorylation of p38MAPK, ERK1/2 and JNK over 24h. Our results 
demonstrated differential activation of the three signalling pathways over time. 
p38MAPK phosphorylation peaked at later time points (6h and 24h), whereas ERK1/2 
and JNK showed earlier activation (ERK1/2: 2h, 6h and 24h; JNK: 4h and 24h). 
Several works on MAP-kinase activation by AgNPs have been reported. In a recent 
study using Jurkat T-cells, it was found that exposure to AgNPs activated p38MAPK 
through Nrf-2 and NF-kB signalling pathways, leading to DNA damage, cell cycle arrest 
and apoptosis [173]. Kaur and colleagues investigated the role of p38MAPK in AgNP-
induced oxidative stress formation. Comparing AgNP response in different cell types, 
they observed maximum activation of p38MAPK in A431 skin carcinoma cells. This 
correlated with the levels of ROS generation and MTT data, both showing maximum 
response in A431 cells [199]. Interestingly, several reports support the association of 
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p38MAPK activation with several pulmonary events, such as during viral [200, 205] or 
bacterial [201] infection and with different pathways, including DNA damage and 
apoptosis [202]. However, because of its implication in cellular responses including 
inflammation, cell death, cell cycle, cell differentiation, senescence, and tumorigenesis, 
emphasis must be placed on p38MAPK function with respect to specific cell types 
[203]. In our study, p38MAPK activation started at 6h and increased at 24h, therefore 
supporting the hypothesis that it might contribute to the molecular mechanisms 
involved in the onset of other cellular events at later time points. 
Contrary to our findings, a study by Comfort et al. showed that 10nm AgNPs inhibited 
ERK1/2 phosphorylation by approximately 20% in the human epithelial cell line 
(epidermoid carcinoma) A431 [204]. ERK1/2 is a dominant factor in the inflammatory 
response, and therefore blocking its activation could lead to a negative regulation of 
inflammation. The difference between their data and ours may be due to the cell type 
used or the fact that Comfort and colleagues only examined one time point, 24h, and 
thus may have missed any earlier activation of the kinase, whereas we carried out a 
broader time-course analysis.   
 
In order to investigate the role of each kinase, pharmacological inhibitors of p38MAPK, 
ERK1/2 and JNK were used prior to AgNP exposure. Both IL-6 and CXCL-8 
expression were significantly inhibited by p38MAPK (p<0.01 and p<0.001 respectively). 
Interestingly, inhibition of ERK1/2 and JNK had no effect, on either IL-6 or CXCL-8 
release. It is known that ERK1/2 signalling can regulate multiple processes, including 
cellular proliferation, cell cycle progression and survival associated with the 
development of cancer and disease [206, 207]. The results obtained with the JNK 
inhibitor may be complicated by the fact that this inhibitor has been shown to inhibit 13 
of the 30 protein kinases tested in the work by Bain et al. with similar or greater 
potency as its inhibition of JNK isoforms [208]. Moreover, cell type-specific differences 
in the role of JNK on the expression of inflammatory genes also seem to exist [208]. 
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2.6 Conclusion   
This study is the first to assess the response of important lung target cells, human 
transformed AT1-like cells (TT1), to AgNPs in the presence and absence of microbial 
ligands. Our results demonstrated that AgNPs induce a significant decrease in cell 
viability at concentrations higher than 50µg/ml at 24h and 30µg/ml at 48 and 72h. 
Interestingly, concentrations of AgNPs of approximately 50µg/ml may be 
physiologically relevant [209]. In fact, according to the pattern of particle deposition 
within the respiratory tract (Section 1.2.3.1), repeated inhalation of similar size NPs 
tend to deposit in the same area, creating “hot spots”. These “hot spots” (approximately 
100µm2 of epithelial tissue) are bio-accumulations of ambient NPs in specific parts of 
the respiratory tract, especially at bifurcation junctions [209], where they can create a 
highly toxic area. Thus, it could be hypothesised that “hot spots” of AgNP 
contamination may develop during localised accidental release, or throughout the life 
cycle of products containing nano-Ag (Section 1.1.3) [210]. Unfortunately, the 
investigation of NP toxic effects is made complex and challenging by the multiplicity of 
their physico-chemical parameters, which vary for every NP. 
To date, one of the paradigms for NP-mediated toxicity includes inflammation. In terms 
of mediator release, exposure to AgNPs induced a concentration-dependent increase 
in IL-6 and CXCL-8 production from TT1 cells. Taken together with the toxicity studies, 
these results provided a better understanding of the optimal concentration of AgNPs to 
use. Showing little decrease in cell viability and sub-optimal release of IL-6 and CXCL-
8, 50µg/ml AgNPs was established as the working concentration for subsequent 
experiments. Following the same considerations, 20µg/ml and 1000ng/ml were the 
chosen concentrations for Poly I:C and LPS respectively. 
 
In favor of our hypothesis, the co-exposure study with AgNPs and Poly I:C revealed a 
potentiation in IL-6 production but also a decrease in CXCL-8 release which might lead 
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to a prolonged inflammation and impaired viral clearance. From a clinical perspective, 
these results suggest that, inhalation of AgNPs during a respiratory viral infection, 
could lead to a worsening of the pulmonary condition. However, further experiments 
are needed in order to reach a better understanding of these findings. Contrary to what 
we hypothesised, exposure to AgNPs and LPS resulted in lower cellular production of 
IL-6 and CXCL-8, suggesting the loss of a physiological TT1 inflammatory response. 
Finally, the pro-inflammatory effect of AgNPs was found to be dependent on the 
activation of p38MAPK. Involvement of this signal transducer indicates that AgNPs 
may be eliciting their cellular reactivity via oxidative mechanisms, either directly or 
indirectly. This subject is investigated in Chapter 4. 
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Figure 2.20 AgNP, Poly I:C and LPS reactivity with TT1 cells at 24h. On the left: Effect of AgNPs, Poly I:C and LPS on their own. (I) The most significant 
inflammatory response is induced by Poly I:C (via TLR-3) and AgNPs (via p38MAPK), whereas LPS (via TLR-4) causes only a low release of IL-6; (II) AgNPs 
cause reduced cell viability probably through necrotic pathways. On the right: cells are co-exposed to AgNPs and Poly I:C or LPS. (I) While co-exposure to 
AgNPs and Poly I:C induces a synergistic effect on IL-6 release, co-exposure to AgNPs and LPS results in antagonism of both IL-6 and CXCL-8 release; (II) 
the decrease in cell viability measured after co-exposure to AgNPs and Poly I:C or LPS seems to happen through necrotic pathways. 
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3. SILVER NANOPARTICLE REACTIVITY: 
AUTOPHAGY AND DNA DAMAGE 
3.1 Introduction 
Besides the inflammatory response, investigated in Chapter 2, AgNPs may affect 
different cellular processes (e.g. autophagy) and even target the DNA [10,76,100]. At 
present, genotoxicity studies are being increasingly introduced in health risk 
assessments of new pharmaceuticals, chemicals, or products containing NPs. 
As for autophagy, Poly I:C and LPS are known to activate autophagy by inducing TLR-
3 and TLR-4 respectively, leading to autophagosome formation [95,211]. This takes 
place in order to be able to cope with and digest pathogens. Therefore, the 
investigation of the effects of AgNPs on autophagy and cellular DNA, in the presence 
and absence of Poly I:C and LPS, is the aim of this part of the study.  
3.1.1 The importance of the autophagic flux 
The autophagic process, introduced in Chapter 1 (Section 1.4.2), is being increasingly 
associated with pulmonary diseases (e.g. COPD, pulmonary hypertension, cystic 
fibrosis and respiratory infections [212]). Interestingly, various kinds of NPs such as 
gold, quantum dots and fullerenes, have recently been shown to activate autophagy 
and have been defined as “a novel class of autophagy activators” [213]. Furthermore, 
since autophagy is the only cell process able to degrade large cellular components, 
including internalised foreign material (e.g. microorganisms), it could be postulated that 
NPs may be captured and cleared by cells using the autophagic pathway. 
A frequent misconception when studying autophagy is that an increased number of 
autophagosomes in the cell corresponds to higher autophagic activity. Being a highly 
dynamic and complex process, autophagy is regulated at many different levels. Thus, it 
is fundamental to discriminate between increased LC3-II levels (which correspond to 
an increased number of autophagosomes) and activation of the autophagic flux. 
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Autophagic flux is defined as a process involving all the different steps from the 
autophagosome synthesis to its degradation inside the lysosome (Section 1.4.2.2, 
Figure 1.10). Therefore, autophagosome accumulation might be the result of either 
activation of the autophagic flux or suppression of autophagosome degradation [93]. 
To distinguish between these two possibilities it is necessary to perform “autophagic 
flux assays”. One of the most commonly used methods to measure autophagic flux is 
the monitoring of LC3 turnover using lysosomotropic reagents, such as chloroquine 
(CQ) that decreases lysosomal acidity, thus inhibiting the degradation process. The 
rationale behind using these inhibitors is based on the observation that LC3-II is 
degraded in autolysosomes, so the total amount of LC3-II is determined by a balance 
between LC3-II production and degradation. However, when lysosomal degradation is 
inhibited, the amount of LC3-II is strictly dependent on LC3-II production. Since there is 
no formation of new autophagosomes downstream of the pathway in a defective flux, 
there will be no increase in LC3-II protein. By comparing the amount of LC3-II 
measured in the presence and absence of a lysosome degradation inhibitor, the state 
of the autophagic flux (active or blocked) is more accurately deduced [93]. 
3.2 Hypothesis 
We hypothesised that exposure to AgNPs activates autophagy and induces DNA 
damage. Furthermore, on the basis of the previously described observations of co-
incubation with Poly I:C or LPS, we hypothesised that AgNPs, in the presence of viral 
(Poly I:C) or bacterial (LPS) infection, lead to defective autophagy and increased DNA 
damage.  
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3.3 Materials and Methods 
3.3.1 Materials 
Poly I:C, LPS, cell culture and Western blotting reagents and materials were sourced 
as described in Section 2.3.1. MES solution was purchased from Invitrogen (Paisley, 
UK). Chloroquine (CQ), anti-LC3 antibody, Tris/Borate/EDTA (TBE), hydrogen peroxide 
and 1kb DNA ladder were obtained from Sigma Aldrich (Poole, UK). Anti-
GAPDH+H2A.X+cleaved-PARP and anti-β-actin antibody were purchased from Abcam 
(Cambridge, UK). Bacteriophage ФX174 RF DNA, restriction enzyme and restriction 
buffer were sourced from Promega (London, UK). GelRedTM Nucleic Acid Gel Stain 
was obtained from Biotium (Cambridge, UK). 
3.3.2 Methods 
3.3.2.1 Measurement of autophagy activation by AgNPs alone or in 
combination with Poly I:C (or LPS) 
3.3.2.1.1 Exposure to AgNPs in the presence or absence of chloroquine 
(CQ)  
TT1 cells were prepared in 6-well plates (see Section 2.3.2.3) and serum starved 24h 
prior to the experiment. In order to select the most appropriate time point to study the 
autophagy process, cells were exposed to AgNPs (50μg/ml) over time. At 4, 6, 8 and 
24h, TT1 cells were collected for whole-cell extraction, protein quantification and 
Western blotting (see Section 2.3.2.13). Running buffer MES (50mM MES, 50mM Tris-
base, 0.1% SDS, 1mM EDTA made up to 500ml with deionised water) was used 
instead of MOPS. The use of MES allowed for better separation of low molecular size 
proteins, such as LC3 (major band at 18kDA, minor band between 14 and 16kDa). 
Autophagosome formation was calculated as LC3-II/β-actin ratio, where β-actin was 
used as a loading control. Three independent experiments were performed using three 
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separate TT1 cell passage generations. Proteins were detected using the primary 
antibodies shown in Table 3.1.  
Once the optimal time point was determined, cells were treated with AgNPs (50μg/ml) 
in the presence or absence of CQ (100µM). CQ was added to the cells 2h before the 
end of the time point. This lysosomotropic agent decreases lysosomal acidity, thus 
inhibiting the fusion of autophagosome and lysosomes (see Section 3.1.1 for full 
explanation). Western blotting and protein detection were performed as described 
previously (Section 2.3.2.13). Three independent experiments were performed. Gels 
were imaged using Ultraviolet Transilluminator GelDoc-It and densitometric 
quantification was performed using Visionworks. 
3.3.2.1.2 Co-exposure to AgNPs and Poly I:C (or LPS), in the presence or 
absence of CQ 
TT1 cells were prepared in 6-well plates and serum starved 24h prior to the 
experiment. Cells were then exposed to AgNPs (50μg/ml) for 1h, when either Poly I:C 
(20μg/ml) or LPS (1000ng/ml) was added for another 23h. Since the exposure time 
was different for the 3 substances involved (AgNPs, Poly I:C/LPS and CQ), the design 
of the experiment required different time points (8h, 24h and 2h respectively). As the 
co-exposure studies on inflammation (see Section 2.4.3.7.4) were conducted over 24h, 
these experiments were performed over the same time. Therefore, TT1 cells were first 
exposed to Poly I:C or LPS (20μg/ml and 1000ng/ml respectively; t=0) and after 16h 
AgNPs were added for a total period of 8h (8h corresponds to the peak of autophagy 
activation). Finally, 2h before the end of exposure (at 22h), cells were stimulated with 
100µM of CQ (Figure 3.1). Western blotting and protein detection were performed as 
previously described (Section 2.3.2.13). Three independent experiments using three 
different TT1 cells passage were performed. Proteins were detected using the primary 
antibodies shown in Table 3.1. Gels imaging and analyses were performed as 
previously described (Section 3.3.2.1.1). 
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Figure 3.1 Scheme of the protocol used in co-exposure experiments in presence 
of CQ. Cells were first exposed to Poly I:C (t=0h) and at 16h to AgNPs, for a total 
period of 8h. At 22h, CQ was added to the cells for 2h. The total time of exposure was 
24h. The same scheme was applied to the experiments with LPS. 
3.3.2.2 Measurement of DNA damage by AgNPs alone or in 
combination with Poly I:C (or LPS) 
Following cell preparation and serum starvation, cells were exposed to increasing 
concentrations of AgNPs (1, 10, 30, 50μg/ml) for 24h. For co-stimulations, cells were 
exposed first to AgNPs (50μg/ml) for 1h, then either Poly I:C (20μg/ml) or LPS 
(1000ng/ml) were added for a total period of 24h. DNA damage was detected using the 
antibody cocktail Anti-GAPDH + H2A.X + cleaved-PARP. Histone H2A (16kDa) is 
recruited and phosphorylated at the site of DNA damage, therefore phosphorylated 
levels of H2A are a marker for DNA damage and can be easily detected by Western 
Blotting. PARP is a marker for apoptosis; full-length PARP is an 116kDa protein 
involved in the repair of DNA, in differentiation and in chromatin structure formation. 
During apoptosis, this protein is cleaved by caspase-3, and possibly other caspases, 
into an 89kDa fragment [214]. As in the autophagy studies, Western blotting was 
performed using MES running buffer. GAPDH (Glyceraldehyde 3-phosphate 
dehydrogenase) was used as a loading control. Three independent experiments were 
performed. Primary antibodies used to detect the proteins are listed in Table 3.1. Gel 
imaging and analysis were performed as previously described (Section 3.3.2.1.1). 
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Primary Antibody 
(dilution) 
Company 
Secondary 
Antibody (dilution) 
Molecular Weight 
of target protein 
(kDa) 
LC3-B 
(1:10,000) 
Sigma 
Rabbit 
 (1:2,500) 
18 (LC3-I) 
14-16 (LC3-II) 
β-actin 
(1:300,000) 
Abcam 
Mouse  
(1:3,000) 
45 
GAPDH+H2A.X    
+ PARP 
(1:10,000) 
Abcam 
Mouse 
(1:3,000) 
36+16+89 
 
Table 3.1 Antibodies used for protein detection. kDa: kilo Dalton. 
3.3.2.3 Assessment of intrinsic AgNP oxidative capacity  
In order to assess the intrinsic oxidative capacity of AgNPs, free radical-induced 
damage of supercoiled DNA was measured using a plasmid assay. The principle of 
this assay is that any free radical associated with particles could damage the 
supercoiled DNA, thus unfolding it. Further damage would result in complete 
linearisation, followed by fragmentation. These changes in DNA quaternary structure 
alter the electrophoretic mobility of the DNA, allowing separation and quantification on 
an agarose gel [127]. Thus, the plasmid assay was used to monitor possible damage 
to supercoiled DNA by free radicals generated directly at the AgNP surface [126]. 
Icosahedral bacteriophage ϕX174-RF DNA was selected as the optimum plasmid, due 
to its sensitivity to oxidative damage [126]. Three different controls were used: control 
samples (DNA incubated in water), linear control (or positive control, DNA incubated in 
Pst1 restriction endonuclease, restriction buffer and water), and oxidative control (DNA 
incubated in a 1mM H202 solution and water). Different concentrations of AgNPs (1, 10, 
30, 50μg/ml) were tested. All incubations were carried out to a final volume of 20μl, 
each containing 200ng DNA and 4μl of loading dye. Samples were left overnight in an 
incubator, at 37oC, containing 5% CO2. The gels were prepared with 0.8% agarose and 
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2μl GelRed and were run in a 80V electrophoretic current for 3h 30min at RT in 1% 
Tris-Borate-EDTA (TBE) buffer. Bioreactivity was calculated as the combined amount 
of DNA in the relaxed and linear (damaged) forms, as a proportion of the total amount 
of DNA in each lane. 
3.3.2.4 Statistical analyses 
All statistical tests were performed using GraphPad Prism 4 software. Results are 
presented as fold-change ± standard error of the mean (SEM); n=3 (unless otherwise 
stated), where 3 independent experiments were performed using 3 separate TT1 cell 
passage generations. Data was considered to follow a normal distribution. We elected 
a priori to compare treated groups to the untreated control. Thus, significant effects of 
AgNPs, Poly I:C and LPS on protein expression/activation were determined using one-
way ANOVA followed by Dunnett’s post-test to compare all treatments against the 
unexposed control. Alternatively, Bonferroni’s Multiple Comparison test was used as a 
post-test when comparing all pairs of treatments. A p value of <0.05 was considered to 
be statistically significant.  
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3.4 Results 
3.4.1 Effect of AgNPs on autophagy activation 
In order to investigate the possible activation of autophagy (assessed by 
autophagosome formation, i.e. LC3-II formation) by AgNPs, a time course analysis was 
performed and Western blotting data were quantified using the ratio LC3-II/β-actin. TT1 
cells stimulated with AgNPs (50µg/ml) revealed a peak in autophagosome formation at 
8h (8-fold increase; p<0.001) that decreased at 24h but remained significant (4.8-fold 
increase; p<0.001) (Figure 3.2). On this basis 8h was chosen as the optimal time point 
for subsequent experiments. 
3.4.2 Effect of AgNPs on the autophagic flux  
As detailed in Section 3.1.1, a study of autophagy requires the investigation of the 
“autophagic flux”. In our studies we used CQ, a later stage inhibitor of the degradation 
process of autophagy [91]. Western blotting analyses showed that, at basal level, the 
addition of CQ revealed a strong autophagic flux (7.5-fold increase; p<0.001) (Figure 
3.3). After stimulation with AgNPs, the amount of LC3-II detected in the presence of 
CQ was significantly higher (p<0.05) than without CQ (Figure 3.3). This indicates that, 
when blocking a later stage of autophagy (lysosomal degradation), the 
autophagosomes accumulate, proving that the conversion from LC3-I to LC3-II was still 
happening and new autophagosomes were being formed. Therefore, exposure to 
AgNPs did not impair the autophagic flux. 
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Figure 3.2 Effect of AgNPs on autophagy activation. TT1 cells were exposed to 
AgNPs (50μg/ml) and collected at different time points (4, 6, 8 and 24h). Whole cell 
extracts were run in SDS-PAGE/Western blotting and normalised against the 
expression of β-actin. Autophagosome formation over 24h was calculated as a ratio 
LC3-II/β-actin. Representative blot of 3 independent experiments (A) and graph (B) 
showing autophagy activation over time. NT=non treated. Data are presented as fold-
change ± SEM (n=3) and analysed by one-way ANOVA followed by Dunnett’s post-
test; ***p<0.001. 
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Figure 3.3 Effect of autophagy inhibitor CQ on AgNP-induced autophagy. TT1 
cells were exposed to AgNPs (50μg/ml) for 8h, and 2h before the end of the exposure, 
CQ (100µM) was added to the cells. Whole-cell extracts were run in SDS-
PAGE/Western blotting and normalised against the expression of β-actin. 
Autophagosome formation was calculated as a ratio LC3-II/β-actin. Representative blot 
of 3 independent experiments (A) and graph (B) showing the effect of CQ on AgNPs 
stimulation. Data are presented as fold-change ± SEM (n=3) and analysed by one-way 
ANOVA followed by Bonferroni’s post-test. **p<0.01; ***p<0.001 (vs. unexposed 
control);  #p<0.05 (AgNPs vs. CQ+AgNPs). 
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3.4.3 Effect of co-exposure to AgNPs and Poly I:C (or LPS) on the 
autophagic flux  
In the second part of our hypothesis we proposed that AgNPs, in the presence of a 
viral and bacterial infection, induce defective autophagy and increase DNA damage. In 
order to address this, we performed the same experiment previously described (refer to 
Section 3.4.2), with the addition of Poly I:C or LPS for 24h. Western blotting analysis 
showed that Poly I:C alone activated autophagy (p<0.01), as expected, but co-
exposure to AgNPs and Poly I:C did not induce any potentiation compared to the effect 
of each of the stimuli alone (Figure 3.4). Measurement of autophagic flux using CQ 
showed that Poly I:C alone did not impair the flux, as the amount of LC3-II detected 
with CQ was significantly higher (p<0.001) than that measured without CQ. Confirming 
the previous findings (Section 3.4.2), AgNPs activated autophagy (p<0.001) without 
impairing the flux. Interestingly, when comparing the amount of LC3-II detected in each 
condition in the presence of CQ (Poly I:C=53-fold; AgNPs=59-fold; AgNPs+Poly 
I:C=41-fold) to the corresponding sample in the absence of CQ (Poly I:C=17-fold; 
AgNPs=31-fold; AgNPs+Poly I:C=29-fold), the smallest (least significant) difference in 
autophagosome formation was measured in the co-exposure (Poly I:C=36-fold, 
p<0.001; AgNPs=28-fold, p<0.001; AgNPs+Poly I:C=12-fold, p<0.05), suggesting that 
the co-exposure to AgNPs and Poly I:C slowed the autophagic flux. 
 
The same experiment was repeated using 1000ng of LPS (Figure 3.5). As opposed to 
Poly I:C, LPS did not induce autophagy and neither affected AgNP-induced 
autophagosome formation. 
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Figure 3.4 Effect of autophagy inhibitor CQ on AgNP- and/or Poly I:C-induced 
autophagy. TT1 cells were first exposed to Poly I:C (20µg/ml) for a total 24h in which 
AgNPs (50μg/ml) and CQ (100μM) were added in the last 8h and 2h, respectively. 
Whole-cell extracts were run in SDS-PAGE/Western blotting and normalised against 
the expression of β-actin. Autophagosome formation was calculated as a ratio LC3-II/β-
actin. Representative blot of 3 independent experiments (A) and graph (B) showing the 
effect of CQ on AgNP- and/or Poly I:C-induced autophagy. Data are presented as fold-
change ± SEM (n=3) and analysed by one-way ANOVA followed by Bonferroni’s post-
test. **p<0.01; ***p<0.001 (vs. unexposed control); #p<0.05; ###p<0.001 (CQ-
unexposed vs. CQ-exposed).  
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Figure 3.5 Effect of autophagy inhibitor CQ on AgNP- and/or LPS-induced 
autophagy. TT1 cells were first exposed to LPS (1000ng/ml) for a total 24h in which  
AgNPs (50μg/ml) and CQ (100μM) were added in the last 8h and 2h, respectively. 
Whole-cell extracts were run in SDS-PAGE/Western blotting and normalised against 
the expression of β-actin. Autophagosome formation was calculated as a ratio LC3-II/β-
actin. Representative blot of 3 independent experiments (A) and graph (B) showing the 
effect of CQ on AgNP- and/or LPS-induced autophagy. Data are presented as fold-
change ± SEM (n=3) and analysed by one-way ANOVA followed by Bonferroni’s post-
test. *p<0.05 (vs. unexposed control); ###p<0.001 (CQ-unexposed vs. CQ-exposed). 
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3.4.4 Effect of AgNPs on DNA damage  
In order to investigate the genotoxic potential of AgNPs, phosphorylation of H2A.X was 
measured by Western blotting. We found that AgNPs caused a concentration-
dependent increase in DNA damage (Figure 3.6), which was significant at 30μg/ml 
(4.7-fold increase; p<0.05) and 50μg/ml (9-fold increase; p<0.001). 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6 Effect of AgNPs on DNA damage. TT1 cells were exposed to increasing 
concentrations of AgNPs (1, 10, 30 and 50μg/ml) for 24h. Whole-cell extracts were run 
in SDS-PAGE/Western blotting and phosphorylation levels of H2A.X were normalised 
against the expression of GAPDH. Representative blot of 3 independent experiments 
(A) and graph (B) showing increasing levels of DNA damage in TT1 cells. NT=non-
treated. Data are presented as fold-change ± SEM (n=3) and analysed by one-way 
ANOVA followed by Dunnett’s post-test; *p<0.05; ***p<0.001. 
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3.4.5 Effect of co-exposure to AgNPs and Poly I:C (or LPS) on DNA 
damage 
The effect of viral and bacterial infections on AgNP-induced DNA damage was 
investigated by measuring the levels of phosphorylation of H2A following co-exposure 
to AgNPs and Poly I:C or LPS. Western blotting analysis revealed that Poly I:C alone 
did not cause significant DNA damage (Figure 3.7). However, when AgNPs and Poly 
I:C were combined, the level of DNA damage was significantly greater (10.4-fold 
increase over the unexposed control; p<0.001) than the damage caused by Poly I:C 
(Poly I:C vs. AgNPs+Poly I:C= p<0.01) or AgNPs (AgNPs vs. AgNPs+Poly I:C= 
p<0.05) alone. 
Exposure to LPS alone (1000ng) did not induce any DNA damage, and when co-
exposed with AgNPs, it did not potentiate AgNP effects (Figure 3.8). Although not 
significant, we measured a reduction in the levels of phosphorylation of H2A.X during 
co-stimulation compared to AgNPs alone. 
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Figure 3.7 Effect of co-exposure to AgNPs and Poly I:C on DNA damage. TT1 
cells were exposed first to AgNPs (50μg/ml) and, after 1h, to Poly I:C (20μg/ml) for 
another 23h. Whole cell extracts were run in SDS-PAGE/Western blotting and 
phosphorylation levels of H2A.X were normalised against the expression of GAPDH. 
Representative blot of 3 independent experiments (A) and graph (B) showing 
increasing levels of DNA damage in TT1 cells. Data are presented as fold-change ± 
SEM (n=3) and analysed by one-way ANOVA followed by Bonferroni’s post-test. 
*p<0.05; ***p<0.001 (vs. unexposed control); #p<0.05; ##p<0.01 (AgNPs or Poly I:C 
alone vs. co-exposure to AgNPs and Poly I:C). 
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Figure 3.8 Effect of co-exposure to AgNPs and LPS on DNA damage. TT1 cells 
were exposed first to AgNPs (50μg/ml) and, after 1h, to LPS (1000ng/ml) for another 
23h. Whole cell extracts were run in SDS-PAGE/Western blotting and phosphorylation 
levels of H2A.X were normalised against the expression of GAPDH. Representative 
blot of 3 independent experiments (A) and graph (B) showing levels of DNA damage in 
TT1 cells. Data are presented as fold-change ± SEM (n=3) and analysed by one-way 
ANOVA followed by Bonferroni’s post-test; *p<0.05 (vs. unexposed control); NS=non 
significant (AgNPs vs. AgNPs+LPS). 
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3.4.6 Oxidative capacity of AgNPs 
We assessed the effect of AgNPs on free supercoiled DNA in order to elucidate 
whether the NPs possess intrinsic oxidative capacity. Therefore, we monitored free 
radical-induced damage to supercoiled DNA in a cell-free system using a plasmid 
assay. Any damage to the DNA caused by the NPs will first unfold the supercoiled 
DNA (relaxed form), which, following further damage, will linearise (linear form). In case 
of a major damage, the DNA will appear fragmented. Thus, an increase in the relaxed 
and/or linear form, together with a decrease in the supercoiled form, indicates damage 
to the DNA, correlating to the AgNP intrinsic oxidative capacity. Our findings showed a 
concentration-dependent increase in DNA damage following incubation of AgNPs to 
the supercoiled DNA (Figure 3.9). In fact, the optical density of the supercoiled fraction 
decreased from 1 (AgNPs 1μg/ml; lane 4) to 0.35 (AgNPs 50μg/ml; lane 7), which was 
similar to the value of the positive control H2O2 (0.25; lane 3). On the contrary, the 
optical density of the relaxed form increased from 1.1 (AgNPs 1μg/ml; lane 4) to 1.55 
(AgNPs 50μg/ml; lane 7). Furthermore, in every sample containing AgNPs (lane 4, 5, 6 
and 7) we also detected a linear form of DNA (fragmented DNA). The values of the 
different DNA fractions were normalised against the non-treated sample containing 
only DNA (lane 1).  
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Figure 3.9 Effect of increasing concentrations of AgNPs on supercoiled DNA.  
DNA (200ng) was incubated with increasing concentrations of AgNPs (µg/ml) for 12h. 
Samples were loaded in a 0.8% agarose gel and run at 80V for 3h 30min at RT. 
Representative blot of 2 independent experiments (A) and graph (B) showing changes 
in the optical density of supercoiled and relaxed forms of the DNA. Data are presented 
as fold-change ± SEM; (n=2). L=ladder; 1=DNA + water; 2=DNA + Pst1; 3=DNA + H202 
1mM; 4=DNA + AgNPs 1µg/ml; 5=DNA + AgNPs 10µg/ml; 6=DNA + AgNPs 30µg/ml; 
7=DNA + AgNPs 50µg/ml. 
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3.4.7 AgNP-induced PARP cleavage in the presence and absence of 
Poly I:C (or LPS)  
In order to further investigate our findings on AgNP-induced apoptosis (see Section 
2.4.3.6), we investigated the presence of cleaved-PARP in our cells following AgNP 
treatment. The antibody against cleaved-PARP was part of the antibody cocktail Anti-
GAPDH+H2A.X+cleaved-PARP, used to detect DNA damage (Section 3.4.4 and 
3.4.5). Following exposure to AgNPs alone (Figure 3.10, A) and in combination with 
Poly I:C or LPS we did not detect any cleaved-PARP formation (Figure 3.10, B and C). 
These findings are in agreement with our previous data on Annexin V staining and 
further substantiate our hypothesis that AgNPs induced cell death, but not through an 
apoptotic pathway. 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.10 Effect of AgNPs on PARP cleavage in the presence and absence of 
Poly I:C or LPS. TT1 cells were exposed to (A) increasing concentrations of AgNPs 
(1, 10, 30 and 50μg/ml); (B) AgNPs (50μg/ml) and, after 1h, to Poly I:C (20µg/ml); (C) 
AgNPs (50μg/ml) and, after 1h, to LPS (1000ng/ml). Time point for every exposure was 
24h. Whole cell extracts were run in SDS-PAGE/Western blotting and levels of 
cleaved-PARP were normalised against the expression of GAPDH. Representative blot 
of 3 independent experiments.  
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3.5 Discussion 
3.5.1 Autophagy  
3.5.1.1 Autophagy and nanoparticles 
This study demonstrates for the first time that AgNPs activate autophagy in human 
alveolar epithelial cells. Other NPs such as iron oxide, silica, fullerene and cadmium 
have also been reported to induce autophagy in different cell types (e.g. human brain-
derived cells and HeLa cells among others [215–217]), suggesting that this may be a 
well conserved protective response to particle exposure. As anticipated (Section 3.1.1), 
a number of studies have defined NPs as a “novel class of autophagy activators” 
[213,215,217,218]. In order to properly investigate autophagy, the assessment of the 
autophagic flux is fundamental (see Section 3.1.1); however, in some studies, the flux 
has not been fully assessed. The use of lysosomal inhibitors, such as CQ, is one of the 
methods that allow a correct interpretation of the flux [93]. Electron microscopy is also 
used in order to visualise the double membrane typical of autophagosomes [93]. 
However, although being a powerful tool, electron microscopy is not a perfect method 
to investigate autophagy, mainly because it can lead to several misinterpretations [93]. 
At the ultra-structural level, an autophagosome is defined as a double-membrane 
structure. However, it is not always clear how to interpret double-membrane structures 
that contain a pathogen. In fact, the life cycle of certain pathogens might include an 
autophagic-like intermediate structure, thus difficult to distinguish from the actual 
autophagosome. Another difficulty lies in the distinction between autolysosomes and 
other cellular membranous compartments. The autolysosome is the product of the 
fusion between an autophagosome with a lysosome, and as such it contains 
cytoplasmic material at different stages of degradation. Therefore, when the 
degradation process is already advanced, it becomes very difficult to trace the origin of 
the material contained inside. Furthermore, it is often challenging to distinguish an 
“autophagic structure” from other endocytic compartments based only on their internal 
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material [93]. Hence we decided to use the lysosome inhibitor CQ in the current study. 
We showed that AgNPs did not affect autophagic flux; in fact, in the presence of CQ, 
we still measured autophagosome formation, indicating competent flux. Among all the 
studies investigating the effect of NPs on autophagy, only the one by Ma et al. 
assessed the flux using CQ [219]. In contrast to our findings, the authors reported that, 
in normal rat kidney cells, gold NPs induced blockage of autophagic flux, rather than 
induction of autophagy [219]. Besides the cell type difference, as autophagy is a 
process regulated by several signalling pathways, it is difficult to find an explanation to 
the difference between this study and ours. In addition, Ma and colleagues calculated 
the autophagosome formation as a LC3-II/LC3-I ratio, whereas we used the LC3-II/β-
actin ratio. As previously explained, (Section 1.4.2.2), the ratio of conversion LC3-I to 
LC3-II is generally accepted as a marker of autophagosome formation; nevertheless, it 
has been questioned as a valid detector of autophagy. In the literature, there are 
conflicting hypotheses surrounding how LC3 Western blotting data should be 
interpreted [220]. In fact, the use of LC3-II/LC3-I ratio gave numerous false-positive 
and false-negative results. For example, commercial antibodies have differential 
affinities for LC3-I compared to LC3-II; also, depending on cell line and tissue, different 
expression levels of LC3-I and LC3-II have been found. Additionally, LC3-II itself is 
subject to autophagic degradation within the lysosome. Thus, a consensus has been 
reached using normalisation of LC3-II levels against a loading control, such as β-actin 
or α-tubulin [221], to determine changes in autophagosome formation, hence our 
decision to analyse the data using the LC3-II/β-actin ratio. 
 
The mechanisms that lead to autophagy activation are still poorly understood. For 
example, Li et al. hypothesised that, while gold NPs treatment induced oxidative stress, 
the cell could avoid cell death through autophagic pathways [222]. Shvedova et al. 
proposed that, as NPs are frequently of the same shape and size as microorganisms, 
the immune system could recognise NPs through conserved pathways [223]. Others, 
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like Moore, suggested that it could be the oxidative environment created by NPs that 
triggers directly the autophagic process [224]. Similarly, we can hypothesise that 
AgNPs, entering TT1 cells, are recognised as intracellular foreign bodies and are 
enclosed into autophagosomes. However, it could also be that AgNPs induce ROS 
formation that in turn activates autophagy. ROS formation and oxidative stress are 
discussed in Chapter 4 and possible internalisation of AgNPs by TT1 cells is 
addressed in Chapter 5. 
3.5.1.2 Autophagy and microbes 
To test the second part of our hypothesis, i.e. whether AgNPs altered viral- and 
bacterial-induced autophagy, we simulated viral and bacterial infection (by using Poly 
I:C and LPS respectively) and investigated their effect on autophagy activation in the 
presence and absence of AgNPs. Our studies demonstrated that Poly I:C alone 
activated autophagy, whereas LPS had no effect. It is well established that viruses [95] 
and bacteria [96, 99] activate autophagy. Delgado and colleagues, for example, 
reported that recognition of Poly I:C by TLR-3 triggered autophagy through TRIF, which 
interacted with Beclin-1 [98]. However, there are also examples of viruses inducing 
defective flux. Sir et al. showed that HuH-7.5 (hepatocarcinoma cells) transfected with 
Hepatitis C virus formed autophagosomes which, due to inefficient fusion with 
lysosomes, did not convert into autolysosomes [225]. Other viruses have been 
reported to inhibit autophagy. The viral proteins of human immunodeficiency virus-1 
(HIV-1) and influenza A virus have been shown to block autophagosome maturation by 
a still poorly defined mechanism through their interaction with Beclin-1 [226,227]. In 
studies with Coxsackie virus B3 (CVB3) it was demonstrated that protein levels of LC3-
II increased over time, suggesting that viral infection lead to accumulation of 
autophagosomes due to a block in autolysosomal degradation [228]. 
 
When cells were exposed to LPS, we did not detect activation of autophagy with LPS 
alone or when combined with AgNPs. In contrast, there is evidence that, upon 
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stimulation with LPS, factors such as MyD88 and TRIF interact with Beclin-1, which 
results in activation of autophagy [211]. LPS has been shown to induce autophagy via 
a number of mechanisms in macrophages [229] although, similar to our findings, it 
failed to induce autophagy in primary mouse macrophages [230]. In an attempt to give 
an explanation to the absence of autophagy stimulation by LPS, we hypothesise that 
alveolar epithelial cells, due to their unique role and function at the alveolar membrane, 
are less responsive to bacterial products than other immune phagocytic cells (see 
Section 2.5.3). 
 
Following investigation of the effect of PAMPs alone on autophagy, we co-stimulated 
cells with PAMPs and AgNPs. To our knowledge, there are no previous studies 
assessing the effect of AgNPs and microbial ligands on the autophagic flux. Our results 
demonstrate that, when AgNPs are added to the cells with Poly I:C, Poly I:C-induced 
autophagic flux is reduced, compared to the flux obtained with Poly I:C alone. We do 
not know the mechanism behind this effect. We can only speculate that, in case of a 
threat (such as Poly I:C), the cell tries to initiate an immune response and degrade 
unwanted foreign material through autophagy. However, exposure to AgNPs might 
lead to Poly I:C-induced altered autophagy, which in turn could negatively affect the 
physiological immune response of the cell, potentially leading to chronic inflammation 
[230] and higher vulnerability to infection [92]. 
3.5.1.3 Consequences of impaired autophagy 
Considering the fundamental role autophagy has in maintaining cellular homeostasis, 
any dysfunction or impairment in this process might result in detrimental consequences 
for the cell. Indeed, defects in autophagy are believed to contribute to the chronic 
inflammation observed in a number of lung diseases. For example, lung epithelial cells 
isolated from patients with cystic fibrosis, characterized by bacterial colonisation, 
showed defective autophagy and consequent accumulation of polyubiquitinated 
proteins [229,231]. Increased autophagosome formation and expression of LC3-II have 
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been found in human lung specimens from patients with COPD [212]. The role of 
autophagy in the response of the lung to microbial infections underlines the importance 
of host autophagy in modelling a successful response against bacteria or viruses. In 
fact, a number of therapies that stimulate autophagy activity have been shown to 
mount an effective response against Mycobacterium tuberculosis infection [212]. 
Furthermore, in its vital role in maintaining correct turnover of proteins and removing 
degraded organelles and cellular debris, autophagy is also believed to represent an 
anti-aging process [232]. Interestingly, analysis of gene expression in the brain in 
elderly people as compared with young people revealed down-regulation of autophagy 
genes [233]. It is possible that defective autophagy could lead to accelerated aging of 
the lung and potentially the development of cancer, as shown in some studies [234]. 
Thus, a down-regulation in autophagy, as measured with AgNPs and Poly I:C together, 
may represent a serious threat for the immune system and the lung.  
3.5.2 Nanoparticle-induced DNA damage  
In this study, we demonstrated that AgNPs induced an increase in phosphorylation of 
H2A.X protein, indicative of DNA double strand breaks. In agreement with our findings, 
other studies have reported AgNP-induced genotoxicity. An enhanced level of 
phosphorylated histone H2A.X was observed in AgNP-treated human hepatoma cells 
[157], T cells [173], mouse embryonic fibroblasts and stem cells [144]. Formation of 
micronuclei, another marker of cellular genotoxicity, was also detected in human 
hepatoma cells [160], lung fibroblasts and glioblastoma cells following exposure to 
AgNPs [173]. Examples of AgNP-induced genotoxicity also exist in in vivo studies. 
Leukocytes from rats, intravenously exposed to AgNPs, showed an increase in DNA 
breakage [235], and liver tissue from zebrafish also exhibited high levels of phospho-
H2A.X [236]. 
Given the ability of AgNPs to damage the DNA, we were interested in elucidating 
whether the NPs possess an innate oxidative capacity or the effect on DNA was only a 
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consequence of their interactions with biological systems. Thus, we performed an 
acellular in vitro plasmid assay, showing that increasing concentrations of AgNPs 
generated increasing DNA damage. Since this is a cell free assay, any damage 
detected in the DNA would be induced directly by the NPs. The only work that used 
this type of assay for the study of NPs was completed by Greenwell et al. [127]. 
Similarly to our data, the authors showed that particulate matter caused relaxation of 
the supercoiled DNA and its consequent fragmentation [127]. Altogether, these findings 
suggest that, if NPs gain access to the nucleus or become enclosed in the nucleus 
following mitosis, when the nuclear membrane dissolves [100], direct damage may be 
caused by the particles. 
It is also worth mentioning that, because of the ability of AgNPs to release ions (Ag+) 
(Section 2.1.2), ionic Ag could translocate into the nucleus and cause damage. 
However, from the literature it seems Ag ions do not express the ability of damaging 
the DNA in either cell lines [173] or C. elegans [237]. Further in-depth dissolution 
analysis would be necessary to assess whether a possible mechanism of action of the 
AgNPs used in the current study could involve ionic dissolution and its consequent 
damage to the DNA.  
 
As previously described, NPs can also induce DNA damage indirectly, without a 
physical interaction with the DNA molecule (Section 1.4.3.1). Among a number of 
proposed mechanisms, chronic inflammation is thought to play an important role in 
DNA damage. Indeed, evidence associates chronic inflammation with tumorigenesis 
[105,106]. Although the specific role of inflammation in lung carcinogenesis has not 
been clarified yet, there is strong epidemiological evidence linking pulmonary chronic 
inflammation to a higher risk of lung cancer [238]. For example, chronic obstructive 
airway disease appears to be an independent predictor of lung cancer risk. Also, 
various studies have shown an increased risk of cancer among adults with asthma, 
tuberculosis, or post-inflammatory pulmonary interstitial fibrosis [238]. We believe NP-
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induced inflammation might play a role in the generation of the increased DNA damage 
measured in the co-exposure of AgNPs and Poly I:C. In fact, although Poly I:C alone 
did not cause any DNA damage, when we exposed TT1 cells to AgNPs and Poly I:C 
together, the DNA damage induced was much greater than that measured with AgNPs 
alone. Since no previous work on the effect of co-stimulation between NPs and TLR 
ligands on DNA was identified, we can only hypothesise a possible mechanism of 
action between AgNPs and Poly I:C in relation to DNA damage formation. Considering 
our results up to this point, we found that, in TT1 cells, AgNPs alone induce 
inflammation and significant damage to the DNA, whereas Poly I:C generates a strong 
pro-inflammatory response but no damage to the DNA. Inflammation is the 
physiological response of the cells to tissue injury. It includes increased supply of 
blood, enhanced vascular permeability and migration of white blood cells 
(granulocytes, monocytes and lymphocytes), with concomitant production of soluble 
mediators such as cytokines [239,240]. However, if the levels of inflammation are not 
controlled or rapidly resolved, the inflammation becomes chronic, due to continuous 
production of cytokines, ROS and reactive nitrogen species (RNS). Direct 
consequences of this include an increased number of mutations in the genetic material 
and alterations of important enzymes and proteins (e.g. activation of oncogene 
products and/or inhibition of tumor-suppressor proteins and DNA repair enzymes), thus 
leading to the multistage carcinogenesis process [106]. It has been proposed that 
some pro-inflammatory cytokines particularly contribute to carcinogenesis. These 
include IL-6, CXCL-8 and tumor necrosis factor-α (TNF-α), among others. Their effect 
is thought to influence the survival, growth, DNA mutation and proliferation of both 
tumor and stromal cells [241]. Therefore, we speculate that, in our system, the cells, 
initially exposed only to AgNPs, responded with an inflammatory response (Section 
2.4.3.7) and a certain level of DNA damage (Section 3.4.4). The consequent addition of 
Poly I:C, which itself was unable to induce damage to the DNA but was responsible for 
strong release of inflammatory mediators, potentiated an inflammatory response upon 
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AgNP exposure, causing release of IL-6 and CXCL-8, which could therefore promote 
the onset of genotoxic consequences [106]. 
In addition, there is evidence from both human and in vivo studies that some of the 
ROS and RNS generated in inflamed tissues can cause genetic and epigenetic 
changes [242]. ROS are reactive molecules that, if in excess, can cause oxidative 
stress in cells, which may result in oxidative damage to lipids, proteins, carbohydrates, 
and nucleic acids, thus leading to tumorigenesis and cell death. This subject is 
discussed in Chapter 4. 
In relation to the absence of Poly I:C-induced DNA damage in our results, we can 
suggest that it might be an effect of the type of virus used. In fact, in studies reporting 
evidence of DNA viruses triggering DNA damage responses, the live viruses and their 
complete replication process were applied, whereas in the current study only the 
synthetic ligand was used. Examples of the viruses used in these previous studies 
include herpes simplex virus (HSV) [243], Epstein-Barr virus (EBV) [244], polyomavirus 
[245] and simian virus 40 (SV40) [246].  
3.5.3 Evaluation of a possible apoptotic pathway  
In the previous chapter we showed a decrease in cell viability in response to AgNPs 
and Poly I:C/LPS co-exposure (see Section 2.4.3.1-2.4.3.5), which we believed was 
due to necrotic cell death rather than apoptosis (Section 2.4.3.6). Thus, we further 
investigated this using an antibody for cleaved-PARP, a marker of apoptosis. The total 
absence of the cleaved protein was a further confirmation that AgNP-induced cell 
death was via a non-apoptotic pathway. 
Apoptosis and necrosis are the two major forms of cell death that have been described. 
Apoptosis, also called programmed cell death, is an energy-driven process by which a 
cell actively destroys itself, whereas necrosis has been considered a passive process 
[247]. However, since it can involve active processes, necrosis has also been defined 
as a controlled form of programmed cell death [248]. Apoptosis is characterised by the 
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ordered cellular degradation of proteins and organelles, maintenance of plasma 
membrane integrity, and non-inflammatory phagocytosis of the dying cell [249]. On the 
contrary, typical features of necrosis are cytoplasmic swelling, rupture of plasma 
membrane, dilution of cytoplasmic organelles, moderate chromatin condensation and 
onset of an acute inflammatory response [247]. A cell can undergo necrosis rather than 
apoptosis depending on the intracellular oxidant/antioxidant balance, the level of ATP 
in the cell and the extent of induced membrane damage [250,251]. Intracellular 
antioxidant systems normally protect from cell death by scavenging ROS, as long as 
the cell can maintain its intracellular reducing environment. However, when the levels 
of stress exceed the antioxidant system’s ability to scavenge intracellular ROS, cells 
become unable to maintain their intracellular reducing environment and they undergo 
necrosis [252]. In light of this, we speculated that, in our model, cells were unable to 
combat AgNP-induced stress and underwent necrosis. Considering the data on 
necrosis (Section 2.4.3.6) and DNA damage (Section 3.4.4), our results support this 
hypothesis. In fact, 24h exposure to AgNPs (50µg/ml) induced necrosis and the highest 
level of DNA damage observed. Therefore, this might suggest that 50µg/ml is an 
overwhelming concentration of AgNPs for the cell, which is unable to cope with the 
stress and subsequently initiates an active necrotic process as a defence mechanism 
for the surrounding cells. Indeed, it is known that necrotic cell death following DNA 
damage occurs selectively in cells committed to replicate [247]. This prevents the 
survival of cells at risk of accumulating mutations as a result of DNA replication prior to 
DNA repair. In addition, this form of programmed necrosis induces an inflammatory 
response that provides additional protection against the accumulation of damaged or 
aberrant cells, and initiates the repair of the damaged tissue [247]. It has been 
proposed that programmed necrosis might have a biological function under conditions 
where an immune reaction to the dying cell is desirable, such as in microbial infection 
[253]. Therefore, it is conceivable that, on co-exposure to AgNPs and Poly I:C, the 
level of stress on the cell is such that the cellular reaction is detrimental to viability. The 
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autophagic system results in slowed autophagosome formation, while the damage to 
the DNA becomes significantly greater. Overall, the cell, overwhelmed by this 
extracellular stress, initiates a necrotic process in order to protect the surrounding 
cellular environment. 
Moreover, the link between ROS generation, DNA damage and levels of apoptosis or 
necrosis is well documented [254]. A potentially deleterious effect of ROS production in 
mitochondria is the facilitation of Ca2+-dependent mitochondrial permeability transition 
(MPT), which plays a key role in certain modes of cell death. MPT results in 
mitochondrial failure, which can lead to necrosis due to ATP depletion. Not surprisingly, 
oxidative stress is a conserved signal for cell death [113]. On this basis, the role of 
oxidative stress in our study will be assessed in Chapter 4. 
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3.6 Conclusion 
In this study we have demonstrated that AgNPs activate autophagy and induce double 
strand DNA breaks in TT1 cells. The molecular mechanisms that trigger autophagy 
activation after AgNP exposure are still unknown; however, as AgNPs were shown to 
cause inflammation and DNA damage, we suggested a possible involvement of 
oxidative stress in the process. The role of oxidative stress in AgNP-induced effects is 
investigated in the next Chapter. 
 
During co-exposure to AgNPs and Poly I:C we found that the autophagic flux was 
reduced. Possible consequences of altered autophagy could include difficulties in 
delivering pathogens to the immune system, in removing degraded intracellular 
organelles and a down-regulation in autophagy-regulated genes. The clinical 
implications of those processes may involve dysfunctions in the immune system, 
chronic inflammation and accelerated ageing of the lung.   
By demonstrating that AgNPs can induce DNA damage both in cellular and acellular 
assays, we suggested that the particles themselves may be genotoxic as well as 
potential generators of genotoxic ROS in the cell. Furthermore, the combination of 
AgNPs and Poly I:C resulted in a significantly greater degree of damage than that 
observed for AgNPs alone. This potentiation in DNA damage could be linked to a 
strong inflammatory response and perhaps to ROS generation. 
 
On the contrary, LPS stimulation did not induce autophagy or DNA damage. By 
comparing these data with those presented in Chapter 2, we can suggest that the 
hypo-responsiveness of TT1 cells to LPS is most likely due to the nature of the cells. 
Covering over 95% of the whole alveolar surface area and thus being constantly in 
contact with endotoxins and bacterial products, TT1 cells need to have a lower 
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threshold of reactivity to LPS in order to avoid a constant level of pulmonary 
inflammation. 
 
These results, taken together with the previous findings regarding inflammation, raise 
concerns about inhaled NPs and their effect on human health. The activation of these 
pathways represents a threat for the cell and the organism overall, as they have been 
associated with several pathologies (cancer, aging, neurodegeneration and others; 
refer to Sections 3.5.1.3 and 1.4.3.2). 
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Figure 3.11 Effects of 24h exposure to AgNPs alone (left) and in combination with Poly I:C or LPS (right) on TT1 cells. Left: AgNPs induce autophagy 
activation, DNA damage formation and a decrease in cell viability caused by necrosis. Right: While co-exposure to AgNPs and Poly I:C slows down the 
autophagic flux and increases DNA damage formation, co-exposure to AgNPs and LPS does not affect autophagy activation and DNA damage. 
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4. SILVER NANOPARTICLE REACTIVITY: THE ROLE 
OF OXIDATIVE STRESS 
4.1 Introduction 
NPs, such as AgNPs, titanium dioxide, zinc oxide and cerium oxide have been shown 
to localise at the cellular surface or in subcellular organelles, and induce signalling 
cascades that eventually result in oxidative stress and subsequent inflammation and 
toxicity [76]. As previously explained (Section 1.4.4.1), oxidative stress is an imbalance 
between the production of ROS and the system’s ability to detoxify them. The 
mechanisms for ROS generation are likely to be different for each NP and are still 
incompletely understood. However, it is inaccurate to assume that ROS generation is 
an absolute prerequisite to NP-induced toxicity; some studies have reported direct 
toxicity of NP without inducing ROS [255,256]. It is therefore crucial to establish 
whether the NPs generate oxidative stress as part of their mechanism of action. 
Indeed, as mentioned in Section 1.4.4.1, there is mounting evidence that oxidative 
stress plays a role in several clinical conditions, including atherosclerosis, malignant 
diseases and chronic inflammation amongst others [114]. 
The aim of this Chapter is to evaluate whether oxidative stress may be generated by 
AgNPs, in order to develop a better understanding of their mechanism of action. 
4.2 Hypothesis 
We hypothesised that the AgNP-induced inflammatory response, autophagy and DNA 
damage observed in the previous findings are driven by oxidative stress. We also 
hypothesised that an important source of oxidative stress within the cell is the 
mitochondria. 
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4.3 Materials and Methods 
4.3.1 Materials 
Cell culture, ELISA and Western blotting reagents and materials were sourced as 
described in Section 2.3.1 and Section 3.3.1. L-glutathione was bought from Sigma 
Aldrich (Poole, UK); mitochondrial membrane potential disruptor CCCP (carbonyl 
cyanide 3-chlorophenylhydrazone) and superoxide indicators Dihydroethidium and 
MitoSOX Red were obtained from Invitrogen (Paisley, UK). Inhibitor of NAD(P)H 
oxidase VAS-2870 3-benzyl-7-(2-benzoxazolyl) thio-1,2,3-triazolo (4,5-d) pyrimidine 
was purchased from Enzo Life Science (Exeter, UK); Hankʼs balanced salt solution 
with calcium and magnesium HBSS/Ca/Mg was obtained from Gibco (Paisley, UK). 
4.3.2 Methods 
4.3.2.1 Dihydroethidium (DHE) staining  
Intracellular oxidative stress was detected by imaging the fluorescence generated from 
oxidation of DHE. DHE is a dye readily internalised by cells and oxidised by ROS 
(primarily superoxide anion), to yield ethidium, which binds to DNA and produces a 
detectable red fluorescence. Using the protocol of Budd et al. [257], TT1 cells were 
exposed to AgNPs (1, 50, 100µg/ml) for 1, 4, 6 and 24h. Positive control H2O2 was 
added for 15min only. Cells were then washed with warm PBS and incubated with DHE 
(40μM) in serum-free DCCM-1 culture medium for 20min. Following incubation, cells 
were washed with PBS to remove extracellular probe and visualised by fluorescence 
microscopy. Exposures were repeated in triplicate using three separate cell passages.  
 
157 
4.3.2.2 Treatment of TT1 cells with antioxidant glutathione (GSH) 
4.3.2.2.1 Evaluation of GSH effect on AgNP-induced IL-6 and CXCL-8 
release 
TT1 cells were plated in 96-well plates, as previously detailed (Section 2.3.2.3), and 
pre-incubated with antioxidant GSH (1mM) for 1h. Cells were subsequently treated with 
AgNPs (50µg/ml) for 24h. IL-6 and CXCL-8 release into the supernatant was detected 
by ELISA, as previously described in Chapter 2 (Section 2.3.2.9). 
4.3.2.2.2 Evaluation of GSH effect on AgNP-induced autophagy activation 
and DNA damage 
Cells were prepared in 6-well plates and pre-incubated with the antioxidant GSH 
(1mM) for 1h. Cells were subsequently treated with AgNPs (50µg/ml) for either 8h 
(autophagy activation measurement) or 24h (DNA damage measurement). AgNP-
induced autophagy activation and DNA damage formation, in the presence/absence of 
GSH, was measured by Western blotting (Sections 2.3.2.13, 3.3.2.1 and 3.3.2.2). The 
antibodies used for these studies are shown in Table 4.1. Gels were imaged using 
Ultraviolet Transilluminator GelDoc-It and densitometric quantification was performed 
using Visionworks. 
 
Primary Antibody 
(dilution) 
Company 
Secondary 
Antibody(dilution) 
Molecular Weight of 
target protein (kDa) 
LC3B 
(1:10,000) 
Sigma 
Rabbit           
(1:2,500) 
18 
β-actin 
(1:300,000) 
Abcam 
Mouse          
(1:3,000) 
45 
GAPDH+H2A.X+PARP 
(1:10,000) 
Abcam 
Mouse          
(1:3,000) 
36+16+89 
 
Table 4.1 Antibodies used for protein detection. kDa: kilo Dalton 
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4.3.2.3 MitoSOX Red mitochondrial superoxide indicator  
Mitochondrial superoxide is generated as a by-product of oxidative phosphorylation. In 
the mitochondrial coupled electron transport chain, approximately 1–3% of 
mitochondrial oxygen consumed is incompletely reduced. These “leaky” electrons can 
rapidly interact with molecular oxygen to form superoxide anion, the predominant ROS 
in mitochondria. MitoSOX Red is a fluorogenic dye highly selective for detection of 
superoxide in the mitochondria of live cells. MitoSOX reagent freely permeates live-cell 
membrane and is rapidly and selectively targeted to the mitochondria, where it is 
oxidised by superoxide anions to generate red fluorescence. The oxidation product 
becomes highly fluorescent upon binding to mitochondrial nucleic acids. Briefly, TT1 
cells seeded in 96-well plates were stimulated with AgNPs (50µg/ml) for 1, 4 and 24h. 
A 5mM MitoSOX reagent stock solution was prepared by dissolving the contents 
(50μg) of one vial of MitoSOX mitochondrial superoxide indicator in 13μl of cold DMSO. 
The working concentration of 10μM was made up in HBSS/Ca/Mg, then added directly 
to the cells and incubated in the dark for 30min at 37˚C. After this time, the solution 
was removed, cells were washed with HBSS/Ca/Mg and the same solution was used 
to measure fluorescence (Ex/Em: 510/580 nm). The mitochondrial uncoupler carbonyl 
cyanide 3-chlorophenylhydrazone (CCCP) was used as a positive control. 
4.3.2.4 Treatment of TT1 cells with NADPH oxidase inhibitor 
4.3.2.4.1 Optimisation of a working concentration of NADPH oxidase 
inhibitor 
VAS-2870 is a known NADPH oxidase inhibitor [258] that was shown to work at 
concentrations between 5 and 50µM [259,260]. We used the same range of 
concentrations in order to optimise the appropriate working concentration in our model. 
TT1 cells seeded in 24-well plates were pre-incubated with 5, 20 and 50μM of VAS-
2870 for 1h, then treated with AgNPs (50µg/ml) for 4h. After this time, cells were 
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stained with DHE (refer to Section 4.3.2.1) and samples were visualised using inverted 
fluorescent microscope. 
4.3.2.4.2 Evaluation of the effect of NADPH oxidase inhibitor on AgNP-
exposed cells  
TT1 cells seeded in 24-well plates were pre-incubated with 5μM of VAS-2870 for 1h, 
then treated as previously described (Section 4.3.2.4.1). Two time points were 
analysed: 4h and 24h. 
In addition, the effect of NADPH oxidase-induced ROS on mitochondrial ROS 
production at 24h was measured using the MitoSOX assay. Cells were pre-treated with 
VAS-2870 for 1h, exposed to AgNPs (50µg/ml) for 24h, and the MitoSOX assay was 
then performed (Section 4.3.2.3). 
4.3.2.5 Statistical analyses 
All statistical tests were performed using GraphPad Prism 4 software. Results are 
presented as fold-change ± standard error of the mean (SEM); n=3 (unless otherwise 
stated), where 3 independent experiments were performed using 3 separate TT1 cell 
passage generations. Data was considered to follow a normal distribution. We elected 
a priori to compare treated groups to the untreated control. Thus, significant effects of 
AgNPs and GSH on cytokine/chemokine release and protein expression/activation 
were determined using one-way ANOVA with Bonferroni’s Multiple Comparison Test as 
a post-test to compare all pairs of treatments. All statistical tests have been performed 
on the raw data. A p value <0.05 was considered to be statistically significant.  
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4.4 Results 
4.4.1 Time course analysis of AgNP-induced ROS generation 
AgNP-induced ROS generation in TT1 cells was monitored at different time points (1, 
4, 6 and 24h) using the DHE assay, which mainly detects superoxide anion. H2O2 
(50µM) was used as a positive control and added to the cells 15min before the end of 
the AgNP-exposure, in order to avoid extensive cell death. The unexposed control 
showed minimal ROS production, confirming the sensitivity of the assay (Figure 4.1). 
Cells exposed to AgNPs (1, 50 and 100µg/ml) showed ROS generation from 4h up to 
24h. In fact, after 1h of exposure, there was no detectable ROS formation. However, 
ROS generation peaked at 4h, decreased at 6h and increased again at 24h, at which 
point it was still detectable, especially after exposure to 50µg/ml AgNPs, albeit at lower 
levels than those observed at 4h (Figure 4.1). 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1 Light micrographs showing AgNP-induced ROS generation in TT1 cells. Cells were exposed to AgNPs (1, 50 and 100µg/ml) for 1, 4, 6 and 
24h, then stained with DHE. H2O2 (50µM) was used as a positive control and added 15min prior staining. ROS generation is shown in red. NT= non-treated. 
Magnification x100. Graphs representative of 3 independent experiments. 
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4.4.2 Effect of supplementary GSH on AgNP-induced IL-6 and 
CXCL-8 release 
In order to assess the role of oxidative stress in AgNP-induced inflammation, TT1 cells 
were pre-treated with the antioxidant GSH (1mM) and then exposed to AgNPs 
(50µg/ml). Our results demonstrated that GSH alone did not affect the baseline release 
of either IL-6 or CXCL-8 (Figure 4.2). However, pre-treatment with GSH prior to AgNP 
exposure completely inhibited release of both IL-6 and CXCL-8 (p<0.001). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2 Effect of GSH on AgNP-induced IL-6 and CXCL-8 release. TT1 cells 
were pre-treated for 1h with GSH (1mM) before 24h exposure to AgNPs (50µg/ml). IL-6 
and CXCL-8 expression over 24h was evaluated by ELISA. Data are expressed as 
fold-change ± SEM; (n=3); ***p<0.001 (vs. unexposed control); ###p<0.001 (AgNPs vs. 
GSH+AgNPs). 
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4.4.3 Effect of supplementary GSH on AgNP-induced autophagy 
activation 
The role of oxidative stress in AgNP-induced autophagy activation was measured by 
pre-treating cells with GSH (1mM). Following 8h exposure to AgNPs (50µg/ml), 
Western blotting was performed and data analysis revealed that GSH inhibited 
autophagy activation by 94% (p<0.01) (Figure 4.3). 
   
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3 Effect of GSH on AgNP-induced autophagy activation. TT1 cells were 
pre-treated for 1h with GSH (1mM) before 8h exposure to AgNPs (50µg/ml). Whole cell 
extracts were run in SDS-PAGE/Western blotting and LC3-II levels normalised against 
the expression of β-actin. Autophagosome formation was calculated as a ratio of LC3-
II/β-actin. Representative blot of 3 independent experiments (A) and graph (B) showing 
the effect of GSH on autophagy activation. Data are expressed as fold-change ± SEM; 
(n=3); **p<0.01 (vs. unexposed control); ##p<0.01 (AgNPs vs. GSH+AgNPs). 
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4.4.4 Effect of supplementary GSH on AgNP-induced DNA damage 
GSH pre-incubation in cells exposed to AgNPs (50µg/ml) resulted in a significant 
decrease in AgNP-induced phosphorylation level of H2A.X (95% inhibition; p<0.05) 
(Figure 4.4).  
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4 Effect of GSH on AgNP-induced DNA damage. TT1 cells were pre-
treated for 1h with GSH (1mM) before 24h exposure to AgNPs (50µg/ml). Whole cell 
extracts were run in SDS-PAGE/Western blotting and phosphorylation levels of H2A.X 
were normalised against the expression of GAPDH. Representative blot of 3 
independent experiments (A) and graph (B) showing the effect of GSH on DNA 
damage formation. Data are expressed as fold-change ± SEM; (n=3); *p<0.05 (vs. 
unexposed control); #p<0.05 (AgNPs vs. GSH+AgNPs). 
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4.4.5 AgNP-induced ROS generation: role of the mitochondria 
In order to measure possible ROS generation in the mitochondria we used the 
MitoSOX Red assay at 3 different time points (1, 4 and 24h), using the ionophore 
Carbonyl cyanide m-chlorophenyl hydrazone (CCCP) as a positive control. CCCP 
causes uncoupling of the proton gradient established in the electron transport chain, 
resulting in increased mitochondrial superoxide production. Our findings showed 
significantly higher levels of mitochondrial superoxide production by CCCP at every 
time point (Figure 4.5; dotted bars). No detectable ROS were found 1h and 4h after 
AgNP-exposure, whereas a significant increase in mitochondrial superoxide generation 
by AgNPs was measured after 24h (Figure 4.5; blue bars). Interestingly, pre-incubation 
with GSH (1mM) reduced AgNP-induced superoxide production, although this 
reduction did not reach significance (blue dotted bars). 
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Figure 4.5 Effect of AgNPs on mitochondrial ROS production in TT1 cells. Cells 
were exposed to AgNPs (50µg/ml) for 1, 4 and 24h, then MitoSOX Red assay was 
performed. CCCP (50µM) was used as a positive control. At 24h, cells were pre-
treated with GSH (1mM) for 1h before exposure to AgNPs (50µg/ml). NT=non treated. 
Data are expressed as fold-change ± SEM; (n=3); *p<0.05; **p<0.01; ***p<0.001 (vs. 
unexposed control); NS=non significant (AgNPs vs. GSH+AgNPs). 
4.4.6 AgNP-induced ROS generation: role of NADPH oxidase 
4.4.6.1 Optimisation of a working concentration of NADPH oxidase 
inhibitor  
In order to identify the cellular source of AgNP-induced ROS production detected at 4h, 
we investigated the role of NADPH oxidase, known to be a significant source of cellular 
ROS (see Section 1.4.4.3). We first optimised the working concentration of NADPH 
oxidase inhibitor VAS-2870 by measuring ROS generation, using DHE assay, in 
response to increasing concentrations (5, 20 and 50µM) of the inhibitor alone (Figure 
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VAS-2870 (5µM) VAS-2870 (50µM)VAS-2870 (20µM)
NT H2O2
4.6). VAS-2870 induced a concentration-dependent increase in ROS generation, which 
would have been a confounding factor in our subsequent measurements of ROS. 
Therefore, in order to avoid this, we established that the lowest concentration tested 
(5µM) was the optimum concentration as it caused minimal ROS production (Figure 
4.6). 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.6 Effect of NADPH oxidase inhibitor on ROS production. TT1 cells were 
treated with VAS-2870 (5, 20 and 50µM) for 1h, then stained with DHE. H2O2 (50µM) 
was used as a positive control and added 15min prior to staining. ROS generation is 
shown in red. NT=non-treated. Graphs representative of 3 independent experiments. 
4.4.6.2 Effect of NADPH oxidase inhibitor on AgNP-exposed TT1 cells 
DHE staining of TT1 cells exposed to AgNPs (50µg/ml) confirmed ROS formation at 4h 
(Figure 4.7, A), as previously shown (see Figure 4.1), whereas VAS-2870 (5µM) 
induced very low levels of ROS that were comparable with the untreated control. Pre-
incubation with VAS-2870 (5µM) for 1h inhibited AgNP-induced ROS production to 
near baseline levels (Figure 4.7, A). When this was repeated at 24h, AgNP-induced 
ROS was only partially reversed by VAS-2870 (Figure 4.7, B). 
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Figure 4.7 Effect of NADPH oxidase inhibitor on AgNP-induced ROS production 
at 4h (A) and 24h (B). TT1 cells were pre-treated with VAS-2870 (5µM) for 1h, then 
exposed to AgNPs (50µg/ml) for 4h (A) or 24h (B). After this, cells were stained with 
DHE. H2O2 (50µM) was used as a positive control and added 15min prior to staining. 
ROS generation is indicated in red. NT=non-treated. Graphs representative of 3 
independent experiments. 
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4.4.6.3 Role of NADPH oxidase in mitochondrial ROS generation 
Having measured ROS generation at 4h (due to NADPH oxidase activity) and 24h (due 
to mitochondrial dysfunction), we investigated the possible link between these two 
sources of ROS. In order to answer the question of whether early NADPH oxidase 
activity triggered the later mitochondrial ROS production observed, cells were pre-
treated with VAS-2870 prior to 24h stimulation with AgNPs (50µg/ml). Results 
demonstrated a 4-fold increase in AgNP-induced mitochondrial superoxide production 
at 24h (Figure 4.8, blue bars). In cells pre-treated with VAS-2870 there was no 
significant decrease in AgNP-induced mitochondrial ROS (Figure 4.8, blue dotted 
bars). This suggests that NADPH oxidase activity is not involved in AgNP-induced 
mitochondrial dysfunction.  
 
 
 
 
 
 
 
 
 
 
Figure 4.8 Effect of NADPH oxidase inhibitor on AgNP-induced mitochondrial 
ROS production at 24h. TT1 cells were exposed to AgNPs (50µg/ml) for 24h in the 
presence and absence of pre-treatment with VAS-2870. MitoSOX Red assay was 
performed and CCCP (50µM) was used as a positive control. NT=non-treated. Data 
are expressed as fold-change ± SEM; (n=3); **p<0.01; ***p<0.001 (vs. unexposed 
control); NS=non significant (AgNPs vs. VAS-2870+AgNPs). 
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4.5 Discussion 
4.5.1 AgNP-induced ROS formation  
In this section of the study we have shown that AgNPs induce ROS formation in TT1 
cells. The probe DHE was used to visualise ROS, primarily superoxide anion, which is 
recognised as a general marker of oxidative stress as it is a progenitor for other ROS, 
such as hydrogen peroxide and hydroxyl radical (Section 1.4.4.1). We observed a peak 
in intracellular ROS generation at 4h, which decreased at 6h but remained visible at 
24h, suggesting that AgNPs could lead to oxidative stress in TT1 cells.  
AgNP-mediated ROS generation has been demonstrated in other cell types and cell 
lines. For example, an increase in ROS formation was observed in immortalised 
human lung fibroblasts exposed to AgNPs up to 100µg/ml after a period of 2h and 5h 
[50]. In A549, oxidative stress generation was measured after 24h exposure to AgNPs 
(2.5-15µg/ml) using the 2',7'-dichlorodihydrofluorescein diacetate (H2DCF-DA) probe. 
Pre-treatment of the cells with an antioxidant (n-acetylcysteine, NAC, 10mM) 
significantly reduced ROS levels, suggesting antioxidant scavenging as the mechanism 
of antioxidant-mediated cell survival [174]. Since we showed that ROS formation was 
bi-phasic (4h and 24h), we speculate that the decrease in ROS at 6h might be a 
consequence of cellular antioxidant activation, such as Nrf-2. However, to reach a 
better understanding, this should be investigated further. 
4.5.2 Oxidative stress and inflammation 
In our model, the antioxidant GSH prevented the inflammatory response induced by 
AgNPs, demonstrating that oxidative stress is important in mediating AgNP-induced 
cytokine release in TT1 cells. GSH is a particularly relevant antioxidant for studies 
modelling the lung as it is highly abundant in the lung lining liquid, at levels 
approximately 140 times higher than in the plasma, where it has been calculated to be 
around 3µM [261]. Indeed, several associations have also been made between 
oxidative stress and lung inflammation; elevated sputum levels of the oxidised form of 
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GSH (GSSG) have been measured in COPD subjects and were linked to increased 
inflammation [262]. Interestingly, numerous studies have shown that genes for 
inflammatory mediators such as CXCL-8 and TNF-α are regulated by redox sensitive 
transcription factors such as NF-kB, [263]. For instance, similar to our study, Antonicelli 
et al. showed that thiol-containing antioxidants, such as NAC, blocked the release of 
inflammatory mediators from LPS-stimulated rat macrophages, by a mechanism 
involving increasing intracellular GSH and decreasing NF-kB activation [264]. However, 
no previous studies on the effects of GSH on AgNP-induced inflammation, which could 
be used as a direct comparator to our current study, were found.  
4.5.3 Oxidative stress and autophagy 
We demonstrated that AgNP-induced autophagy activation is also mediated by 
oxidative stress; the addition of GSH prior to AgNP exposure inhibited the activation of 
autophagy almost completely. This is the first study that links NP-induced oxidative 
stress and autophagy in pulmonary epithelial cells. It is known that, under conditions of 
oxidative stress, autophagy is activated to facilitate the degradation of damaged 
oxidised organelles and proteins [89]. As such, successful autophagy contributes to 
cellular recovery. Scherz-Shouval et al. investigated the effects of antioxidants on 
autophagy in three different cell lines (CHO, HeLa, and HEK 293 cells). Similarly to our 
findings, they showed that the use of antioxidants inhibited autophagosome formation, 
abolishing the consequent degradation of proteins [265]. Interestingly, the authors also 
suggested a mechanism through which ROS formation might activate autophagy. They 
demonstrated that the autophagic protein Atg4, a cysteine protease, was involved in 
redox regulation. In physiological conditions, Atg4 is active and works to prevent Atg8 
lipidation, which is a step required to induce autophagy activation. When there is an 
increase in ROS levels, the latter target Atg4, which becomes inactive, allowing for 
Atg8 lipidation and thus autophagy activation [265]. There is also evidence suggesting 
that endogenously produced superoxide anion may play a pivotal role in the induction 
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of autophagy [109]. Starvation-induced autophagy in HeLa cells has been shown to 
require mitochondria-dependent generation of superoxide. In fact, the use of the 
antioxidant catalase reduced autophagy activation by decreasing the levels of 
superoxide anions [109]. The findings from these studies may, in part, contribute to an 
explanation for our own findings. We detected an increase in ROS formation at 4h, 
whereas autophagy activation was observed at 8h. It might be possible that the early 
induction of ROS in TT1 cells in response to AgNPs is a necessary step that, through 
redox regulation, facilitates the subsequent activation of autophagy (8h), needed to 
degrade the ROS-induced damage to cellular proteins or organelles. Hence, by 
lowering ROS levels, pre-treatment of the cells with the antioxidant GSH prevents Atg4 
modification, which, in its active form, delipidates Atg8 and therefore prevents 
autophagy activation from occurring. 
4.5.4 Oxidative stress and DNA damage 
In our studies, pre-treatment of TT1 cells with GSH inhibited AgNP-induced DNA 
damage, demonstrating that oxidative stress is central to this process. Previous studies 
have shown a significant decrease in AgNP-induced DNA damage when BEAS-2B 
cells were co-treated with AgNPs and scavengers such as superoxide dismutase and 
catalase [124]. Similarly, Wan et al. measured a significant decrease in nano-cobalt 
induced DNA damage when A549 cells were treated with NAC or catalase prior to 
nano-cobalt exposure [266]. However, in most studies investigating the correlation 
between NPs, oxidative stress and DNA damage, this link is made without actually 
proving that NP-induced oxidative stress is the direct cause of the DNA damage. For 
example, Sharma et al. observed oxidative stress and DNA damage following 
exposure of human epidermal cells to zinc oxide NPs and concluded that oxidative 
stress was the cause of the DNA damage [267]. Similarly, Halamoda and colleagues 
made a correlation between the oxidative stress induced by different NPs (e.g. iron 
oxide, silica, titanium) and the DNA damage measured in human cerebral endothelial 
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cells [216]. However, neither study used any antioxidant or ROS inhibitor to assess a 
possible inhibition or decrease in the DNA damage induced by NPs, in order to confirm 
the correlations they described. 
4.5.5 Cellular sources of oxidative stress  
In order to elucidate the source of oxidative stress in TT1 cells exposed to AgNPs, we 
investigated the relative contributions of NADPH oxidase and mitochondrial ROS. 
Results from the MitoSOX assay, which detects mitochondrial superoxide formation, 
demonstrated that AgNP-induced oxidative stress observed at 4h was not generated 
by the mitochondria, as there was no detectable mitochondrial ROS at this time point. 
However, we also showed that mitochondrial ROS was likely to be responsible for the 
ROS generated by the NPs at 24h. Inhibition of NADPH oxidase prevented AgNP-
induced ROS at 4h and, to a lesser extent, at 24h. Taken together these findings 
suggest that, at early time points (4h), NADPH oxidase is the primary source of 
oxidative stress in the cells, whereas mitochondria seem to be the source of ROS at 
later time points (24h). Similarly to our study, Couto and colleagues, by using a 
NADPH oxidase inhibitor, showed that iron oxide NPs trigger neutrophils’ oxidative 
burst in a NADPH oxidase-dependent manner [123]. In another work on the effect of 
AgNPs on BEAS-2B cells, it was hypothesised that, since the NPs were absent from 
the mitochondria, AgNP-induced oxidative stress might have been directly generated 
by AgNPs. Indeed, the authors speculated that, during uptake into the cells, AgNPs 
could interact with and activate NADPH oxidase, thus producing superoxide anion 
[124]. However, as previously mentioned (Section 1.4.4.3), the lack of knowledge 
about the mechanisms of interaction between NPs and NADPH oxidase only allows for 
speculation on this subject, and further work should be performed. 
Interestingly, when trying to examine a possible link between these two intracellular 
sources of ROS, we discovered that the early oxidative stress induced by AgNPs was 
not responsible for the mitochondrial stress at 24h. In fact, the inhibition of NADPH 
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oxidase did not affect the amount of ROS produced by the mitochondria at 24h in 
response to AgNP exposure. Therefore, we speculate that, were the NPs to enter the 
cells, the physical damage produced directly by the NPs inside the cell could be a 
possible cause of the mitochondrial ROS production observed. The possibility of AgNP 
uptake into TT1 cells is investigated in Chapter 5. 
In addition, it should be noted that both of the probes used in this study (DHE and 
MitoSOX) mainly detect superoxide anion. It is therefore possible that the NPs inside 
the cells generate other types of ROS that would remain undetected, but would likely 
be equally important as a source of oxidants which may drive many of the cellular 
responses observed, as seen in the acellular DNA damage assay described earlier.  
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4.6 Conclusion   
We have shown that oxidative stress plays an important role in AgNP reactivity. We 
measured a peak in ROS formation at 4h, which decreased by 6h, to increase again at 
24h, even though to a lesser extent. 
We have previously demonstrated that AgNPs induced inflammation, autophagy 
activation and DNA damage in TT1 cells (see Chapters 2 and 3). By pre-treating the 
cells with the antioxidant GSH, we measured a complete reduction in all three 
processes: inflammatory cytokine release was decreased to basal levels, autophagy 
activation inhibited and DNA damage abolished. These results indicate that AgNP-
induced effects in TT1 cells are oxidative stress-mediated. 
 
We have also shown that two different cellular mechanisms are involved in AgNP-
induced ROS generation (Figure 4.9). At 4h, NADPH oxidase was shown to be the 
source of AgNP-induced ROS, whereas at 24h ROS were detected in the 
mitochondria. Thus, we can hypothesise a possible mechanism of action for AgNPs in 
our cell line. In case AgNPs enter TT1 cells, AgNPs might come into contact with the 
cell-associated enzyme NADPH oxidase during uptake, leading to its activation and 
consequent early ROS generation (4h). Once inside the cell, AgNPs might physically 
damage the mitochondria, potentially resulting in a second source of ROS production 
(24h). The intracellular oxidative stress generated can then lead to other detrimental 
consequences for the cells, such as shortage of ATP or an impact on cell viability. 
 
Oxidative stress has always been associated with several pathologies, such as cancer, 
arteriosclerosis, neurodegenerative diseases amongst others. From a clinical 
perspective, this study reinforces the hypothesis that NPs in general might pose a 
serious threat to human health. In fact, we have clearly proved that the main effect of 
AgNP reactivity is the formation of ROS, consequently causing oxidative stress, which 
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is then responsible for the other detrimental mechanisms induced by AgNPs in the 
cells. Endogenous anti-oxidant defence must therefore be an important mechanism by 
which to counteract the effects of AgNPs. 
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Figure 4.9 Role of oxidative stress in AgNP-mediated effects in TT1 cells. AgNPs can generate ROS formation either at early time points (4h), through 
activation of NADPH oxidase, or after longer exposure (24h), via mitochondria superoxide production. AgNP-induced NADPH oxidase-mediated ROS might 
be responsible for autophagy activation (8h). Both NADPH oxidase- and mitochondria-induced ROS could be responsible for the AgNP-mediated DNA 
damage and inflammation (IL-6 and CXCL-8). 
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5. ROLE OF TLR-3 AND TLR-4 ON SILVER 
NANOPARTICLE-INDUCED CELLULAR EFFECTS 
5.1 Introduction 
We have previously shown that AgNPs induce a strong pro-inflammatory response 
(Chapter 2), autophagy activation and DNA damage (Chapter 3) in TT1 cells. The 
critical role that TLRs and their ligands play, both in the initiation of pro-inflammatory 
responses [58,66] and in the activation of autophagy [268,269], is well established. 
Therefore, in our model, we wanted to investigate the involvement of TLRs in AgNP-
induced inflammation, autophagy activation and DNA damage. Since one of the aims 
of our study was the investigation of the effects of co-exposure to AgNPs and viral 
(TLR-3) or bacterial (TLR-4) infection on the human alveolar epithelium (Section 1.7), 
the roles of TLR-3 and TLR-4 in AgNP-induced effects in TT1 cells were assessed. 
5.1.1 TLR-3   
TLR-3 is part of the TLR family that recognises nucleic acids, in particular dsRNA and 
Poly I:C. The dsRNA recognised by TLR-3 is derived primarily from the genomes of 
dsRNA viruses, for example reovirus. However, a number of studies have 
demonstrated that TLR-3 can also recognise some ssRNA viruses, including 
respiratory syncytial virus (RSV) and encephalomyocarditis virus (EMCV), and even 
dsDNA viruses, such as herpes simplex virus and mouse cytomegalovirus (MCMV) 
[270,271]. This is explained by the fact that, during infection, replication of positive 
sense ssRNA viruses proceeds through a dsRNA intermediate, and dsRNA may also 
be produced as a result of bidirectional transcription of the genomes of dsDNA viruses. 
TLR-3 is expressed in a wide variety of cells, including epithelial cells [272], microglia 
[273], endothelial [274] and dendritic cells [275]. TLR-3, like TLR-7 and TLR-9, is 
primarily found in the intracellular compartment, on the membrane of endosomes. 
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Interestingly, there is also a limited number of studies demonstrating cell surface 
expression of TLR-3 in A549 cells, bronchial epithelial cells [276] and fibroblasts [277]. 
TLR-3 shares structural similarities with the rest of the TLR family: an extra-endosomal 
ligand binding domain, a transmembrane domain and an intra-endosomal TIR domain 
[278] (see Section 1.3.2). In addition, TLR-3 is the only TLR that does not signal 
through the MyD88-dependent pathway. Together with TLR-4, TLR-3 acts via a 
MyD88-independent pathway (see Section 1.3.2, Figure 1.9). 
5.1.2 TLR-4 
TLR-4 is generally known as a plasma membrane bound receptor, although some 
examples of cytoplasmic localisation of TLR-4 also exist [36,279,280]. Evidence 
suggests that several PAMPs can stimulate TLR-4. Among these are LPS from Gram-
negative bacteria, fusion (F) protein from respiratory syncytial virus (RSV) [281] and 
endogenous molecules, termed Damage-Associated Molecular Patterns (DAMPS), 
such as heat-shock proteins [282] or hyaluronic acid [283]. LPS stimulation of TLR-4 
requires the participation of additional co-signalling molecules: LPS binding protein 
(LBP), CD14 and MD-2. LBP is a soluble shuttle protein which directly binds to LPS, 
facilitating LPS association with CD14 [284], which in turn helps the transfer of LPS to 
the TLR-4/MD-2 receptor complex [285]. MD-2 is a soluble protein that non-covalently 
associates with TLR-4 [286] (Figure 5.1). Upon LPS recognition, TLR-4 oligomerizes 
and recruits its adaptor molecules to initiate signalling (Figure 5.1). TLR-4 is unique 
among the human TLRs as it is the only TLR that can signal through two different 
pathways: the MyD88-dependent and MyD88-independent pathways. However, 
compared to the pathways utilized by other TLRs, both TLR-4 signalling pathways 
require additional adaptor molecules. Specifically, TIR-domain-containing adaptor 
protein (TIRAP) is involved in TLR-4 (and TLR-2)-mediated activation of the MyD88-
dependent pathway, whereas TRIF-related adapter molecule (TRAM) is a specific 
adaptor in the TLR-4-mediated MyD88-independent/TRIF-dependent pathway. Both 
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adaptors participate at the very first step of the signalling cascade, by associating with 
the plasma membrane, thus facilitating the TLR-4 signal transduction [66]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1 Schematic representation of the TLR-4 signalling pathways. MyD88-
dependent pathway: in addition to MyD88, TLR-4 activation requires the additional 
adaptor TIRAP; the cascade activates both NF-kB and MAP-kinases, terminating in 
pro-inflammatory cytokine release. MyD88-independent pathway: TRAM is recruited to 
the plasma membrane and facilitates TLR-4 signalling through TRIF, leading to Type 1 
IFN gene transcription. Proteins in the blue box represent signalling molecules 
contributing to the pathways but not mentioned in the text. 
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5.2 Hypothesis 
We hypothesised that, in TT1 cells, TLR-3 and/or TLR-4 play a regulatory role in 
AgNP-induced inflammation, autophagy activation and DNA damage. On the basis of 
the previous findings on oxidative stress and DNA damage, we also hypothesised that 
AgNPs enter the cells, thus eliciting cellular responses such as physical damage to the 
mitochondria and to the DNA molecule. 
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5.3 Materials and Methods  
5.3.1 Materials 
Cell culture, ELISA, Western blotting reagents and materials were sourced as 
described in Section 2.3.1 and Section 3.3.1. Alexa Fluor 555 goat anti-rabbit antibody, 
Prolong gold anti-fade reagent with DAPI and NuPAGE Novex 3-8% Tris Acetate Gels 
were obtained from Invitrogen (Paisley, UK). Accell Human TLR-4 siRNA and Pierce 
LAL Chromogenic Endotoxin Quantification Kit were purchased from Thermo Scientific 
(Denmark); AllStars Negative Control siRNA and HiPerFect Transfection Reagent from 
Qiagen. TLR-3/dsRNA Complex Inhibitor was obtained from Calbiochem (UK); TLR-4 
antagonist LPS-RS Ultrapure from Invivogen (UK) and anti-TLR-3, anti-TLR-4 
antibodies from Abcam (Cambridge, UK).  Poly-L-Lysine coated microscope slides and 
round cover glasses were purchased from VWR International Ltd (Leicestershire, UK). 
5.3.2 Methods  
5.3.2.1 Measurement of TLR-3 and TLR-4 expression in TT1 cells 
TT1 cells were prepared in 6-well plates, as described in Section 2.3.2.3, and treated 
with 50μg/ml of AgNPs alone or in combination with either 20μg/ml of Poly I:C or 
1000ng/ml of LPS. Cells were collected after 24h and Western blotting was performed 
as described in Section 2.3.2.13. TLR-3 and TLR-4 protein expression were assessed 
by probing the membranes with anti-TLR-3 and TLR-4 antibody, respectively. To 
confirm equal whole protein loading, β-actin was used as a control. Primary antibodies 
used in this study are listed in Table 5.1. Gels were imaged using Ultraviolet 
Transilluminator GelDoc-It and densitometric quantification was performed using 
Visionworks. 
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5.3.2.2 Use of TLR-3 and TLR-4 inhibitors for the study of AgNP-
induced IL-6 and CXCL-8 release, autophagy activation and DNA 
damage  
The working concentration chosen for both the inhibitors was 10µM, based on previous 
optimisation performed in our laboratory. TT1 cells were pre-treated with 10µM TLR-3 
or TLR-4 inhibitor for 1h, after which medium was removed and cells were exposed to 
50μg/ml AgNPs for another 24h. AgNP-induced IL-6 and CXCL-8 release was 
measured by ELISA (Section 2.3.2.9). Autophagy activation and DNA damage were 
measured by Western blotting (Sections 3.3.2.1 and 3.3.2.2.), probing the membranes 
with anti-LC3 and anti-H2A.X antibodies, respectively. Proteins were detected using 
the antibodies listed in Table 5.1. Gel imaging and analysis were conducted as 
described in the previous Section. 
 
Primary Antibody 
(dilution) 
Company 
Secondary 
Antibody 
(dilution) 
Molecular Weight 
of target protein 
(kDa) 
TLR-3                
(1:4,000) 
Abcam 
Rabbit 
(1:2,500) 
104  
TLR-4                
(1:4,000) 
Santa Cruz 
Rabbit 
(1:2,500) 
95-120  
LC3B             
(1:10,000) 
Sigma 
Rabbit 
(1:2,500) 
18  
β-actin           
(1:300,000) 
Abcam 
Mouse 
(1:3,000) 
45  
GAPDH+H2A.X+PARP 
(1:10,000) 
Abcam 
Mouse 
(1:3,000) 
36+16+89  
 
Table 5.1 Antibodies used for protein detection. kDa: kilo Dalton. 
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5.3.2.3 Confocal microscopy 
TT1 cells were cultured on glass coverslips placed in 24-well plates. Following 24h 
serum starvation, cells were exposed to AgNPs (50μg/ml), and after 1h to either Poly 
I:C (20μg/ml) or LPS (1000ng/ml), for a total period of 24h. The medium was then 
discarded and cells washed with PBS before being fixed in 4% paraformaldehyde 
(PFA) prepared in PBS for 10min at RT. Following fixation, cells were washed with 
PBS; cells that had been stimulated with Poly I:C (TLR-3 ligand) were then 
permeabilised with 0.1% Triton-X100 for 45min, at RT, then washed again in PBS. 
Permeabilisation was required as the TLR-3 ligand is located intracellularly. All cells 
were then blocked with PBS containing 1% BSA for 1h, washed and incubated with 
either TLR-3 (1:300) or TLR-4 (1:100) primary antibody overnight at 4oC. After 
washing, cells were incubated for 1h at RT, with a fluorescently-labelled secondary 
antibody (1:100). Following this, cells were washed and prepared for nuclear staining. 
To stain the nucleus, 100µl of prolong gold anti-fade reagent with DAPI was added to 
Poly-L-lysine-coated microscope slides. Cells were then placed on top of a Poly-L-
lysine coated microscope slide and fixed in place for confocal microscopy. A Zeiss 
LSM-510 microscope and Zeiss LSM Image Browser software were used. 
In addition to single images, Z-series stacks were taken in order to spatially resolve the 
position of particles within the cells. Z-stacks are a series of images obtained by 
optically sectioning the specimen from top to bottom in the z-axis (Figure 5.2, A). 
Between 10 and 15 slices (or Z-stacks) of a specific sample were generated, using a 
63x magnification objective. To visualise the XZ and YZ planes at any given point of 
the stack, orthogonal views were also taken (Figure 5.2, B). 
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Figure 5.2 Schematic representation of Z-stacks (A) and orthogonal slices of a 
sample (B). A: to achieve the 'stacks' of 2-D pictures, confocal microscopy generates 
images occupying the same x-y position but varying along the z-axis. B: In an 
orthogonal view the sample is sliced through two imaginary lines (XZ and YX lines) to 
allow for two distinct lateral views. Picture B adapted from Fuji’s website [287]. 
5.3.2.4 Optimisation of TLR-4 small interference RNA transfection 
(TLR-4 siRNA) 
Human TLR-4 small interference RNA (siRNA) was transiently transfected into TT1 
cells with HiPerFect Transfection Reagent (see Chapter 8; Supplementary Material). 
Cells were cultured and seeded in 6-well plates as previously described (Section 
2.3.2.3). The following day, cells were transfected for 24 and 48h with Human TLR-4 
siRNA, according to the supplier’s protocol [288]. We first referred to the supplier’s 
protocol for adherent cells, using 5nM siRNA as a starting concentration, which was 
added to 12µl of HiPerfect Transfection Reagent. During the optimisation, the protocol 
was modified by testing increasing concentrations of siRNA and HiPerfect Transfection 
Reagent (Table 5.2). siRNAs with scrambled sequences were used as a negative 
control. Efficiency of siRNA-mediated depletion of TLR-4 was assessed by Western 
blotting 24 and 48h after transfection. To visualise TLR-4 protein, membranes were 
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incubated with anti-TLR-4 antibody and normalised against β-actin (see Table 5.1). Gel 
imaging and analysis were conducted as described in Section 5.3.2.1. 
 
Final siRNA 
Concentration  (nM) 
Volume of HiPerFect 
Reagent (µl) 
5 12 
10 12 
50 12 
75 15 
150 15 
600 18 
 
Table 5.2 Optimisation of siRNA against TLR-4. 
5.3.2.5 Statistical analyses  
All statistical tests were performed using GraphPad Prism 4 software. Results are 
presented as fold-change ± standard error of the mean (SEM); n=3 (unless otherwise 
stated), where 3 independent experiments were performed using 3 separate TT1 cells 
passage generations. Data was considered to follow a normal distribution. We elected 
a priori to compare treated groups to the untreated control. Thus, significant effects of 
AgNPs, Poly I:C and LPS on cytokine/chemokine release and protein 
expression/activation were determined using one-way ANOVA with Bonferroni’s 
Multiple Comparison Test as a post-test to compare all pairs of treatments. All 
statistical tests were performed on the raw data. A p value <0.05 was considered to be 
statistically significant.  
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5.4 Results  
5.4.1 TLR-3 and TLR-4 expression  
We have previously demonstrated that TT1 cells respond to TLR-3 and TLR-4 ligands 
(Section 2.4.3.7), suggesting that these cells expressed both receptors. In order to 
confirm this hypothesis, we performed Western blotting analyses to show TLR-3 and 
TLR-4 expression in TT1 cells. 
5.4.1.1 TLR-3 expression 
Following co-exposure to AgNPs and Poly I:C, Western blotting data showed that TLR-
3 expression slightly increased when Poly I:C was given on its own (16% increase) 
(Figure 5.3). In contrast, when cells were exposed to AgNPs alone or in combination 
with Poly I:C the expression of TLR-3 seemed to decrease (13% and 27% decrease, 
respectively). However, as the experiment was only replicated twice (n=2), we could 
not establish whether the changes observed in TLR-3 expression were statistically 
significant. 
5.4.1.2 TLR-4 expression 
When TT1 cells were exposed first to AgNPs or LPS alone and then in combination, 
TLR-4 expression did not seem to change (Figure 5.4). Only a slight decrease was 
measured in the receptor expression when exposed to AgNPs alone, as well as when 
AgNPs and LPS were given together (10% and 15% decrease, respectively). However, 
as with the TLR-3 data, TLR-4 data were supported by n=2. Therefore, further 
experiments are needed to confirm this finding. 
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Figure 5.3 Effect of AgNPs alone and in combination with Poly I:C on TLR-3 
expression. TT1 cells were treated with AgNPs (50µg/ml) and Poly I:C (20µg/ml), 
alone and in combination, for 24h. Whole cell extracts were run in SDS-PAGE/Western 
blotting and normalised against the expression of β-actin. Representative blot of 2 
independent experiments (A) and graph (B) showing changes in TLR-3 expression. 
Data are expressed as fold-change ± SEM; (n=2). 
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Figure 5.4 Effect of AgNPs alone and in combination with LPS on TLR-4 
expression. TT1 cells were treated with AgNPs (50µg/ml) and LPS (1000ng/ml), alone 
and in combination, for 24h. Whole cell extracts were run in SDS-PAGE/Western 
blotting and normalised against the expression of β-actin. Representative blot of 2 
independent experiments (A) and graph (B) showing small changes in TLR-4 
expression. Data are expressed as fold-change ± SEM; (n=2). 
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5.4.2 Effect of TLR-3 and TLR-4 inhibitors on AgNP-induced IL-6 
and CXCL-8 release 
To address the first part of our hypothesis, i.e. TLR-3 and/or TLR-4 play a regulatory 
role in AgNP-induced cellular effects, we first investigated the role of TLR-3 and TLR-4 
in AgNP-mediated cytokine release. Pre-incubation of TT1 cells with inhibitors of the 
two TLRs (10µM) was followed by exposure to AgNPs. Our results demonstrated that 
pre-incubation with TLR-3 inhibitor did not affect AgNP-mediated IL-6 or CXCL-8 
release (Figure 5.5). On the contrary, inhibition of TLR-4 significantly reduced AgNP-
induced IL-6 (73%; p<0.001) and CXCL-8 (53%; p<0.05) release (Figure 5.6).  
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Figure 5.5 Effect of TLR-3 inhibitor on AgNP-induced IL-6 and CXCL-8 release. 
TT1 cells were pre-treated for 1h with TLR-3 inhibitor (10µM) before 24h exposure to 
AgNPs (50µg/ml). IL-6 and CXCL-8 production after 24h was evaluated by ELISA. 
Data are expressed as fold-change ± SEM; (n=4); *p<0.05; ***p<0.001 (vs. unexposed 
control); NS=non significant (AgNPs vs. TLR-3 inhibitor+AgNPs). 
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Figure 5.6 Effect of TLR-4 inhibitor on AgNP-induced IL-6 and CXCL-8 release. 
TT1 cells were pre-treated for 1h with TLR-4 inhibitor (10µM) before 24h exposure to 
AgNPs (50µg/ml). IL-6 and CXCL-8 production after 24h was evaluated by ELISA. 
Data are expressed as fold-change ± SEM; (n=4); *p<0.05; ***p<0.001 (vs. unexposed 
control); #p<0.05; ###p<0.001 (AgNPs vs. TLR-4 inhibitor+AgNPs). 
 
193 
5.4.3 Effect of TLR-3 and TLR-4 inhibitors on AgNP-induced 
autophagy activation  
When TT1 cells were pre-treated with TLR-3 and TLR-4 inhibitors prior to exposure to 
AgNPs, two different responses were observed in the autophagy activation process 
(Figure 5.7). Western blotting data showed a significant decrease in autophagy 
activation by AgNPs when TLR-4 was inhibited (66%; p<0.001), whereas inhibition of 
TLR-3 did not affect AgNP-induced autophagosome formation.  
5.4.4 Effect of TLR-3 and TLR-4 inhibitors on AgNP-induced DNA 
damage 
The role of TLR-3 and TLR-4 in AgNP-mediated DNA damage formation was also 
assessed using inhibitors of the two TLRs. Western blotting analyses (Figure 5.8) 
suggested that TLR-4 inhibition decreased AgNP-induced phosphorylation of histone 
H2A.X by about 50%. On the contrary, the use of TLR-3 inhibitor did not prevent 
AgNP-induced DNA damage. However, it must be noted that only two replicates of this 
experiment were performed, and therefore the data could not be analysed for statistical 
significance.  
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Figure 5.7 Effect of TLR-3 and TLR-4 inhibitors on AgNP-induced autophagy 
activation. TT1 cells were pre-treated for 1h with either TLR-3 or TLR-4 inhibitor 
(10µM) before 24h exposure to AgNPs (50µg/ml). Whole cell extracts were run in SDS-
PAGE/Western blotting and normalised against the expression of β-actin. 
Autophagosome formation was calculated as a ratio LC3-II/β-actin. Representative blot 
of 3 independent experiments (A) and graph (B) showing the effect of the 2 inhibitors 
on autophagy activation. Data are expressed as fold-change ± SEM; (n=3); *p<0.05; 
***p<0.001 (vs. unexposed control); NS=non-significant (AgNPs vs. TLR-3 
inhibitor+AgNPs); ###p<0.001 (AgNPs vs. TLR-4 inhibitor+AgNPs). 
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Figure 5.8 Effect of TLR-3 and TLR-4 inhibitors on AgNP-induced DNA damage. 
TT1 cells were pre-treated for 1h with either TLR-3 or TLR-4 inhibitor (10µM) before 
24h exposure to AgNPs (50µg/ml). Whole cell extracts were run in SDS-
PAGE/Western blotting and phosphorylation levels of H2A.X were normalised against 
the expression of GAPDH. Representative blot of 2 independent experiments (A) and 
graph (B) showing the effect of the 2 inhibitors on DNA damage. Data are expressed 
as fold-change ± SEM; (n=2). 
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5.4.5 Intracellular localisation of AgNPs 
The second part of our hypothesis investigated the possible uptake of AgNPs by TT1 
cells. To address this, TEM is generally the most commonly used technique; however, 
as our AgNPs are auto-fluorescent, they can be easily visualised by confocal 
microscopy, which we used for these experiments. Since TLR-3 is an intracellular 
receptor that localises in endosomal membranes, by staining for TLR-3 we investigated 
the possible internalisation of AgNPs in endosomal compartments.  
Images from confocal microscopy showed that TLR-3 (Figure 5.9, A; in red) and 
AgNPs (Figure 5.9, C; in green) co-localised (Figure 5.9, E; yellow areas). In 
fluorescence microscopy, the tem “co-localisation” refers to observations of spatial 
overlap between two (or more) different fluorescent labels, each having a separate 
emission wavelength, to see if the different molecules are located in the same area of 
the cell (or very close to one another). The definition can be divided into two different 
phenomena, co-occurrence (presence of two fluorophores in the same pixel, as seen in 
Figure 5.9), and correlation (indicative of a biological interaction between the 
molecules) [289]. In the present study, we only refer to co-occurrence, without 
assuming any biological interaction between the molecules. The co-occurrence 
observed between endosomal marker TLR-3 and AgNPs suggested that the latter 
could be intracellular and specifically localised in endosomes. By analysing the 
confocal pictures we noticed non-overlapping areas characterised by mono-coloured 
spots, either red (indicative of the presence of endosomal TLR-3 only) (Figure 5.9; 
yellow arrows) or green (indicative of the presence of AgNPs only) (Figure 5.9; light 
blue arrows). This suggests that only few AgNPs are associated with the receptors. In 
addition, areas of co-occurrence were clearly distinguishable in yellow spots (Figure 
5.9; white circles), indicative of intracellular endosomal co-occurrence of the AgNPs. 
 
To confirm these findings, some samples were further analysed by taking a series of Z-
stacks (refer to Section 5.3.2.3). The resulting projections provided a better 
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understanding of the localisation of AgNPs. The overlap between AgNPs (Figure 5.10, 
C; in green) and TLR-3 (Figure 5.10, A; in red) was evident in several regions (Figure 
5.10, D; in yellow) of a single Z-stack, proving that AgNPs and TLR-3 were on the 
same plane. This confirmed that AgNPs pass through the cellular membrane and 
reached the inside of the cell, localising in endosomes. 
In addition, several white spots where detected, mainly visible in the lateral section 
(Figure 5.11, B; red arrow), and corresponding to the overlap between AgNPs and 
nuclei (in blue; Figure 5.11). This finding was of particular interest as it implied the 
presence of AgNPs in the nucleus, suggesting important consequences for the cell 
when exposed to NPs, such as the NP contact with the DNA and, possibly, subsequent 
damage to the DNA. Indeed, we have shown DNA damage as a consequence of AgNP 
reactivity with TT1 cells (see Section 3.4.4). 
  
 
 
 
 
 
 
 
 
Figure 5.9 Localisation of AgNPs inside TT1 cells. Cells were exposed to AgNPs (50µg/ml) for 24h and then fixed in 4% PFA for immunofluorescent 
staining of TLR-3 (A) and nuclei using DAPI (B). Panels C, D and E showing AgNPs auto-fluorescence, transmission and merge respectively. Yellow arrows 
indicate presence of endosomal TLR-3 only; light blue arrows indicate AgNPs only; circles represent regions of co-occurrence. NT=non-treated. Images are 
representative of 3 independent experiments. 
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Figure 5.10 Projection from confocal Z-stacks showing the localisation of AgNPs inside TT1 cells (1). Cells were exposed to AgNPs (50µg/ml) for 24h 
and then fixed in 4% PFA for immunofluorescent staining of TLR-3 (A) and nuclei using DAPI (B). Panels C and D show AgNP auto-fluorescence and merge 
respectively. Panel E represents a lateral view of the projection. A series of Z-stacks were taken for each sample. White arrows indicate co-occurrence of 
AgNPs and TLR-3. Images are representative of 3 independent experiments. 
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Figure 5.11 Projection from confocal Z-stacks showing the localisation of AgNPs 
inside TT1 cells (2). Cells were exposed to AgNPs (50µg/ml) for 24h and then fixed in 
4% PFA for immunofluorescent staining of TLR-3 (in red) and nuclei using DAPI (in 
blue). Auto-fluorescent AgNPs appear in green. Frontal (A) and lateral (B) views are 
shown. A series of Z-stacks were taken for each sample. Red arrows indicate co-
occurrence between AgNPs and nuclei. Images are representative of 3 independent 
experiments.  
5.4.6 Assessment of TLR-3, TLR-4 and AgNP cellular localisation 
The immunostaining of TLR-3 and TLR-4 in the presence and absence of their 
respective ligands (Poly I:C and LPS) and AgNPs was carried out in order to 
investigate any possible difference in the expression of the receptors. The time point 
chosen was the same as in previous experiments (24h).  
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5.4.6.1 TLR-3 and AgNPs 
Confocal images of TLR-3 expression (Figure 5.12; red signal) in TT1 cells revealed 
that the receptor was expressed under resting conditions. Following exposure to Poly 
I:C, no change in TLR-3 expression was observed. In contrast, when AgNPs were 
added to the cells (Figure 5.12; green signal), alone or in combination with Poly I:C, 
endosomes appeared less compact and a slight decrease in TLR-3 expression was 
observed; however this decrease was not quantified. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.12 Effect of AgNPs alone and in combination with Poly I:C on TLR-3 
expression. Cells were treated with AgNPs (50µg/ml) and Poly I:C (20µg/ml), alone 
and in combination, for 24h. Cells were fixed in 4% PFA and stained for TLR-3 (red) 
and nuclei using DAPI (blue). Auto-fluorescent AgNPs appear in green. NT=non-
treated. Images are representative of 3 independent experiments. 
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5.4.6.2 TLR-4 and AgNPs 
When TT1 cells were stained for TLR-4 (Figure 5.13; red signal), expression of the 
receptor was observed at baseline all throughout the cells. After 24h exposure to LPS, 
it appeared to be a slight increase in TLR-4 expression or cellular distribution. When 
AgNPs were added to the cells (Figure 5.13; green signal) in combination with LPS, a 
small decrease in TLR-4 expression seemed to occur.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.13 Effect of AgNPs alone and in combination with LPS on TLR-4 
expression. Cells were treated with AgNPs (50µg/ml) and LPS (1000ng/ml), alone and 
in combination, for 24h. Cells were fixed in 4% PFA and stained for TLR-4 (red) and 
nuclei using DAPI (blue). Auto-fluorescent AgNPs appear in green. NT=non-treated. 
Images are representative of 3 independent experiments. 
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Interestingly, in some areas of the cells, TLR-4 localisation was perinuclear (Figure 
5.13), suggesting that the antibody had permeated the cells and recognised 
cytoplasmic TLR-4. A better understanding of the receptor localisation was achievable 
by oversampling. Therefore, we further analysed some samples by taking a series of Z-
stacks. The resulting projections showed cytoplasmic localisation of TLR-4, both in 
control cells (Figure 5.14; red signal) and AgNP-treated cells (Figure 5.15; red signal). 
In the untreated samples (Figure 5.14), the TLR-4 signal (red) was around the nucleus 
(blue) and was consistent throughout the Z-stack (orange and yellow arrows), 
suggesting that the receptor is cytoplasmic. This was further confirmed by an 
orthogonal view of the stack (Figure 5.14, B; yellow arrow), showing the presence of 
TLR-4 in both of the two lateral views. White arrows (Figure 5.14, A and B) indicate a 
signal that looks more membrane-like, but might also have a cytoplasmic component. 
Similarly, when looking at Z-stacks from cells treated with AgNPs (Figure 5.15; green 
signal), a cytoplasmic localisation of TLR-4 was evident (orange and yellow arrows), 
confirmed in the orthogonal view (Figure 5.15, B; yellow arrow). The presence of 
membrane-like signals was also noticed (Figure 5.15; white arrows). No co-occurence 
was observed. 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.14 Projection from confocal Z-stacks of the localisation of TLR-4 inside untreated TT1 cells. Cells were fixed in 4% PFA and stained for TLR-
4 (red) and nuclei using DAPI (blue). Nuclei are differentiated from the perinuclear cytoplasm (indicated in light blue). A series of Z-stacks were taken for each 
sample. Orange and yellow arrows indicate cytoplasmic localisation of TLR-4; white arrows show the positioning of the receptor at the membrane. A gallery of 
Z stacks in X–Y horizontal sections (A) and orthogonal views (B) are shown. Images are representative of 3 independent experiments. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.15 Projection from confocal Z-stacks of the localisation of TLR-4 inside AgNP-exposed TT1 cells. Cells were treated with AgNPs (50µg/ml) 
for 24h, then fixed in 4% PFA and stained for TLR-4 (red) and nuclei using DAPI (blue). AgNPs appear in green. A series of Z-stacks were taken for each 
sample. Orange and yellow arrows indicate cytoplasmic localisation of TLR-4; white arrows show the membrane position of the receptor. A gallery of a Z 
stack in X–Y horizontal sections (A) and orthogonal views (B) are shown. Images are representative of 3 independent experiments. 
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5.5 Discussion  
5.5.1 Interlinked effects between NPs and TLRs 
TLRs and their ligands play a critical role in the initiation of the innate immunity which 
precedes and is required for the establishment of the adaptive immunity [58]. Many 
NPs have been reported to induce inflammatory responses (see Chapter 2), autophagy 
activation and DNA damage (see Chapter 3). However, only a few studies have 
focused on the effects of NPs on TLR activity and consequent interlinked cellular 
effects. In order to investigate the role of TLR-3 and TLR-4 in AgNP-mediated 
responses, we studied the effects of TLR-3 and TLR-4 inhibition upon AgNP 
stimulation. Our previous data demonstrated that AgNPs induce inflammation, 
autophagy activation and DNA damage in TT1 cells and that co-exposure to AgNPs 
and TLR-3/TLR-4 ligands modulates these responses. Thus, we tested the effect of 
TLR-3 and TLR-4 inhibition on these three pathways. Our results showed that TLR-4 
signalling, but not TLR-3, was likely to be involved in AgNP-mediated effects on all 
three processes. 
5.5.1.1 Inflammation 
Inhibition of TLR-4 resulted in a significant decrease in both IL-6 and CXCL-8 release 
from TT1 cells. Similar findings have been reported by Kedmi et al. in primary TLR-4 (-
/-) murine monocytes from T cells and B cells, exposed to neutral, positively- and 
negatively-charged lipid-based NPs without any surface modification [290]. The study 
showed that, in response to positively charged NPs, cytokine expression levels were 
significantly decreased in the TLR-4 (-/-) monocytes compared to wild type cells. 
Interestingly, treatment with neutral or negatively charged NPs had no effect on 
cytokine expression levels. Our experimental data, however, differ from the latter part 
of Kedmi’s study: the AgNPs used in the current study are negatively charged and 
significantly altered the release of cytokines. This contradiction may generate both from 
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differences in NP composition as well as differences in cell type used. Indeed, we used 
metallic NPs, whereas Kedmi’s study focused on lipid-based NPs composed of 
cholesterol and phosphatidylcholine only, which are known to enhance NP stability 
[291].  
The idea of NPs as TLR ligands has also been suggested in other studies. Tamayo et 
al. investigated the effect of Poly (anhydride) NPs on bone marrow dendritic cells from 
mice [292]. These very hydrophobic NPs were chosen since they are licensed in the 
United Kingdom for oral drug delivery [293], and their efficacy as adjuvants in inducing 
Th1 immune responses has largely been demonstrated [294,295]. In order to explain 
the mechanisms responsible for their potent Th1-adjuvant capacity, the authors 
hypothesised that Poly (anhydride) NPs might act as an agonist of some TLRs. By 
demonstrating the absence of NP-mediated activation in a TLR-deficient cell line, the 
hypothesis was confirmed. Therefore, our data, together with these studies suggest a 
role for NPs as TLR agonists. 
5.5.1.2 Autophagy 
As mentioned in Chapter 3, the connection between autophagy and TLRs is well 
documented. It has been shown that TLR-4 stimulation by LPS enhances the 
autophagic elimination of phagocytosed mycobacteria in murine macrophages [99]. 
LPS has also been shown to increase PI3 kinase association with membranes, known 
to be involved in autophagy induction. Furthermore, studies have reported that TLR-2, 
TLR-3, TLR-7 and TLR-8 activation can also induce autophagy [268,269]. Similarly, 
activation of autophagy by NPs has been proved (Section 3.5.1), although the 
underlying mechanisms contributing to the process, as well as the potentially 
interlinked roles and effects between NPs, autophagy and TLRs, remain undiscovered. 
In fact, although the role of TLRs in sensing biological molecules is well-established, 
their recognition of non-biological entities, such as solid, metallic NPs, coupled with the 
mechanism of autophagy, is as yet unknown. 
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In this study we have shown that AgNP-induced autophagy partially involved TLR-4 but 
not TLR-3 activation. In line with our findings, a study by Chen et al. reports that 
graphene oxide (GO) elicits autophagy and TLR signalling in the RAW264.7 murine 
macrophage cell line [296]. They found that GO-induced inflammation and autophagy 
were modulated by the TLR-4 and TLR-9 pathways, and suggested that, in their model, 
only the MyD88-dependent pathway was involved (both in the GO-induced cytokine 
response and autophagy activation), as GO-induced TLR signalling did not elicit IRF3 
activation [297]. However, in the current study, we did not investigate the two TLR-4 
signalling pathways due to toxicity of the MyD88 inhibitor in the TT1 cell line (data from 
unpublished studies in our laboratory). Thus it remains to be proven exactly which 
pathway is involved in AgNP activation of TLR-4 (the MyD88-dependent and/or the 
TRIF-dependent pathway). This could be the subject for future studies. 
In HEK 293 cells and RAW 264.7, it has been shown that engagement of TLR-4 
recruits not only MyD88, but also Beclin-1, into the TLR-4 signalling complex [96]. 
Beclin-1 is the mammalian homologue of yeast Atg6 and serves as a scaffold for other 
autophagy proteins that associate with it, thus initiating the formation of 
autophagosomes [298]. On this basis, we could also hypothesise a similar signalling 
cascade for our model. 
Considering the role of autophagy and TLRs in eliminating intracellular microbes 
(Section 1.3.2), we could speculate that NP-triggered autophagy is a mechanism 
adopted by the cells to react to as well as remove internalised NPs. There is evidence 
that autophagy delivers cytosolic PAMPs to endosomal TLRs, so that the innate 
immune response can be triggered [95]. A similar mechanism can be hypothesised for 
NPs, which, once inside the cell, can activate autophagy and subsequently be 
delivered to TLRs.  
5.5.1.3 DNA damage  
Another significant finding of this study was the involvement of TLR-4 signalling in 
AgNP-induced DNA damage. Despite many studies demonstrating the ability of some 
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NPs to cause DNA damage, as well as the presence of a link between ROS and TLR-4 
[299], or between oxidative stress, TLR-4 expression and DNA damage [299,300], 
none have implicated TLR-4 as the principal mediator for the NP-induced genotoxicity. 
For example, it has been reported that hepatocytes from murine liver respond in vivo to 
heat inactivated E. Coli by increasing TLR-4 expression, which appeared to regulate 
the hepatic oxidative stress generated from the infection and was responsible for 
mitochondrial DNA (mtDNA) damage. Indeed, TLR-4-/- mice were protected from 
mtDNA damage [300]. In another work, Menendez and colleagues showed that it was 
the ROS generated from cellular stress (e.g. ionizing radiation) that was responsible for 
an increase in TLR-4 expression, which resulted in a sensitisation of the cells to the 
initial stressor (radiation) that in turn generated further ROS [299]. 
Therefore, the present study, by indicating a link between NPs, TLR-4 activity and DNA 
damage, provided a further step in the understanding of the underlying mechanisms of 
NP-induced genotoxicity. 
 
In order to confirm the findings obtained with pharmacological inhibitors, we 
investigated the use of siRNA to knockdown TLR-4 expression (see Chapter 8; 
Supplementary Material). Although only one experiment was performed (Figure 8.2), 
TLR-4 knockdown did not alter AgNP-induced IL-6 and CXCL-8 production. This may 
be due to an insufficient level of TLR-4 knockdown (46%). Therefore, in future studies, 
certain experimental conditions (e.g. type of transfection reagent, siRNA) will be 
modified to see whether knockdown can be improved.  
 
We have previously shown that TT1 cells are responsive to LPS. Here, we suggest that 
AgNPs could also signal through TLR-4. Whilst both LPS and AgNPs elicit responses 
through TLR-4, the signalling mechanisms may be different. The same hypothesis has 
been proposed in a work by Mano et al. using human pulmonary epithelial cells. The 
authors showed that LPS and TiO2NPs signal through TLR-4 but using two different 
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pathways. During cellular uptake of TiO2NPs, TLR-4 did not form a complex with LBP 
and CD14, which is typical of the LPS-mediated response. Instead, for TiO2NPs, TLR-4 
acted as an independent signalling receptor, without utilising the protein complex of 
LBP and CD14 [301]. Thus, it is possible that in our model, LPS and AgNPs, both 
signalling through TLR-4, may act through two separate pathways, thus explaining their 
different reactivity with TT1 cells and the antagonistic effects they exert on 
inflammation, autophagy and DNA damage. 
5.5.2 AgNP uptake in TT1 cells 
To address the second part of our hypothesis regarding the ability of AgNPs to enter 
TT1 cells, we used confocal microscopy. By using TLR-3 as a marker of endosomes, 
we observed an overlapping signal between the receptor and our auto-fluorescent 
AgNPs, suggesting a likely co-occurrence of the two molecules (refer to Section 5.4.5 
for an explanation). However, the use of co-occurrence by itself might not be sufficient 
to conclude that the NPs are inside the endosome. For instance, the particles might 
appear to be inside the cell and co-occurring with the endosome (TLR-3), but may 
instead be on the cellular surface or even on another plane. A particular advantage of 
confocal microscopes is the ability to take optical sections and create three 
dimensional representations of a specimen without actually cutting or sectioning the 
specimen. This allows for a greater understanding of the overall structure, providing 
positional information of the NPs, which is otherwise impossible to gather. We 
generated Z-stacks series of approximately 0.5µm (Figure 5.9) and then created a 
projection through these data as a movie of the multiple viewpoints (Figures 5.10 and 
5.11). The presence of cells (blue nuclei) above and below AgNPs (in green) led us to 
conclude that the particles were inside the cell. Furthermore, we provided evidence of 
the presence of AgNPs inside the nucleus (Figure 5.11). In agreement with our 
findings, Asharani et al. [50] found that starch-coated AgNPs (6-20nm) were 
internalised in normal human lung fibroblast cells (IMR-90) and human glioblastoma 
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cells (U251). Analysis by TEM indicated the presence of these AgNPs inside the 
mitochondria and the nucleus, implicating their direct involvement in the mitochondrial 
toxicity and DNA damage measured. However, it has previously been suggested that 
nuclear pores can only be dilated to around 39nm to allow for molecules to translocate 
the membrane [302]. Considering that the size of the AgNPs used is 80-100nm, we 
could hypothesise that the NPs may become enclosed in the nucleus following mitosis 
when the nuclear membrane dissolves (see Section 3.5.2), or by active transport. To 
definitively illustrate the intracellular localisation of AgNPs, further experiments using 
techniques such as TEM or lysosomal tracking would be required. Therefore, based on 
AgNP-induced cytotoxicity and ROS generation measured in our study, we speculate 
that in addition to the effects that extracellular AgNPs exert on the cell, once the NPs 
gain access to the cell, they may generate further toxic effects directly into cellular 
components. For example, AgNPs could physically damage the mitochondria thus 
causing the oxidative stress measured at 24h post-exposure (Section 4.4.5). Having 
proved their ability of directly generating oxidative stress (Section 3.4.6), the NPs 
themselves could be the source of more ROS in the cell. Also, intracellular AgNPs 
could directly activate autophagy and, during mitosis, gain access to the nucleus, 
where a possible interaction with the DNA might be responsible for the DNA damage  
reported 24h post-exposure (Section 4.4.5). 
 
Interestingly, when staining for TLR-4, we noticed that the receptor localisation was 
also perinuclear. As already mentioned (Section 5.1.2), the possibility of intracellular 
TLR-4 has been previously reported [36,279,280]. Although we could argue that we did 
not permeabilise the samples stained for TLR-4, it is known that fixation techniques 
can cause damage to the cell membrane, altering their permeability. To address the 
possibility of an intracellular localisation of TLR-4, we further processed some cell 
samples, generating Z-stacks. We collected galleries of images from both untreated 
and AgNP-exposed cells, showing a clear cytoplasmic localisation of TLR-4. Therefore, 
 
212 
having demonstrated that AgNPs are internalised by TT1 cells and that TLR-4 can also 
be found in the cytoplasmic compartment, our results imply that AgNPs could interact 
with the receptor from inside the cell as well, which could explain some of the 
observations previously described (i.e. cytokine release, autophagy activation and 
damage to the DNA). 
Perinuclear TLR-4 staining has also been shown by Hornef and colleagues in murine 
intestinal epithelial cells [303]. In this work, TLR-4 was shown to co-localise with the 
Golgi apparatus and to be absent from the cellular membrane. The authors proposed 
that this TLR-4 localisation, which requires LPS internalisation, represents another 
regulatory barrier to prevent uncontrolled LPS-induced stimulation in epithelial cells. A 
study using the BEAS-2B epithelial cell line also demonstrated that TLR-4 was 
expressed intracellularly only, and that exposure to LPS activated MAP-kinases and 
induced cytokine secretion [191]. Interestingly, in the latter study, at least 1µg/ml of 
LPS was required to elicit a cytokine response and LPS exposure did not induce 
further TLR-4 expression, also demonstrated in our work. Therefore, tying together our 
findings on LPS with those on TLR-4 expression, which was found to be both inside 
and on the surface of TT1 cells, we can refute our hypothesis that the hypo-
responsiveness of TT1 cells we previously measured was related to a lack of TLR-4 
expression on the cells (Section 2.5.2). In this scenario, the hypo-responsiveness of 
TT1 cells to LPS may be a protective mechanism to prevent an exaggerated 
inflammatory response in the airways where LPS exposure is constant. 
 
In general, the mechanisms of cellular uptake can be either active (pinocytosis, 
caveolae-mediated endocytosis, clathrin mediated endocytosis and phagocytosis) or 
passive (diffusion) (see Section 1.2.3.2). The specific mechanism by which NPs enter a 
cell is likely to depend on their physico-chemical properties, cell type or type of 
interaction between the cell and the particles. Several papers have shown that cationic 
NPs promote the internalisation rate and increase the amount of endocytic processes 
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more than anionic particles, likely due to electrostatic interactions between the 
negatively charged cellular membrane and the positively charged particles 
[27,304,305]. Interestingly, a study conducted in our laboratory showed that passive 
uptake is an important mechanism in TT1 cells, particularly for negatively charged 
particles [35]. In this study, 75% of TT1 cells internalised negatively charged 
polystyrene particles, while positively charged particles were taken up by less than 
55% of the cells [35]. However, considering that AT1 cells contain caveolae and 
clathrin-mediated vesicles and that the AgNPs used in this study are 80-100nm in size, 
active mechanisms of uptake cannot be excluded. The type of particle uptake used by 
TT1 cells was not the focus of this study, but it would be interesting to consider it 
further in future investigations.  
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5.6 Conclusion 
The aim of this study was to investigate the role of TLR-3 and TLR-4 in AgNP-induced 
inflammation, autophagy activation and DNA damage in TT1 cells. Furthermore, we 
also assessed the potential uptake of AgNPs in TT1 cells by using confocal 
microscopy. 
  
Our findings demonstrated that TLR-4 inhibition resulted in significant changes in the 
three pathways investigated. In fact, the use of a TLR-4 inhibitor significantly reduced 
AgNP-mediated IL-6 and CXCL-8 release and partially inhibited AgNP-induced 
autophagy and DNA damage formation. On the contrary, inhibition of TLR-3 had no 
effect on these pathways. This led us to conclude that, in TT1 cells, TLR-4, which we 
proved to be both intracellular as well as cell surface membrane-bound, plays a 
fundamental role in mediating AgNP effects, thus becoming a putative “transmembrane 
receptor of AgNPs”. The future use of siRNA TLR-4 will serve to confirm or refute these 
findings. 
In addition, using confocal microscopy we demonstrated that AgNPs were internalised 
by the cells and co-occurred with endosomal marker TLR-3. A remarkable discovery 
was the presence of AgNPs inside the nuclei, demonstrating their ability to enter the 
nucleus and possibly damage the DNA. 
 
This study suggests that a possible mechanism of action for inhaled AgNPs might be 
through cellular receptors, at least one of which is TLR-4. The ability of the NPs to 
penetrate the alveolar cell raises the question of their possible translocation into the 
underlying endothelium and/or systemic organs, where the cytotoxic effects could be 
expanded. 
 
 
 
215 
Cytoplasm
AgNPs
Autophagy
Nucleus
DNA damage
IL-6, CXCL-8
ROS
ROS
Mitochondria
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.16 Role of TLR-4 in AgNP-induced effects in TT1 cells. AgNPs can act via 
TLR-4 to elicit (I) inflammation (IL-6 and CXCL-8 release), (II) autophagy activation and 
(III) DNA damage. AgNPs can also penetrate the cytoplasmic membrane where they 
may (I) activate autophagy, (II) generate intracellular ROS, (III) physical damage the 
mitochondria and (IV) enter the nucleus, thus damaging the DNA directly. 
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6. SUMMARY DISCUSSION 
6.1 Summary 
The aim of this study was to investigate the effects of AgNPs on the human alveolar 
epithelium in order to elucidate any possible harmful effects they could exert on 
humans. As the lung is continuously exposed to environmental air, and therefore 
coming into contact with microbes, we also focused on understanding the effects of 
AgNPs on viral/bacterial infection. In order to investigate this, we simulated viral and 
bacterial infections by using Poly I:C (a synthetic viral dsDNA; TLR-3 ligand) and LPS 
(a bacterial product; TLR-4 ligand) respectively. The use of TT1 cells conferred the 
unique advantage of performing experiments on a highly relevant cell type that covers 
over 95% of the alveolar surface area, thus representing the most important alveolar 
target cell type to interact with inhaled NPs [32]. 
Our primary hypothesis anticipated that inhaled AgNPs trigger a pro-inflammatory 
response in the human alveolar epithelium and synergise with microbial ligands to 
further activate the immune response. We first assessed the basic responses of TT1 
cells to AgNPs, Poly I:C and LPS stimulations in terms of cytotoxicity and inflammatory 
mediator release. This also provided a benchmark to establish appropriate 
concentrations and time points to be used in subsequent studies. AgNPs and Poly I:C 
exposure each induced a concentration-depend decrease in TT1 cell viability, 
significant at concentrations greater than 50µg/ml. On the contrary, LPS showed no 
toxicity. The AgNP-induced decrease in cell viability was shown to be caused by 
necrosis. In fact, lack of Annexin V staining showed formation of necrotic cells 24h 
post-exposure. When the staining was repeated for Poly I:C, a signal of necrosis was 
not detected, suggesting that the decrease in cell viability observed was probably due 
to inhibition of cell proliferation. Further evidence showing that necrosis was the 
mechanism responsible for AgNP-induced cell death was the total absence of cleaved 
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PARP (marker of apoptosis) in AgNP-exposed cells. Necrotic cell death occurs in cells 
exposed to levels of stress that exceed the cellular system’s ability to detoxify. Cells 
are therefore unable to maintain an intracellular reducing environment high enough to 
prevent mutations [247], and as a consequence they undergo necrotic process in order 
to protect the surrounding cellular population. Necrotic cells also activate an 
inflammatory response as a protective signal to the neighbouring cells [247]. AgNPs, 
alone and in combination with Poly I:C and LPS, likely represented a high level of 
stress for the cells, which, unable to cope, underwent necrosis while inducing 
inflammation. We measured a strong pro-inflammatory response involving the release 
of IL-6 and CXCL-8 following exposure to both AgNPs and Poly I:C, whereas LPS was 
less pro-inflammatory, characterised only by IL-6 increase. Interestingly, co-exposure 
to AgNPs and Poly I:C potentiated IL-6 production but had an antagonistic effect on 
CXCL-8. Considering the role of these two mediators in the inflammatory response, our 
findings suggest that inhalation of AgNPs during a respiratory viral infection might 
result in acute or prolonged (chronic) inflammation (IL-6 increase) as well as impaired 
viral clearance (CXCL-8 decrease). Indeed, studies have shown that increased levels 
of IL-6 are associated with chronic inflammation [196]. When cells were challenged 
with AgNPs and bacterial LPS, the production of both IL-6 and CXCL-8 was reduced, 
suggesting that the whole inflammatory response was affected. We hypothesized that 
this decrease in IL-6 and CXCL-8 release might have been the result of AgNPs and 
LPS competing for the same receptor, but signalling through different pathways. On the 
contrary, dual exposure to AgNPs with Poly I:C indicated that AgNPs could potentiate 
the Poly I:C-induced inflammatory response, resulting in higher levels of inflammation. 
Clearly, inhalation of AgNPs during a viral or a bacterial respiratory infection could 
impair microbial clearance and, in the case of viruses, it could also prolong the 
inflammatory response, which is a critical component of neoplastic processes and 
chronic inflammatory diseases [239–241,306]. 
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LPS reactivity with TT1 cells was much lower than that of AgNPs and Poly I:C. We 
initially hypothesised that the reason for TT1 cell hypo-responsiveness to LPS could be 
related to low levels of TLR-4 on the cellular membrane, as suggested by other studies 
using airway epithelial cells [189]. However, confocal microscopy studies disproved this 
hypothesis. In fact, we demonstrated that TLR-4 are expressed in TT1 cells, both on 
the membrane and intracellularly. Therefore, we hypothesise that hypo-responsiveness 
to LPS might be a regulated mechanism of cellular protection aimed at avoiding the 
onset of unnecessary inflammatory events and alterations of the airway epithelial 
barrier which is constantly exposed to ambient air containing LPS. 
Consistent with the findings concerning inflammation, we reported activation of the 
three MAP-kinases p38MAPK, Erk1/2 and JNK following AgNP exposure. Specifically, 
we found p38MAPK to play an important role in AgNP-induced IL-6 and CXCL-8 
production, unlike Erk1/2 and JNK, which are not involved in the process. Associated 
with several cellular pathways (e.g. inflammation, DNA damage and cell death [202]), 
p38MAPK has been shown to be activated by TLR-4 [307], which we found to be a 
receptor for AgNPs (discussed later). Thus, it is possible that in TT1 cells, AgNPs, 
signalling through TLR-4, cause p38MAPK activation, which in turn mediates IL-6 and 
CXL-8 production. The downstream transcriptional factors induced by p38MAPK are 
numerous and include NF-kB and tumor suppressor protein p53, among others. 
However, they have not been examined in this study. 
 
Our study also involved the investigation of another important cellular pathway, the 
autophagy process. Autophagy plays a vital role in maintaining cell survival by 
degrading unwanted cellular material (cargo) through lysosomal hydrolases [89]. 
Furthermore, autophagy is also fundamental for the host immune response as it is 
involved in capturing and clearing pathogens [92]. Indeed, it is known that viruses [95] 
and bacteria [96, 99] activate autophagy. In this process, autophagy captures the 
antigen, digests it and mounts an immune response. The best known marker of 
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autophagy is the autophagosome, a double-membrane structure in which the cargo is 
degraded. In order to properly assess autophagy activation, the autophagic flux must 
be taken into account. The autophagic flux is defined as the full life cycle of an 
autophagosome, from its formation to its degradation. We showed that in AgNP-
exposed cells the autophagy pathway was active and the flux fully functional. We also 
confirmed that Poly I:C, but not LPS, activates autophagy and induces an efficient flux. 
We expected both Poly I:C and LPS to activate the flux, as the former is a synthetic 
virus and the latter a bacterial component. We suggest that the lack of a response to 
LPS from TT1 cells might be due to the hypo-responsiveness of the cells, as previously 
explained. However, when AgNPs and Poly I:C were given to the cells in combination, 
Poly I:C-induced autophagic flux was slowed down by AgNPs. Therefore, AgNPs could 
negatively impact how alveolar cells cope with viral infections, possibly by altering viral 
clearance and by impairing the host immune response. Considering that the 
mechanisms responsible for autophagy activation are still largely unknown, these 
results contribute to a better understanding of how inhaled NPs might exert their effects 
on autophagy and how autophagy might be activated in order to mount a successful 
response to AgNPs. We speculate that AgNPs, once inside the cell (discussed later), 
are recognised as foreign bodies and then enclosed into autophagosomes to be 
degraded. In addition, we do not reject the hypothesis that the autophagic process is 
activated by the oxidative environment generated by the AgNPs. Indeed, not only has it 
been shown that ROS can trigger autophagy [265], ROS and the consequent 
generation of oxidative stress are a distinctive feature in cellular responses to NP 
exposure [76]. Therefore, we assessed the role of ROS formation and oxidative stress 
in our system. Interestingly, following AgNP exposure, we discovered two different 
sources of ROS generation: the membrane enzyme NADPH oxidase and the 
mitochondria. The former induced an early generation of ROS (4h), the latter a later 
one (24h). By using the antioxidant GSH, we confirmed that the AgNP-induced effects 
we observed were all oxidative stress-dependent. In fact, pre-incubation with GSH 
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totally inhibited AgNP-induced IL-6 and CXCL-8 production and autophagy activation. 
Whereas there is plenty of evidence linking NP exposure to oxidative stress generation 
[76], inflammation [183,184] and autophagy activation [222,308], direct evidence 
showing these NP-induced processes are mediated by oxidative stress is scarce. We 
suggest that the early intracellular generation of ROS by AgNPs might be responsible 
for the later activation of autophagy (at 8h) as a defence mechanism to capture and 
eliminate NPs. However, as explained above, in the event of co-exposure to AgNPs 
and a viral ligand, the host autophagic pathway might be impaired by the presence of 
AgNPs. This could lead to a defective immune response, where cells cannot capture, 
process and properly clear viruses, thus resulting in higher vulnerability to infections. 
Another AgNP-induced process that we found to be oxidative stress-dependent was 
DNA damage. AgNP-exposed cells showed a concentration-dependent increase in 
DNA damage, which was totally prevented by GSH and that significantly increased 
when Poly I:C was added to AgNPs. It is known that DNA damage leads to mutations, 
responsible for cancerogenesis [106]. Considering that chronic inflammation could 
represent the onset of the multistage carcinogenesis process [105,106], we propose 
that AgNP-induced inflammation might have a role in this synergistic effect between 
AgNPs and Poly I:C on DNA damage. In fact, AgNP-exposed cells responded with an 
inflammatory response and a degree of DNA damage. However, when the cells were 
challenged with both AgNPs and Poly I:C (which was unable to damage the DNA 
alone), the inflammatory response was potentiated and prolonged (as previous 
explained), thus acting as a possible trigger for genotoxic alterations. In addition, using 
an acellular in vitro plasmid assay, we demonstrated that AgNPs were able to directly 
damage the DNA, reinforcing the hypothesis that, once inside the cell, AgNPs could 
cause genotoxicity, perhaps during mitosis, when the nuclear membrane degrades, 
leaving the DNA molecule free. At a cellular level, some of the typical consequences of 
DNA damage involve cell cycle arrest, apoptosis and tumorigenesis. In humans, this 
translates into a higher susceptibility to tumors [50]. 
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Considering the fundamental role of TLRs in the initiation of the innate immune 
response and the involvement of these receptors in different NP-mediated cellular 
processes [58,178,268,269], we hypothesised that TLR-3 and/or TLR-4 had a role in 
the AgNP-mediated events investigated. By using inhibitors of both TLR-3 and TLR-4, 
we showed that TLR-4 is the signalling receptor for AgNP-induced IL-6 and CXCL-8 
release, autophagy activation and DNA damage. The novelty of these findings lies in 
the fact that, despite several studies describing the ability of NPs to induce an 
inflammatory response, autophagy or DNA damage [100,183,184,222,308], very little is 
known about the signalling pathways involved in these processes. Interestingly, it has 
been shown that TLR-activated autophagy is regulated by the interaction of MyD88 or 
TRIF with Beclin-1 [96,296]. This could also happen in TT1 cells, thus linking the 
AgNP-induced TLR-4 signalling with the subsequent activation of autophagy. As for the 
AgNP-induced DNA damage, we have not found previous published work able to either 
confirm or refute our findings. Therefore, we intend to continue in this area of research 
in order to elucidate a possible mechanism of action for AgNP-induced genotoxicity in 
human alveolar cells. 
 
We were particularly interested in understanding whether AgNPs were able to enter the 
cells or were simply exerting their effects from the outside, via membrane receptors. 
Confocal microscopy revealed the presence of AgNPs not only inside TT1 cells, but 
also in the nucleus, thus providing a possible explanation for some of the AgNP-
mediated processes we observed. Intracellular localisation of the NPs could explain the 
excessive mitochondrial ROS production measured after 24h AgNP-exposure. Having 
demonstrated the absence of a link between the early NADPH oxidase-mediated ROS 
formation and the later mitochondrial ROS formation, we speculate that the latter is 
induced by physical damage to the mitochondria caused by internalised NPs. 
Furthermore, AgNP uptake supports the hypothesis that autophagy could be activated 
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by the NPs directly (NPs could be recognised as foreign bodies) or by the oxidative 
environment created by them inside the cell. Finally, the presence of AgNPs in the 
nucleus provided a possible explanation for the DNA damage observed at 24h.  
In addition, these findings support a previous study in our group that demonstrated how 
TT1 cells avidly internalise NPs in contrast to AT2 cells [35]. We consider this as 
further proof of the physiological relevance of using TT1 cells to investigate the 
properties and reactivity of inhaled NPs on human airways. 
 
Overall, tying the results together, we propose speculative interactions that might occur 
following TT1 exposure to AgNPs (Figure 6.1). Through the respiratory system, inhaled 
AgNPs reach the alveolar unit, where they react mainly with TLR-4 (Figure 6.1; blue 
pathway); however, we do not exclude the involvement of other receptors. Once 
activated, TLR-4 can partially regulate three AgNP-induced mechanisms: inflammation 
(IL-6 and CXCL-8 release), autophagy activation, and DNA damage (Figure 6.1; blue 
pathway). At the same time, AgNPs can enter the cell, possibly via an endocytic 
process (Figure 6.1; red pathway). Considering that AT1 cells possess caveolae and 
clathrin-mediated structures and that the AgNPs used in the study were 80-100nm in 
size and negatively charged, active uptake is the most likely explanation. Once inside 
the cell, AgNPs can generate oxidative stress, activate the autophagic pathway and 
physically damage the mitochondria, inducing further ROS (Figure 6.1; red pathway). 
AgNP ability to enter the nucleus and to interact directly with genetic material could 
result in DNA damage. In addition, during uptake, AgNPs may react with membrane-
bound NADPH oxidase (Figure 6.1; green pathway), resulting in early ROS production 
(4h). This source of ROS might be responsible for autophagy activation (8h), 
inflammatory mediator release and DNA damage (24h). The oxidative environment 
generated, together with the inflammatory response and the DNA damage, can 
contribute to cell death by necrosis. 
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This work has clearly shown that, following the fast development and the broad use of 
consumer products engineered with NPs, particular attention must be paid to the type 
of NPs being brought into the market, as well as their use and disposal. Their different 
physico-chemicals properties can possibly result in toxicity, both to humans and the 
environment. Regarding AgNPs, we have provided extensive proof that their effects on 
human cells can be deleterious. In particular, the use of TT1 cells enabled us to 
investigate and demonstrate AgNP effects in a physiologically relevant model that best 
portrays what might happen in real life exposure. The next step would be the use of in 
vivo models in order to validate the most relevant findings (i.e. the onset of an 
inflammatory response, oxidative stress and damage to the DNA). 
Considering the current growing interest in the clinical use of NP-based products and 
strategies, it is fundamental to develop a critical knowledge that will allow us to avoid 
the harmful/detrimental aspects of NPs and instead exploit the beneficial ones. 
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Figure 6.1 Putative signalling pathways and interlinked events following AgNP exposure in TT1 cells. AgNPs can signal through TLR-4 (blue pathway) 
and induce inflammation, autophagy activation and DNA damage. AgNPs can enter the cell (red pathway) and once in the cytoplasm can directly activate 
autophagy, generate ROS and physically damage the mitochondria, leading to further ROS generation. AgNPs can also enter the nucleus, where they can 
damage the DNA. During cellular uptake, AgNPs can activate NADPH oxidase (green pathway) thus generating ROS, which in turn can induce DNA damage, 
autophagy activation and inflammation. ROS, inflammation and DNA damage can contribute to cell death through necrotic pathways. 
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6.2 Future studies 
This study has provided new information about AgNPs, showing their effects on human 
alveolar cells and some of the mechanisms responsible for these effects. However, this 
body of work has also opened up other potential subjects of investigation. 
 With respect to the studies focusing on TLR-4, which revealed a possible role for 
this receptor in AgNP-mediated signalling pathways, future studies should optimize 
a TLR-4 knockdown model. This would clarify whether AgNPs signal through TLR-
4, thus indicating, for the first time, one of the receptors responsible for AgNP-
induced cellular reactions. Moreover, should TLR-4 be the receptor for AgNPs, the 
use of a TRIF inhibitor would further clarify the signalling pathway activated by 
AgNPs. A more detailed understanding of the signalling pathways used by AgNPs 
may provide an answer as to why two different stimuli (AgNPs and LPS) acting on 
the same receptor (TLR-4) result in such different responses.  
 Whilst we have clearly demonstrated that TT1 cells take up AgNPs, it would be 
interesting to understand the nature and the degree of TT1 cell uptake. While the 
former aim would be addressed using endocytic pathway inhibitors, TEM could be 
useful to measure the degree and the specific intracellular localisation of the NPs. 
In this context, another current subject could be investigated: the possible NP 
translocation across the epithelial-endothelial barrier. For this kind of study, an 
epithelial-endothelial co-culture using trans well plates would allow us to recreate a 
model of the gas exchange unit, thus mimicking the possible mechanisms occurring 
in a real life exposure. 
 Throughout the study we have mentioned that AgNPs possess the ability to release 
ions that could contribute to their toxicity. Although conflicting opinions exist on the 
subject [157,160,161] and the presence of the NPs inside TT1 cells let us conclude 
that the actual NPs are responsible, to a certain degree, for the AgNP-induced 
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mechanisms observed, it would be interesting to assess whether ion dissolution 
can also have a role in those processes.  
 In future studies we could also investigate some of the main effects of AgNPs (e.g. 
inflammation, ROS generation, autophagy activation and DNA damage) in primary 
cells of the lung. The first candidate would be AT2 cells which, although not being 
as involved as TT1 cells in NP uptake [35], hold the fundamental function of 
synthesising and releasing surfactant. Surfactant represents the first line of defence 
against inhaled NPs, and has been reported to modify some physico-chemical 
properties of NPs, for example by favouring their aggregation, thus reducing their 
toxicity [309]. 
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8. SUPPLEMENTARY MATERIAL 
8.1 Optimisation of a working concentration of TLR-4 siRNA 
In order to confirm the findings on TLR-4 as a possible mediator for AgNP-induced 
effects, TLR-4 knock-down by siRNA was performed at 24 and 48h time points. After 
24h, the two highest concentrations of siRNA used (300 and 600nM) reduced TLR-4 
protein expression by 39% and 46%, respectively (Figures 8.1). At 48h, the decrease 
in protein expression was no longer observed (data not shown). Therefore, we decided  
to use 600nM of TLR-4 siRNA at 24h for subsequent experiments.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.1 Optimisation of TLR-4 siRNA knock-down. TT1 cells were transfected 
with 3 different concentrations of TLR-4 siRNA: 150nM, 300nM, 600nM or random 
oligonucleotide control (RO), for 24h. Whole cell extracts were run in SDS-
PAGE/Western blotting and levels of TLR-4 were normalised against β-actin. Blot (A) 
and graph (B) showing the effect of increasing concentrations of TLR-4 siRNA. Data 
are expressed as fold-change (n=1). 
RO 150 300 600
0.0
0.5
1.0
1.5
TLR-4 siRNA
[nM]
T
LR
-4
 s
iR
N
A
/ 
-a
ct
in
(f
o
ld
-c
h
a
n
ge
)
A 
 
B 
 
TLR-4
β -actin
+        - +       -
- +- +TLR-4 siRNA
[nM]
RO +      -
- +
150 300 600
 
251 
0
35
70
RO          RO       TLR-4    TLR-4      siRNA
-  +            -             +           AgNPs
IL
-6
(f
o
ld
-c
h
an
ge
)
0
35
70
C
XC
L-
8
(f
o
ld
-c
h
an
ge
)
However, when we performed TLR-4 knock-down and looked at AgNP-induced 
cytokine release, no meaningful data could be generated (Figure 8.2). Although only 
one experiment was performed, the decrease in AgNP-induced IL-6 and CXCL-8 
production measured in the presence of TLR-4 siRNA, compared to the control siRNA, 
was small (15%). Additional experiments are needed to confirm this finding and to 
determine its significance. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.2 Effect of TLR-4 siRNA knock-down on AgNP-induced IL-6 and CXCL-8 
release. TT1 cells were transfected with random oligonucleotide (RO) control or TLR-4 
siRNA (600nM) for 24h, then exposed to AgNPs (50µg/ml) for another 24h. IL-6 and 
CXCL-8 expression was evaluated by ELISA. Data are expressed as fold-change 
(n=1). 
 
